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Glucocorticoids profoundly influence the immune system and pharmacological doses 
exert potent anti-inflammatory actions. During inflammation, glucocorticoids limit 
oedema and influence cell trafficking, differentiation programmes and gene transcription 
in glucocorticoid-sensitive leukocytes. Within cells, glucocorticoid action is modulated 
by a pre-receptor mechanism; glucocorticoid metabolism by the enzyme 11β-
hydroxysteroid dehydrogenase (11β-HSD). Two 11β-HSD isozymes exist: 11β-HSD1, 
which catalyses amplification of glucocorticoid levels in intact cells by oxo-reduction of 
intrinsically inert cortisone (11-dehydrocorticosterone in rodents) into active cortisol 
(corticosterone in rodents) and 11β-HSD2, which performs the opposite reaction. Thus, 
amplification of intracellular glucocorticoid levels by 11β-HSD1 may represent an 
endogenous anti-inflammatory mechanism. This hypothesis has been tested in   
Hsd11b1-/- mice (homozygous for a targeted disruption in the Hsd11b1 gene, encoding 
11β-HSD1), using carageenan-induced pleurisy and experimental model of arthritis 
induced by injection of arthritogenic antibodies. In both models, Hsd11b1-/- mice 
showed more severe acute inflammation than control mice. During carrageenan-induced 
pleurisy, Hsd11b1-/- mice recruited more inflammatory cells to the pleural cavity than 
congenic controls, with a greater proportion of viable cells, at the onset and peak of 
pleurisy, suggesting a worse inflammatory response. Histological examination suggested 
impaired resolution of inflammation in Hsd11b1-/- mice with persistence of 
inflammation in the visceral pleura, activation of lymphoid aggregates, and uniquely in 
Hsd11b1-/- mice, formation of fibrous adhesions between lung lobes 48h after initiation 
of pleurisy. During experimental arthritis induced by injection of serum from arthritic 
 iii 
K/BxN mice, clinical signs of inflammation occurred earlier in Hsd11b1-/- mice and 
were slower to resolve than in control mice. Histological assessment of the acute phase 
(2d) of arthritis showed no difference in joint pathology between genotypes, despite 
greater oedema and higher clinical scores in the Hsd11b1-/- mice. However, when the 
inflammation had resolved (21d following injection of serum), compared to control 
mice, Hsd11b1-/- mice showed more severe exostosis, intense periarticular inflammation, 
more collagen deposition and uniquely, ganglion cyst formation. At 21d, whereas basal 
(morning) plasma corticosterone levels were normal in control mice, they remained 
elevated in Hsd11b1-/- mice, suggesting ongoing inflammation and persistent activation 
of the hypothalamic-pituitary-adrenal axis. Mast cells are critical in the initiation of an 
inflammatory response and are essential in this model of arthritis. Mast cells expressed 
11β-HSD1 (but not 11β-HSD2) mRNA and activity. Although mast cell number did not 
differ in joints or peritoneum of Hsd11b1-/- mice, 11-HSD1-deficient mast cells had a 
lower threshold for degranulation induced by K/BxN arthritogenic serum. As well as 
implicating a role for mast cell 11β-HSD1 in limiting initial inflammation in arthritis, 
these findings also have implications for infection, allergy and tolerance. Collectively, 
these data suggest that 11β-HSD1 deficiency worsens acute inflammation and results in 
slower resolution. Therefore, amplification of intracellular glucocorticoids levels, by 
11β-HSD1, may represent an important mechanism to limit the acute inflammatory 
response and programme its subsequent resolution. Increasing leukocyte 11β-HSD1 or 
local delivery of substrate affords a novel approach for anti-inflammatory therapy. 
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Chapter 1. Introduction and Review of Literature 
 2 
1.1  Introduction  
Inflammation, comprising altered blood flow, recruitment and activation of immune 
cells, is an essential part of the response to injury, characterized by a rise in temperature, 
redness, swelling, and pain at the injured site. Glucocorticoids (GC) are potent regulators 
of the immune system and have been widely used to treat inflammatory and auto-
immune diseases for over 50 years. Today, synthetic GC, as well as natural GC 
(cortisone and cortisol), are commonly prescribed for a variety of inflammatory 
conditions and immune disorders (eg. eczema, asthma and auto-immune diseases) as 
well as the management of the immune response in organ transplantation. Philip S. 
Hench was the first to recognize the potent anti-inflammatory properties of the 
endogenous adrenal hormone cortisone (Hench et al., 1949), first discovered by Edward 
Calvin Kendall. In 1950, together with Kendall and Tadeus Reichstein, Hench was 
awarded a Nobel Prize, initiating the beginning of GC therapy for the treatment of 
inflammatory and autoimmune diseases. Since then, research into the protective ‘anti-
inflammatory’ mechanisms of adrenal hormones has revealed that GC levels during 
physiological stress and at pharmacological doses exert powerful immuno-suppressive 
effects, whereas normal circulating GC levels have modulatory effects on the immune 
system (Munck et al., 1984). Overall, it is commonly accepted that GC serve to limit an 
immune response, preventing its overshoot. Moreover, during the onset of inflammation 
they attenuate oedema and regulate leukocyte trafficking, haematopoietic differentiation 
programs and gene transcription within GC sensitive cells (Munck et al., 1984; McEwen 
et al., 1997; Ashwell et al., 2000). The mechanism(s) by which GC prevent and/or 
suppress inflammation resulting from infectious, mechanical, chemical, and 
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immunological stimuli is still unclear. Better knowledge of the regulation of endogenous 
GC action during an inflammatory response will improve our understanding of 
susceptibility to and development of diseases as well as possibly leading to improved 
treatment and/or disease prevention. Regulation of GC action is multi-level and is 
dependent on the concentration of steroid in the circulation as well as the distribution 
and concentration of receptors. The last decade has produced a wealth of information on 
the importance of pre-receptor GC metabolism by an intracellular enzyme, 11β-
hydroxysteroid dehydrogenase (11β-HSD), which modulates the amount of GC that 
reaches the receptors. 11β-HSD interconverts active GC (cortisol in humans, 
corticosterone in rodents) and intrinsically inert 11-keto metabolites (cortisone in 
humans, 11-dehydrocorticosterone or 11-DHC in rodents). Whereas 11β-HSD Type 2 
(11β-HSD2), predominantly inactivates GC, in vivo 11β-HSD1 predominantly 
reactivates GC (Figure 1.1). Therefore, 11β-HSD1 orchestrates a further and important 
level of regulation over GC action, influencing cellular GC action by increasing GC 
concentration within target cells. Thus, orally administered cortisone is first converted 
by 11β-HSD1 to the active GC, cortisol, in order to be effective. This chapter will 
review the current knowledge of GC metabolism and GC physiology, emphasizing the 
role of 11β-HSD1 and its effect on inflammation. The chapter concludes with the 












Figure 1.1 Intracellular regulation of GC levels by 11β-HSD.  
11β-HSD enzyme modulates the amount of GC that reaches the receptors by 
interconverting active GC (cortisol in humans, corticosterone in rodents) and 
intrinsically inert 11-keto metabolites (cortisone in humans, 11-dehydrocorticosterone or 
11-DHC in rodents). Two isozymes exist; 11β-HSD2 inactivates GC (Albiston et al., 
1994; Brown et al., 1996), whilst within intact cells 11β-HSD1 is predominantly a GC 
reactivating enzyme (Low et al., 1994a; Jamieson et al., 1995; Brem et al., 1995; Rajan 
et al., 1996; Jamieson et al., 2000). 11β-HSD2 expression is mainly restricted to kidney 
and sweat glands, whereas 11β-HSD1 is more widespread with highest expression in 
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1.2  Inflammation 
Inflammation is a central feature of the host’s defense system and although specific 
characteristics depend on the immune exposure (irritant versus pathogen), the 
recruitment process and activation of inflammatory cells are common. For the most part, 
inflammation is an essential part of a response to injury and is necessary to return the 
body to homeostasis by successful elimination of the irritant (eg. bacteria) ultimately 
leading to resolution and tissue repair (Savill et al., 2002; Hanson et al., 2005). Although 
categorically distinct, the innate (mainly myeloid cells) and adaptive (T and B 
lymphocytes) immune systems interact and often overlap during an inflammatory 
response. However, this thesis concentrates on the role played by the innate system in 
the inflammatory response and the early induced responses that do not generate 
immunological memory. Thus, the following section focuses specifically on myeloid 
cells.  
 
In general, an inflammatory response consists of 3 separate phases; onset, expansion and 
effector/resolution. The onset or ‘induction’ phase begins when a regional or systemic 
insult is detected. Resident innate immune cells such as macrophages (M) and mast 
cells (MC) play key roles in the induction phase (Metcalfe et al., 1997; He & Walls, 
1998), providing important sources of the inflammatory mediators that cause oedema 
and recruit leukocytes and instruct the adaptive immune system. Circulating leukocytes 
migrate toward the location of the initiating stimulus in response to a concentration 
gradient of inflammatory mediators; chemokines and cytokines. The inflammatory 
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mediators secreted by resident M and MC include prostaglandins, histamine, 
leukotrienes, complement derived peptides and cytokines particularly cytokines 
interleukin (IL)-1, IL-6 and tumour necrosis factor alpha (TNF-) and the 
chemoattractants, IL-8 and monocyte chemotactic protein (MCP)-1 (Lewis & Holmes, 
1991; Topley et al., 1993; Topley et al., 1994; Bauermeister et al., 1998; Kolaczkowska 
et al., 2001; Kolaczkowska et al., 2002). These mediators regulate and shape the 
subsequent inflammatory response, influencing growth, differentiation and activation of 
immune cells (Borish & Steinke, 2003). Pro-inflammatory cytokines activate cells 
through binding to surface receptors and trigger signal transduction pathways including 
receptor tyrosine kinases, mitogen-activated protein kinases (MAPK), and janus kinases. 
Chemokine gradients attract and guide leukocytes to the source of injury leading to the 
second stage of an inflammatory response. 
 
The expansion phase is characterized by an influx of neutrophils (which dominate the 
early response), followed by inflammatory monocytes that will subsequently 
differentiate into inflammatory M (Serhan & Savill, 2005). Extravasation of leukocytes 
into the tissue is accommodated by increased vascular diameter, blood flow, expression 
of adhesion molecules on endothelial cells and vascular (local) permeability. It is 
important to note that non-immune cells, such as fibroblasts that line the serosal cavities 
(eg. peritoneal and pleural), also participate in an inflammatory response by 
manipulating the local environment through the production of cytokines and chemokines 
(Witowski et al., 2001; Loghmani et al., 2002).  
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The third stage of the inflammatory response is the ‘effector’ or resolution phase, when 
the initiating stimulus is neutralized and inflammation is resolved. Resolution requires 
neutrophils to undergo apoptosis (Jonsson et al., 2005) followed by their successful 
removal, primarily by phagocytic leukocytes (Savill et al., 2002). “Professional” 
phagocytes (such as neutrophils and M) ingest microbial pathogens and debris from 
apoptotic and necrotic cells (reviewed in (Greenberg & Grinstein, 2002)). Phagocytosis 
is an essential process for innate immunity and, because phagocytosis by M and 
dendritic cells (DC) leads to presentation of antigen on the cell surface, also serves as a 
bridge between innate (eg. DC) and acquired (lymphocyte) immune responses. Adequate 
removal of apoptotic leukocytes and cell debris prevents release of cytotoxic granules 
and pro-inflammatory mediators from the dying cells. Failure to resolve acute 
inflammation leads to a chronic inflammatory state that can progress to irreversible 
organ damage (Savill et al., 1989; Stern et al., 1992; Meagher et al., 1992; Heasman et 
al., 2003).  
 
 
1.2.1 Mast Cells 
The work in this thesis places strong emphasis on MC and therefore the following 
section grants more attention to these cells. Although discovered over 130 years ago, 
until relatively recently, most research on MC focused on allergic and hypersensitivity 
reactions. This view has now changed so that MC are recognized as “effector” immune 
cells with a direct impact on many other cells, shaping and regulating immune 
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responses. MC are critical in host defense mechanisms against certain microbes and 
parasites, and they participate in tissue remodeling processes such as wound healing, 
angiogenesis, and fibrogenesis following chronic inflammation (reviewed in (Marshall & 
Jawdat, 2004)).  
Mature MC exist exclusively in tissues as resident cells and are not present in the 
circulation. MC accumulate in chronically inflamed tissue in humans and in mice, and 
have consistently been observed in high numbers in human rheumatoid arthritis 
(reviewed by (Woolley, 2003), in Crohn’s disease (Gelbmann et al., 1999) and in the 
bronchus of asthmatic patients (reviewed in (Kassel & Cato, 2002)). Whilst MC act as 
potent effector cells releasing various molecules that collectively enhance the 
inflammatory response (see below), in turn, inflammatory mediators released by MC and 
other leukocytes modulate the course of MC proliferation and differentiation.  
In vitro, MC development from bone marrow (BM) progenitors is dependent on IL-3 
(Razin et al., 1984) and SCF (Stem cell factor, also known as kit ligand). SCF is also 
required for MC survival; its removal from human or mouse MC culture (and IL-3 from 
the latter) leads to MC apoptosis (Mekori et al., 1993; Iemura et al., 1994). IL-3 is 
produced mainly by T cells, but also by monocytes, endothelial cells, natural killer (NK) 
cells, keratinocytes and MC themselves (reviewed by (Frendl, 1992)). SCF is a stromal 
cell derived cytokine released by fibroblasts (Furitsu et al., 1989) which not only 
regulates MC growth but also regulates the function of mature MC (Hogaboam et al., 
1998). In addition to IL-3 and SCF, numerous cytokines (such as IL-4, 9, 10, 13) and 
TGF-β, also contribute to MC development, however, these are not essential for their 
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survival (reviewed (Hu et al., 2007)). MC are heterogeneous and, like M, have been 
subtyped; in the case of MC into ‘mucosal’ and ‘connective tissue’ types, based on 
histochemical staining that differs according to the type of heparin proteoglycan present 
in the secretory granules (Reynolds et al., 1990; Stevens et al., 1994).   
Mature MC contain cytoplasmic granules loaded with preformed inflammatory 
mediators, while the cell surface contains numerous receptors which, upon activation, 
can trigger exocytosis of granules. Following stimulation, MC release various preformed 
inflammatory mediators (Figure 1.2) and continue to synthesize additional molecules by 
new gene transcription and translation (Gordon & Galli, 1990; Sylvestre & Ravetch, 
1996). These mediators act to recruit a variety of inflammatory cells (monocytes, 
neutrophils, DC, lymphocytes and eosinophils), stimulating them to produce their own 
inflammatory mediators. MC degranulation can be stimulated by cross-linking of 
immunoglobulin E (IgE) with high affinity cell surface Fcε-RI-receptors, as happens in 
allergy (reviewed in (Turner & Kinet, 1999)). MC can also be activated by IgG-
dependent signaling through Fcγ-RII and Fcγ-RIII-receptor, as well as directly or 
indirectly by pathogens (bacteria, viruses and parasites) via Toll-like receptors (TLRs) 
(reviewed in (Marshall & Jawdat, 2004; Galli et al., 2005)). Non-immunological 
stimulatory pathways have also been described, such as physical stress (cold, trauma, 
ischemia/reperfusion-induced oxidant production) (Kanwar & Kubes, 1994) and various 
secretagogues (eg. neuropeptide substance P (SP) and polypeptide analogue compound 
48/80) (Gibbs et al., 2001).  






Figure 1.2 Activation of MC leads to release of inflammatory mediators which 
generate a wide array of biological effects.  
These mediators (and others not listed) act to enhance vasopermeability, induce 
endothelial expression of adhesion molecules, recruit circulating leukocytes, and activate 
infiltrating, as well as resident, immune cells (reviewed in (Gordon & Galli, 1990; 
Marshall & Jawdat, 2004)). VEGF, Vascular endothelial growth factor; GM-CSF, 
Granulocyte/Mcolony stimulating factor; TNF-α, Tumor necrosis factor alpha; IL, 
Interleukin; MCP-1, Monocyte chemoattractant protein l; MIP-1α, M-inflammatory 
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Finally, MC have been implicated in arthritis (Woolley, 2003). In human inflamed 
synovium,  MC together with neutrophils and TNF-α and IL-1 significantly contribute to 
the pathogenesis of rheumatoid arthritis (Kiener et al., 1998; Olsson et al., 2001). In 
mice, MC have been implicated in the K/BxN arthritis model as one of the key and early 
regulators of pathogenic mechanisms (Lee et al., 2002; Binstadt et al., 2006). Following 
K/BxN serum transfer, there is a rapid (within minutes) degranulation of MC leading to 
tissue oedema and infiltration of leukocytes (Binstadt et al., 2006). MC degranulation 
has also been detected during the chronic phase of K/BxN serum transfer-mediated 
arthritis, suggesting their ongoing participation (Lee et al., 2002). Indeed, KitW/W-v mice 
which are deficient in MC, are resistant to the development of arthritis following transfer 
of K/BxN serum (Nagle et al., 1995). Synovial MC show a “connective tissue” 
phenotype, yet adoptive transfer of MC into KitW/W-v mice confers susceptibility to the 
disease with a similar disease course to normal control mice (Lee et al., 2002). MC have 
also been implicated in sterile peritonitis, being required for changes in vascular 
permeability and maximal leukocyte recruitment following injection of zymosan 
(Ajuebor et al., 1999; Kolaczkowska et al., 2001) or thioglycollate (TG) (Qureshi & 
Jakschik, 1988). 
Although MC are widely portrayed as “promoters” of inflammation, in specific 
biological responses these cells can have anti-inflammatory properties, albeit perhaps at 
different stages of the inflammatory response. For example, both IL-10 and transforming 
growth factor beta (TGF-β), often considered “anti-inflammatory”, are stored and 
released by MC (Gordon & Galli, 1990; Grimbaldeston et al., 2007). Recently, MC 
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derived IL-10 has been shown to limit ear swelling associated with certain types of 
contact hypersensitivity (Grimbaldeston et al., 2007)). Thus, the precise role of MC 
during inflammation, particularly with reference to the different stages of inflammation 
and type of stimulus, remains to be clarified.  
 
1.3  The Immune and Neuroendocrine Connection 
The neuroendocrine system plays an important role in the control of systemic and local 
immune function through neurons and endocrine cells. For example, neuropeptides such 
as SP, corticotrophin-releasing hormone (CRH), and vasoactive intestinal peptide (VIP), 
exert double-edged effects (both pro- and anti-inflammatory) on the immune system 
(Delgado et al., 2004; Guhl et al., 2005). In turn, the immune system communicates with 
the neuroendocrine system through a complex network of cytokines, chemokines and 
other inflammatory messengers resulting in bi-directional signaling between the systems 
(Figure 1.3 and reviewed in (Sternberg, 2006)). Importantly, the central nervous system 
(CNS) has direct control over the endocrine system, including corticosteroid synthesis 
and GC release through the hypothalamic-pituitary-adrenal (HPA) axis (discussed 
below). Overall, this forms a vast and complex network of reciprocally regulated 
mechanisms that are aimed at the appropriate initiation of an inflammatory response, 
neutralization of threat and effective down-regulation of the response in order to prevent 
unnecessary tissue damage. GC regulation of the immune system is discussed in more 
detail in Section 1.5.2.1. 
 







Figure 1.3 The immune system and neuroendocrine cross-talk.  
Through the HPA axis, GC orchestrate control over both systemic and local immune 
function. As well as directly mediating the inflammatory response, cytokines produced 
at the site of inflammation enter the circulation, cross the blood-brain barrier and 
stimulate the HPA axis increasing GC secretion (reviewed in (Chesnokova & Melmed, 
2002)). CNS, central nervous system; CRH, corticotrophin-releasing hormone; ACTH, 



















Chapter 1. Introduction and Review of Literature 
 14
1.4  HPA Axis and GC Biosynthesis 
Classically activated by stress, the HPA axis controls adrenal cortical function partly 
through the synthesis and release of adrenocorticotrophic hormone (ACTH) from the 
anterior pituitary. ACTH is the principal hormone stimulating adrenal GC biosynthesis, 
and is itself regulated by two neuropeptides; CRH (Vale et al., 1981) and arginine 
vasopressin (AVP) (Salata et al., 1988). These neuropeptides are secreted from the 
paraventricular nucleus (PVN) of the hypothalamus in response to various stressors. 
CRH and AVP travel through the portal hypophyseal circulation to the corticotroph cells 
of the anterior pituitary where they stimulate the synthesis and processing of pro-
opiomelanocortin (POMC), a precursor of ACTH (Horrocks et al., 1990; Mountjoy & 
Wong, 1997). After ACTH binds to its cognate receptor a biochemical pathway is 
activated leading to an increase in intracellular cyclic adenosine monophosphate 
(cAMP). Increased cAMP levels induce the expression of steroidogenic acute regulatory 
protein (StAR), a rate-limiting step in GC steroidogenesis in the zona fasciculata and, to 
a lesser extent, the zona reticularis of the adrenal cortex. StAR mediates the entry of 
cholesterol (the precursor to steroids), through the inner membrane of the mitochondria, 
leading to increased GC synthesis and secretion through a series of enzymatic steps. 
However, GC are not stored in the adrenal gland, but are synthesised de novo and 
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1.4.1 Regulation of the HPA Axis 
HPA activity is regulated in a circadian rhythm manner (in humans GC plasma levels 
are highest just prior to waking and reaching a nadir in the evening) and by 
physiological stress. GC production itself is autoregulated via a negative feedback 
control loop at the level of both the hypothalamus and the pituitary (De Kloet et al., 
1991). An increase in plasma GC levels reduces CRH and AVP production in the 
hypothalamus and inhibits ACTH production in the pituitary. Inflammatory stimuli 
activate the HPA axis by promoting production of ACTH and other inflammatory 
mediators; noradrenaline, pituitary adenylate cyclase-activating polypeptide, vasopressin 
and other cytokines, released both within the CNS and in the periphery (Chesnokova & 
Melmed, 2002). Dysregulation of the HPA axis at any level, is associated with 
autoimmunity and inflammatory and allergic diseases in humans and animal models 
(Neeck et al., 1990; Lechner et al., 1996; Cutolo et al., 1999). 
 
 
1.5  Glucocorticoids 
GC directly or indirectly regulate multiple processes within the CNS, cardiovascular, 
immune and reproductive systems, as well as intermediary metabolism, homeostatic 
processes, growth and development. The bioactivity of GC is associated with the 
hydroxyl group at carbon 11 (Figure 1.1), such that C11-keto-GC do not bind to GC 
receptor (GR), whereas C11-hydroxy-GC bind to GR and are therefore active. 
Circulating cortisol/corticosterone is ~95% bound to carrier proteins; chiefly 
corticosteroid binding globulin (CBG) (Dunn et al., 1981), but also albumin. In contrast 
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to active GC, cortisone/11-DHC remains unbound and apparently crosses cell 
membranes freely (Figure 1.4). The binding of the steroid to CBG prohibits the 
combined molecules from crossing cell membranes of the target tissues, thus CBG is an 
important regulator of circulating GC availability. CBG becomes saturated at high 
physiological GC levels, as seen following stress, allowing for greater availability of 
free steroids, which may play a role in GC delivery during inflammation (Hammond et 
al., 1990).  
 
 
1.5.1 GC Receptor  
GC bind to 2 nuclear receptor subtypes; the mineralocorticoid receptor (MR), and the 
GR. GC exert most of their physiological effects through the 94 kDa GR protein which 
is a member of the superfamily of nuclear receptors, designated as nuclear receptor 
subfamily 3, group C, member 1 (NR3C1). MR have a high affinity for physiological 
GC, ~10-fold greater than that of GR (eg. MR Kd is ~0.5nM, while GR Kd is ~5nM for 
corticosterone), and they are anatomically restricted to specific tissues including the 
kidneys, sweat glands, colon and brain (reviewed in (Funder, 1997; Odermatt & 
Atanasov, 2009)). In contrast, GR is distributed throughout the periphery and brain 
(Reul & de Kloet, 1985; Reul et al., 1989). GR expression levels vary between and 












Figure 1.4 Schematic representation of GC action.  
Showing a) extracellular ligand (active GC), b) intracellular active GC binding to GR, 
dissociation of HSP, c) import of GC-GR complex into the nucleus, and binding to GRE. 
d) inactive GC cross cell membranes freely and e) are subjected to reversible inter-
conversion between active and inactive GC by 11β-HSD. The role of 11β-HSD in 
modulating GC function is discussed in detail in Section 1.6. GR, glucocorticoid 
receptor; GREs, glucocorticoid-response elements; HSP, heat shock proteins.  
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In the absence of ligand, GR resides predominantly in the cytoplasm as part of a multi-
protein complex comprising several heat shock proteins (hsp), notably hsp90, but also 
hsp70, and several other proteins, which keep the receptor in an inactive state and 
prevent GR from entering the nucleus (reviewed in (Grad & Picard, 2007)). The 
molecular chaperone hsp90 regulates receptor folding, trafficking and transcriptional 
activation (reviewed in (Pratt & Toft, 1997). Upon ligand binding, the GR-ligand 
complex dissociates from these proteins, forms homodimers and shifts to the nucleus. 
Once in the nucleus, together with other transcription factors, GR homodimers induce 
gene transcription by binding to specific DNA sequences (i.e. GC response elements or 
GRE) in the regulatory regions of target genes, leading to chromatin remodeling and 
recruitment of RNA polymerase II to sites of local DNA unwinding (Ito et al., 2000). At 
some genes, the GR-GC complex binds to DNA and acts as a transcription repressor. 
Repression by GR may also be effected by non-DNA binding mechanisms, for example 
by binding to activator protein-1 (AP-1) or nuclear factor κB (NFκB) (Auphan et al., 
1995) to inhibit transactivation by these transcription factors. This mechanism, however, 
remains controversial and more recent data suggest that many of the “repressive” actions 
of GC are actually mediated by mechanisms involving gene activation (reviewed in 
(Necela & Cidlowski, 2004)). 
 
Moreover, although most of the literature shows that GC exert their effects by regulating 
genomic activity, there is some evidence which suggests that GC can also exert 
non-genomic actions through membrane-bound GR (Bartholome et al., 2004) or by 
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cytosolic GR (Croxtall et al., 2002). The effects of GC are apparent within minutes of 
addition of GC, too rapid for changes in gene transcription to occur. Two possible 
explanations might be that signaling at the membrane occurs via classical GR which 
localizes in the vicinity of the cell surface or by another (distinct) membrane receptor. 
Alternatively, dissociation of GR from chaperone proteins results in the release of other 
proteins (eg. FKBP51/52) which may also signal.   
 
 
1.5.2 GC Function 
A significant amount of the literature describing the effects of GC, particularly those 
relating to the immune system, is based on in vitro or in vivo experiments using very 
high doses of GC (in excess of 1µM), or synthetic GC such as dexamethasone       
(DEX; 9α-fluoro-16α-methyl-11β, 17α, 21-hydroxypregn-1, 4-diene-3, 20-dione). 
Dexamethasone is 10-30x more potent than endogenous GC due to its higher affinity for 
GR (Kd ~0.5nM) and also its higher t1/2 in the circulation (Tailor et al., 1999; Almawi & 
Tamim, 2001; Schramm et al., 2002). At supra-physiological concentrations, the 
immune-suppressive effects of GC are likely to predominate, and thus findings may not 
reflect the true physiological relevance of GC action. Caution must be therefore applied 
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1.5.2.1 The Immune System and GC  
At pharmacological concentrations, GC have profound inhibitory effects on 
inflammation and the immune system in general (Sapolsky et al., 2000), which account 
for their most common therapeutic application. Suppression of inflammation is 
commonly regarded as the prevalent, clinically relevant function of GC. Much of the 
research focuses on the anti-inflammatory properties of GC, overshadowing the critical 
point that GC are a necessary component of a coordinated inflammatory response. In 
fact, GC are essential for survival following administration of endotoxin or cytokine 
challenge with pro-inflammatory cytokines, such as IL-1 and TNF-α (Bertini et al., 
1988). Mice lacking GR in M exhibit high mortality following lipopolysaccharide 
(LPS) administration and fail to suppress M p38 MAPK and its downstream targets, 
cyclo-oxygenase 2 (COX-2), IL-6 and TNF-α  (Bhattacharyya et al., 2007). In contrast, 
mice with 2 additional copies of the GR gene show reduced mortality after LPS 
challenge (Reichardt et al., 2000).  
 
It is important to stress, that despite an overwhelming amount of evidence in the 
literature highlighting the immunosuppressive functions of GC, there is parallel evidence 
that they are not exclusively anti-inflammatory, and endogenous levels exert both 
suppressive and stimulatory effects during an inflammatory response (Figure 1.5) 
(Sapolsky et al., 2000). Thus, perhaps the physiological function of GC is best termed as 
immunomodulatory rather than immunosuppressive (Munck et al., 1984; Sapolsky et al., 
2000; Yeager et al., 2004).   







Figure 1.5 Concentration of GC determines the degree of protective immune 
response.  
Bell-shaped curve representing the degree of protection of immune function by GC over 
a range of endogenous (unbound) cortisol levels. The permissive, or stimulatory, effects 
(green line) occur under low concentrations of GC that occur during normal diurnal 
variation, whilst the high concentrations (red line), such as seen during stress response, 
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GC regulate both the adaptive and innate immune systems (Miller et al., 1998). They 
inhibit maturation of various immune cells, such as DC (Matyszak et al., 2000), 
programme the maturation of monocytes into highly phagocytic M (Giles et al. 2001), 
and induce apoptosis in other cells, such as lymphocytes. GC have direct actions on both 
T and B lymphocytes by inhibition of immunoglobulin synthesis, thus altering T-cell 
function and B-cell proliferation (Cupps et al., 1985). Furthermore, GC modulate the 
cellular function of the immune system by altering the distribution and trafficking of 
immune cells (Asai et al., 1993; Poon et al., 2001). They decrease circulating 
lymphocyte, monocyte and eosinophil numbers by reducing the availability of 
chemoattractants and suppressing adhesion molecules (eg. ICAM-1 and E-selectin) 
(Schneider et al., 1997). GC also alter granulocyte apoptosis (Meagher et al. 1996). Most 
circulating leukocytes decrease in number after GC treatment, however, neutrophil 
numbers in blood increase in response to GC (Nakagawa et al., 1998), possibly due to 
longer survival (delay in apoptosis (Zhang et al., 2001)) and/or increased mobilization 
from BM. Moreover, GC promote the resolution of inflammation, for example by 
inducing M phagocytosis of apoptotic leukocytes (Liu et al., 1999; Heasman et al., 
2003) and increasing the expression of anti-inflammatory mediators such as IL-10 and 
IL-1ra (Barnes 1998).  
 
The benefits of GC are a result of multiple and complex mechanisms; including the 
regulation of differentiation programs and gene transcription, and whilst some are 
known, the exact pathways remain uncertain. GC are commonly accredited with down-
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regulating gene transcription of pro-inflammatory molecules (Schobitz et al., 1993) 
while up-regulating transcription of anti-inflammatory mediators (Eisen et al., 1988; 
Tonko et al., 2001; Erlandsson et al., 2002) (Table 1.1 lists some but not all of the 
genes).  
 
However, GR binding sites are absent from many pro-inflammatory genes, such as those 
regulated NFκB and AP-1 (Demoly et al., 1992), and suppression occurs through GR 
interference with the action of these transcription factors. For example, activation of the 
NFκB pathway by inflammatory stimuli (eg. TNF-α) leads to separation of NFκB from 
its inhibitor IκB, allowing it to move freely into the nucleus and influence gene 
transcription. GC inhibit the effects of NFκB, which is a potent pro-inflammatory 
mediator that up-regulates genes promoting inflammation (eg. IL-1), cell adhesion and 
angiogenesis. However, there is no clear consensus as to which pathway is responsible 
for this and the exact mechanism by which GR antagonizes NFκB and AP-1 function 
remains the subject of debate.  
 
Briefly, several mechanisms by which GR interferes with NFκB and AP-1 function have 
been described including; (a) GR directly interferes with action of transcription factors 
in a manner independent of DNA binding. This was supported by generation of mice 
which do not dimerize GR and therefore cannot bind to the palindromic GREs 
(Reichardt et al., 2000). However, this interpretation was called into question with the 
demonstration that the mutant GR can bind to alternative arrangement of GRE binding 
sites (as occurs in the PNMT gene) to activate transcription (Adams et al., 2003). (b) GR 
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induces expression of IκB (Auphan et al., 1995; Scheinman et al., 1995). (c) More 
recently, an alternative mechanism has been suggested where GR induces expression of 
DUSP-1 (through gene activation) which controls MAPK signaling cascade ((Abraham 






























Table 1.1 Examples of immune-related genes regulated by GC 
 
  




Granulocyte M stimulating factor (GM-
SCF) 
Secretory leukocyte inhibitory protein 
(SLPI) Stem cell factor (SCF) 
Phospholipase A2 inhibitor (CC10) RANTES 
IL-1 receptor antagonist 
Monocyte chemoattractant protein 
(MCP)-1, 3, 4 
MAPK phosphatase (MKP-1)  Eotaxin 
Cluster differentiation (CD)163 M inflammatory protein (MIP)-1α 
 Inducible cyclo-oxygenase (COX-2) 
 Endothelin-1 
 
     Adhesion molecules (ICAM-1,        
E-selectin) 
 Neurokinin receptors (1 and 2) 
 Inducible nitric oxide synthase (iNOS) 
    
RANTES, regulated upon activation normal T-cell expressed and secreted; 
ICAM-1, intercellular adhesion molecule I; 
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1.5.2.2 Metabolism and GC  
Although not the focus of the work in this thesis, it is important to note that GC play a 
important role in the regulation of daily energy flow and mobilization of energy (glucose 
and free fatty acids) during a stress response (Munck et al., 1984). GC promote hepatic 
glucose output (increased gluconeogenesis), mobilizing stored glycogen and decreasing 
glucose uptake into peripheral tissues (eg. muscle). They also promote lipolysis of stored 
triglycerides from adipose tissue. Moreover, GC play a key role in differentiation of pre-
adipocytes into adipocytes and in the overall regulation of fat metabolism (Gaillard et 
al., 1991), as well as determination of fat distribution in favour of preferential storage of 
central fat (Andrews & Walker, 1999; Stewart & Tomlinson, 2002). Intriguingly, GC 
excess (e.g. in Cushing’s syndrome, (Lindholm, 2000)) is characterized by central 
obesity, insulin resistance, hyperglycemia and hypertension. On the other hand, GC 
insufficiency (as for example in Addison’s disease) results in weight loss and 
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1.6 11β-Hydroxysteroid dehydrogenase  
 
1.6.1 11β-HSD2 
11β-HSD2 is a 40kDa, NAD dependent enzyme, with high substrate affinity (KM values 
for corticosterone and cortisol of 5.1nM and 47nM, respectively) and predominant 
dehydrogenase reaction direction in vivo and in vitro (Albiston et al., 1994; Brown et al., 
1996). Its expression is largely restricted to classical mineralocorticoid target tissues 
(kidneys, colon, sweat and salivary glands, etc.) and the placenta  (Brown et al., 1996; 
Sun et al., 1997; Stewart & Krozowski, 1999). This isozyme is absent from the pituitary 
and most regions of the adult CNS (Roland et al., 1995; Robson et al., 1998). In the 
kidney 11β-HSD2 inactivates GC, preventing inappropriate binding to MR (Edwards et 
al., 1988; Funder et al., 1988). Inhibition or congenital deficiency of 11β-HSD2 in 
kidney leads to the GC-dependent ‘syndrome of apparent mineralocorticoid excess’ 
characterized by hypertension, hypokalemia and hypernatremia (Mune et al., 1995; 
Kotelevtsev et al., 1999). In contrast, in the fetus and placenta 11β-HSD2 prevents GC 
binding to GR and lack of this inhibition due to decreased levels of 11β-HSD2 may 
“programme” decreased birth weight in the offspring and alter their behaviour in 
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1.6.2 11β-HSD1 
11β-HSD1 uses NADP(H) as co-substrate and has a lower affinity for GC (apparent KM 
in intact cells is ~200nM for cortisol and 2µM for corticosterone), than 11β-HSD2, with 
which it shares less than 30% identity. Although 11β-HSD1 is bi-directional in vitro 
(Lakshmi & Monder, 1988) (and is frequently assayed in the dehydrogenase direction in 
homogenates), within intact cells it is predominantly a GC reactivating enzyme 
(including in hepatocytes and in liver (Jamieson et al. 1995; Jamieson et al. 2000) and 
vascular smooth muscle cells (Brem et al. 1995)). Mice which lack 11β-HSD1 
(discussed in detail below) cannot convert 11-DHC to corticosterone in vivo, proving 
this is the only 11β-reductase enzyme in mice (Kotelevtsev et al., 1997). The 
predominant reductase direction of 11β-HSD1 in vivo results from its colocalisation with 
hexose-6-phosphate dehydrogenase (H6PDH) within the endoplasmic reticulum 
(Atanasov et al. 2004; Bujalska et al. 2005; and reviewed in (Hewitt et al. 2005)).  
 
It is now accepted that 11β-HSD1 provides an important intracellular amplification of 
GC action by activating inert 11-ketosteroids derived from blood to yield active GC 
(Seckl & Walker 2001). The enzyme is widely distributed throughout the body; with the 
highest levels in the liver, and more modest levels elsewhere, including adipose tissue, 
skeletal muscle, vasculature, kidney (proximal tubules), lung, brain, anterior pituitary, 
and the ovaries (reviewed in (Stewart & Krozowski 1999; Seckl and Walker 2001; 
Tomlinson et al. 2004)). Although not the focus of this thesis, it is important to note that 
11β-HSD1 is expressed in the brain (Moisan et al., 1990; Rajan et al., 1996) and 
contributes to the feedback regulation of HPA activity (Harris et al., 2001). 
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Importantly, in obese humans and in some rodent genetic models of obesity, 11β-HSD1 
is increased in adipose tissue, with levels unchanged or even decreased in the liver 
(Livingstone et al., 2000; Rask et al., 2001). These findings have led to the proposal that 
increased 11β-HSD1 in adipose tissue, contributing to elevated GC actions in this tissue, 
is causal in the pathogenesis of the metabolic syndrome (Bujalska et al., 1997; Seckl et 
al., 2004). In line with this hypothesis, transgenic mice over-expressing 11β-HSD1 in 
adipose tissue exhibit essential features (such as visceral obesity, insulin resistance, 
dyslipidaemia) of the metabolic syndrome (Masuzaki et al., 2001; Masuzaki et al., 
2003). In contrast, mice that are deficient in 11β-HSD1 (described below in Section 
2.5.3) have a protective metabolic phenotype (Morton et al., 2001), especially on a high 
fat diet  (Morton et al., 2004). Studies in mice using specific 11β-HSD1 inhibitors have 
shown decreased blood glucose levels, improved hepatic insulin sensitivity in 
hyperglycaemic mice and inhibition of atherosclerotic plaque formation (Alberts et al., 
2003; Hermanowski-Vosatka et al., 2005; Wang et al., 2006). Taken together, these data 
suggest that excess GC contribute to pathogenesis of cardio-metabolic disease and 
highlight 11β-HSD1 as a promising drug target for treatment with over 100 patents (for 
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1.6.3 Mice Deficient in 11β-HSD1  
A line of mice homozygous for a targeted disruption in the Hsd11b1 gene encoding 11β-
HSD1 (Hsd11b-/- mice) was generated by replacing a genomic fragment including exons 
3 and 4 with a neomycin-resistance cassette, through specific recombination in mouse 
ES cells, resulting in disruption of the Hsd11b1 gene (Kotelevtsev et al., 1997). The 
Hsd11b-/- mice do not regenerate corticosterone from inert 11-DHC confirming that 11β-
HSD1 is the predominant or sole 11β-reductase in the body (Kotelevtsev et al., 1997). 
These mice have been extremely valuable in elucidating the various roles of 11β-HSD1 
(Seckl, 2004). Hsd11b1-/- mice are viable, fertile and have a phenotype consistent with 
cellular GC deficiency, despite normal (on the C57BL6/J strain background), or mildly 
elevated (on the 129/MF1 background) circulating GC levels (Kotelevtsev et al., 1997; 
Harris et al., 2001; Morton et al., 2004; Yau et al., 2007). Hsd11b1-/- mice show 
defective induction of hepatic PEPCK, the rate-determining enzyme in gluconeogenesis, 
upon fasting (Kotelevtsev et al., 1997) and are protected against metabolic disease when 
fed a high fat diet (reviewed in (Seckl et al., 2004)). They resist cognitive decline as they 
age (Yau et al., 2001; Yau et al., 2007). In addition,  Hsd11b1-/- mice show increased 
angiogenesis following injury suggesting that endogenous GC, amplified by 11β-HSD1, 
regulate angiogenesis in a GC-mediated manner (Small et al. 2005). Recently the 
phenotype of these mice during an inflammatory response has been examined and is 
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1.6.4 11β-HSD1 and the Immune System 
Although the anti-inflammatory effects of GC in the onset and resolution (reviewed in 
(Heasman et al., 2003)) of inflammation are well recognized, the available literature on 
11β-HSD1 expression, function and regulation in the immune system (Figure 1.6) 
remains limited, especially in comparison to the volume of research on the metabolic 
function of 11β-HSD1 and the consequences of its inhibition. Past studies using an 11β-
HSD inhibitor, glycyrrhetinic acid, suggested a role for 11β-HSD in the immune 
response (Finney & Somers, 1958; Pompei et al., 1979; Teelucksingh et al., 1990). 
However, glycerrhetinic acid inhibits both of the 11β-HSD isozymes and therefore, these 
effects are likely to be a result of increased GC in response to inhibition of 11β-HSD2. 
More recently, expression of 11β-HSD1 has been reported in immune cells, including 
M(Thieringer et al., 2001; Gilmour et al., 2006), CD4+, CD8+, and B220+ lymphocytes 
(Zhang et al., 2005), as well as DC (Freeman et al., 2005). Interestingly, although 11β-
HSD1 is not expressed in human monocytes (Thieringer et al., 2001; Freeman et al., 
2005), it is induced upon differentiation to M (Thieringer et al., 2001) or DC (Freeman 
et al., 2005), suggesting tissue-specific and maturation-dependent regulation (regulation 
of 11β-HSD1 is discussed below, Section 2.7). Nonetheless, the relatively small amount 
of research available to date points to a protective, anti-inflammatory role for 11β-HSD1 
during an acute inflammatory response (reviewed in (Chapman et al., 2006; Chapman & 
Seckl, 2008)).  
 
 
























Figure 1.6 Increasing number of publications on 11β-HSD1 expression, function 
and regulation during inflammation. 
Figure represents the increasing trend of publications (line) including research papers 
(light bars) and reviews (dark bars). Publication list obtained from Pubmed search 
(www.pubmed.gov) using key words; ‘11beta HSD1’ and ‘inflammation’ on 27th of 
November 2008. Key word ‘11beta HSD1’ alone generated 597 results, whilst key word 
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In support of a role in inflammation, 11β-HSD1 activity and/or expression increases at 
sites of inflammation (Gilmour et al., 2006; Vagnerova et al., 2006). Rapid up-regulation 
of 11β-HSD1 occurs in peritoneal cells during sterile peritonitis (Gilmour et al., 2006) 
and in colitis (Bryndova et al., 2004; Zbankova et al., 2007). Increased activity of 11β-
HSD1 (in fibroblasts) occurs in human rheumatoid arthritis (Hardy et al., 2008) and 
synovial inflammation (assessed by increased cellularity) correlates with cortisone 
reactivation, suggesting elevated local 11β-HSD1 activity within the synovium (Schmidt 
et al., 2005). 11β-HSD1 is expressed in leukocytes and synovial fibroblasts within the 
rheumatoid joint (Schmidt et al., 2005).  
 
 
1.6.5 Regulation of 11β-HSD1 
There are 3 promoters that drive transcription of the Hsd11b1 gene; the distal promoter 
(P1) (Bruley et al., 2006) mainly used in lung and kidney, the proximal promoter (P2) 
(Bruley et al., 2006) used in liver, adipose tissue and brain, and promoter P3 used in 
kidney (Moisan et al., 1992) (personal communication with Prof Karen Chapman). 
Transcription factors of the CAAT/enhancer-binding protein (C/EBP) family play a key 
role in regulation of 11β-HSD1 both in vivo and in vitro (Williams et al., 2000; Bruley et 
al., 2006; Gout et al., 2006; Sai et al., 2008; Payne et al., 2007). The P2 promoter is 
activated by C/EBP, with C/EBPα having a greater effect than C/EBPβ in hepatocytes 
(Williams et al., 2000), whilst in pre-adipocytes, C/EBPβ appears the major regulator 
(Gout et al., 2006). During adipocyte differentiation of 3T3-L1 cells, 11β-HSD1 mRNA 
increases with C/EBPα expression (Payne et al., 2007). Interestingly, whilst the P2 
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promoter is dependent on C/EBPα, the P1 promoter is C/EBPα-independent (Bruley et 
al., 2006). In support of this, C/EBPα knockout mice exhibit a severe deficit in 11β-
HSD1 mRNA in liver (which uses the P2 promoter), whilst they have normal levels of 
11β-HSD1 mRNA in lung, which uses the P1 promoter (Williams et al., 2000; Bruley et 
al., 2006). Since 11β-HSD1 plays a diverse role in the control of GC action, 
understanding of its regulation is critical. Although there is a report of cortisol-induced 
GR binding to a GRE in the P2 promoter region of 11β-HSD1 in placental cells (Yang et 
al., 2007), in a different system (A549 lung epithelial cells), it appears that 11β-HSD1 
induction by GC is dependent on transcriptional regulation by C/EBPβ (Sai et al., 2008).  
 
Another recognized transcription factor involved in the modulation of 11β-HSD1 is the 
peroxisome proliferator activator receptor (PPAR) which regulates several pathways 
involved in insulin activity (Bahr et al., 2002). Briefly, 11β-HSD1 expression and 
activity is down-regulated by PPARα agonists in liver (Hermanowski-Vosatka et al., 
2000) and by PPARγ in adipocytes (Berger et al., 2001). PPARγ and C/EBPα co-operate 
in their promotion of adipocyte differentiation (Wu et al., 1999), during which time 11β-
HSD1 is switched on (Payne et al., 2007). However, to date there are no reports on 
regulation of 11β-HSD1 through C/EBP and/or PPAR in the immune system, although 
both have been shown to have anti-inflammatory effects (Poli, 1998; Zhang et al., 2007). 
 
The regulation of both the expression and activity of 11β-HSD1 is largely tissue 
specific, and unsurprisingly, the HPA axis and its own modulators are also involved in 
this regulation. Regulation of 11β-HSD1 activity and gene expression involves 
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numerous hormones and growth factors. GC themselves have been shown to up-regulate 
11β-HSD1 in human pre-adipocytes and adipocytes (Bujalska et al., 1999; Engeli et al., 
2004), myoblasts (Whorwood et al., 2001), fibroblasts (Hammami & Siiteri, 1991) and 
rat hepatoma cells (Voice et al., 1996). GC also induce 11β-HSD1 mRNA in vivo in a 
tissue specific manner (Jellinck et al., 1997; Jamieson et al., 1999). In contrast, 11β-
HSD1 activity is inhibited by insulin and expression is reduced by thyroid hormone, 
growth hormone (GH), insulin-like growth factor-1 (IGF-1) and sex steroids (Low et al., 
1994b; Arcuri et al., 1996; Whorwood et al., 1993; Stewart & Tomlinson, 2002). 
Additionally, chronic stress up-regulates 11β-HSD1 (Low et al., 1994a), while the 
sympathetic nervous system both increases (through β-adrenergic stimulation) and 
decreases (through α-adrenergic stimulation) 11β-HSD1 activity (Hochberg et al., 2004).  
 
Although there is increasing evidence that interleukins (especially IL-1) and other 
inflammatory agents (including TNF-α) increase 11β-HSD1 activity and gene 
expression (summarized in Table 1.2), the exact molecular mechanisms governing 
inflammation associated induction of 11β-HSD1 are yet to be determined. Other 
inflammatory mediators, such as prostaglandins, may also be important regulators of 
11β-HSD1 expression (Alfaidy et al., 2001). Despite the significant gaps in the 
understanding of the mechanisms which govern 11β-HSD1 during inflammation, the 
possibility of its anti-inflammatory role (Chapman et al., 2006; Chapman & Seckl, 2008) 
has stimulated much interest in uncovering the regulatory mechanisms and has set the 
precedents for future research.  
 




Table 1.2 Regulation of 11β-HSD1 levels by inflammatory mediators 
 
 
Cytokine Cell Type 11β-HSD1 mRNA 
11β-HSD1 
activity Reference 
IL-1α Ovarian epithelial cells ↑ n/a Rae et al., 2004 
  Ovarian epithelial cells ↑/↔ n/a Gubbay et al., 2005 
IL-1β Glomerular mesangial cells ↑ ↑ Escher et al., 1997 
 Granulosa cells ↑ n/a Tetsuka et al., 1999 
 Amnion fibroblasts n/a ↑ Sun and Myatt, 2003 
 Adipose stromal cells n/a ↑ Tomlinson et al., 2001 
 Aortic smooth muscle cells ↑ ↑ Cai et al., 2001 
 Osteoblasts ↑ ↑ Cooper et al., 2001 
 Monocytes ↔ ↔ Thieringer et al., 2001 
 Ovarian epithelial cells ↑ ↑ Yong et al., 2002 
 Adipocytes n/a ↑ Friedberg et al., 2003 
 BM fibroblasts ↑ ↔ Hardy et al. 2006 
 Dermal fibroblasts ↑ ↑ Hardy et al. 2006 
  Synovial fibroblasts ↑ ↑ Hardy et al. 2006 
IL-4 Granulosa-lutein cells  n/a ↑ Evagelatou et al. 1996 
 Monocytes n/a ↑ Thieringer et al., 2001 
IL-5 Granulosa-lutein cells  n/a ↑ Evagelatou et al. 1997 
IL-6 Granulosa-lutein cells  n/a ↑ Evagelatou et al. 1997 
IL-13 Monocytes n/a ↑ Thieringer et al., 2001 
IL-6 Adipose stromal cells ↑/↔ n/a Tomlinson et al., 2001 
TNF-α Glomerular mesangial cells ↑ ↑ Escher et al., 1997 
 Adipose stromal cells ↑ ↑ Handoko et al., 2000  
 Amnion fibroblasts n/a ↔ Sun and Myatt, 2003 
 Adipose stromal cells ↔ ↑ Tomlinson et al., 2001 
 Aortic smooth muscle cells ↑ ↑ Cai et al., 2001 
 Osteoblasts ↑ ↑ Cooper et al., 2001 
 Monocytes ↔ ↔ Thieringer et al., 2001 
  Adipocytes n/a ↑ Friedberg et al., 2003 
IFN-γ Granulosa-lutein cells  n/a ↑ Evagelatou et al. 1997 
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1.7 11β-HSD-deficiency and Inflammation  
Although Hsd11b1-/- mice have been used extensively for metabolic studies, they have 
only recently been used to investigate the effect of 11β-HSD1-deficiency on the immune 
system. During sterile peritonitis, Hsd11b1-/- mice show delayed acquisition of M 
phagocytic competence in vivo with increased numbers of free apoptotic neutrophils two 
days following injection with TG (Gilmour et al., 2006). In vitro phagocytosis of 
apoptotic neutrophils by M from wild-type mice is stimulated equally by corticosterone 
and 11-dehydrocorticosterone (the substrate for 11β-HSD1), with the effect of the latter 
prevented with carbenoxolone (CBX), an inhibitor for 11β-HSD, confirming the effect is 
due to 11β-HSD1-mediated GC reactivation. Further, whilst corticosterone treatment 
increases the ability of Hsd11b1-/- M to phagacytose apoptotic neutrophils, indicating 
that the mechanism of GC response is intact in these cells, 11-dehydrocorticosterone is 
without effect (Gilmour et al., 2006).  
 
Furthermore, TG-elicited peritoneal M from Hsd11b1-/- mice produce more IL-6 (a GC 
repressed cytokine (Almawi & Tamim, 2001; Schobitz et al., 1993)) following 
stimulation with LPS ex vivo (Gilmour et al., 2006), consistent with impaired GC action. 
The greater cytokine response to LPS by Mfrom Hsd11b1-/- mice (Gilmour et al., 2006; 
Zhang & Daynes, 2007) shows that exposure to 11β-HSD1 substrate (in vivo) affects the 
differentiation and/or activation state of M. In addition, after administration of LPS, 
Hsd11b1-/- mice exhibit greater weight loss and higher serum levels of TNF-, IL-6 and 
IL-12p40 compared to control mice (Zhang & Daynes, 2007). In contrast, in vivo 
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inhibition of 11β-HSD1 in the apoe-/- mouse model, with a specific 11β-HSD1 inhibitor, 
resulted in lower levels of circulating MCP-1, a cytokine that plays a role in the 
recruitment of monocytes to sites of injury (Hermanowski-Vosatka et al., 2005). 
Therefore, it remains to be clarified what effect 11β-HSD1 inhibition has on both the 
immune system and its modulators. Since 11β-HSD1 has been viewed as a therapeutic 
target for the treatment of the metabolic syndrome (discussed above, Section 1.6.2.), 
with 11β-HSD1 inhibitors in clinical trials for type 2 diabetes, it is important to establish 
and clearly define the role of 11β-HSD1 in limiting and resolving inflammation, to 




1.8 Hypothesis and Aims of the Thesis 
 
1.8.1 Hypothesis  
 
Amplification of intracellular GC levels by 11β-HSD1 represents an important 






Chapter 1. Introduction and Review of Literature 
 39
1.8.2 Aims 
This thesis aimed to test the above hypothesis, by determining the contribution of 11β-
HSD1 to an acute inflammatory response, using Hsd11b1-/- mice subjected to 
experimental models of inflammation. Furthermore, to provide insights into its role in 
the inflammatory response, the expression and regulation of 11β-HSD1 was 
investigated in Hsd11b1+/+ control mice. In particular the specific aims were: 
 
FIRSTLY, to identify experimental models of inflammation in which to characterize the 
role of 11β-HSD1 using Hsd11b1-/- mice. 
 
SECONDLY, having identified a suitable model and shown that Hsd11b1-/- mice exhibit 
worse inflammation in this model, to investigate the mechanisms underlying the altered 
inflammatory response in Hsd11b1-/- mice, including identifying the inflammatory cells 
that express 11β-HSD1. 
 
THIRDLY, to test whether MC 11β-HSD1 plays an important role in limiting acute 
inflammation and to use in vitro systems to identify the mechanisms which may 
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2.1. Materials  
 
Unless otherwise stated all chemicals and reagents were purchased from Sigma-Aldrich 
Company Ltd, (Poole, UK) or from Invitrogen Life Technologies (Paisley, UK). Double 
deionized water (H20) was used to prepare buffers and solutions.  
 
 
Buffers and Solutions 
 
Borate buffer: 8.25g Boric acid, 2.7g NaOH, and 3.5ml HCl (33M) was made up to 1L 
with H20 (pH 7.4), then 0.5% BSA (0.5g/100ml) was added and stored at -20°C 
 
C buffer: 63g glycerol, 8.77g NaCl, 186mg EDTA and 3.03g Tris was made up to 
500ml with H20, (pH 7.7) and stored at 4°C 
 
DEPC-treated H20: H20 was mixed with diethylpyrocarbonate (DEPC; 1 drop/100 ml), 
mixed and left overnight prior to autoclaving 
 
Evans Blue Dye: 25mg Evans blue was dissolved in 5ml H20 (0.5% w/v) 
 
Homogenization buffer: 100g glycerol, 300mg Tris and 186mg EDTA was made to 
500ml in H20, (pH 7.5), stored at 4°C and supplemented with 7.7mg dithiothreitol 
(DTT) per 50ml immediately prior to use (buffer was kindly prepared by Ms Lynne 
Ramage, CCVS) 
 
Ketamine/Metatomedine: 0.38ml of ketamine and 0.50ml of metatomedine in 5ml PBS  
 
Lipopolysaccharide (LPS): 10mg LPS (derived from Escherichia coli serotype 
0111:B4) was solubilised in 5ml sterile 0.9% NaCl and stored in 200µl aliquots at -
20°C. For a working concentration of 0.5mg/ml, aliquots were diluted further in sterile 
0.9% NaCl  
 
Nicotinamide Adenine Dinucleotide (NAD): 17.1mg made up to 1ml in C buffer (for 
final concentration of 25mM) 
 
Phosphate buffered Saline (PBS): 1 x PBS tablet (Oxoid Limited, Hampshire, UK) 
(containing 8g/L sodium chloride, 0.2g/L potassium chloride, 1.15g/L Di-sodium 
hydrogen phosphate and 0.2g/L potassium dihydrogen phosphate) dissolved in 100ml 
H20  
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Placental Homogenate: Kindly prepared by Ms Lynne Ramage (CCVS), 2 Wistar rat 
placentas were mechanically homogenised in 1ml homogenisation buffer and stored in 
300µl aliquots at -80°C 
 
10x TBE buffer: 56g Tris, 57.5g boric acid, 20ml 0.5M EDTA was made up to 500ml 
with H20 and autoclaved before use   
 
Thioglycollate solution (10%): 10g of Brewer’s thioglycollate powder (DIFCO, Detroit, 
MI, USA) was dissolved in 0.1L PBS and autoclaved  
 
Toluidine Blue Working Solution: 5ml Toluidine Blue stock solution (1g Toluidine 
blue O in 100ml 70% ethanol) was mixed with 45ml 1% NaCl (pH 2.3), solution was 
always made fresh and discarded after use 
  




Steroids and Radiolabeled Steroids  
 
Dexamethasone (DEX): (FW=392g) was dissolved in 100% ethanol to a stock 
concentration of 10mM and stored at –20C 
 
Corticosterone (B): (FW=346.5g) was dissolved in 100% ethanol to a stock 
concentration of 10mM and stored at –20C 
 
11-Dehydrocorticosterone (A): (FW=344.4g) was dissolved in 100% ethanol to a stock 
concentration of 10mM and stored at –20C 
 
[3H]-Corticosterone: Commercial stock solutions of [3H4]-Corticosterone (specific 
activity ~80 Ci/mmol; Amersham Pharmacia Biotech, Buckingham, UK) in ethanol 
(with concentrations of 13.7nmol/ml) were stored at -20°C  
 
 [3H]-11-Dehydrocorticosterone: [3H4]-11-Dehydrocorticosterone was synthesized in-
house (preparation described in detail in Section 2.3.6.1), re-suspended in ethanol (for 
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2.2. Animals 
All experimentation was conducted in strict accord with accepted standards of humane 
animal care under the auspices of the Animal (Scientific Procedures) Act UK 1986 
following prior approval by the local ethical committee. Unless stated otherwise, male 
mice, homozygous for a targeted disruption of the Hsd11b1 gene (Hsd11b1-/-) on a 
C57BL/6J background (>8 backcrosses) (Kotelevtsev et al., 1997, Morton et al., 2004) 
were bred in-house at the Biomedical Research Facility, Little France, Edinburgh, UK 
and were used with age-matched C57BL/6J wild type controls (Hsd11b1+/+) which were 
either bred in-house or purchased from Harlan (Orlac, Bicester, UK). All mice were 
housed individually or in groups of 2 to 5 mice per cage and kept under controlled 
conditions (7:30am to 7:30pm light/dark cycle, 21˚C) with ad libitum access to H20 and 
standard rodent chow (Special Diet Services, U.K.). Unless stated otherwise, mice were 
killed between 8:00am and 11:00am by cervical dislocation or by intra-peritoneal (i.p.) 





2.3.1. Thioglycollate-induced sterile peritonitis 
Thioglycollate (TG)-induced sterile peritonitis is a mild and self-resolving (by 5d) model 
of systemic inflammation (Gallily et al., 1964). Intra-peritoneal (i.p.) injection of TG 
causes a rapid influx of activated neutrophils (peaking at 6-12h) (Baron & Proctor, 
1982) and monocytes (by 24h) (Melnicoff et al., 1989) into the peritoneum. This model 
was previously used for characterization of the course of inflammation and its resolution 
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in Hsd11b1-/- mice (Gilmour, 2002; Gilmour et al., 2006). The exact stimulus of the 
inflammatory response in this model is not completely known and may be non-specific 
(Li et al., 1997; Ajuebor et al., 1999). TG injection into the peritoneum is also widely 
used to obtain relatively pure populations of M (at 4d). It also allows for M to be 
isolated and manipulated in vivo and analyzed at the onset, peak and resolution stage of 
inflammation.  
 
Peritonitis was induced in mice by i.p. injection of 0.5ml of 10% thioglycollate (TG) 
solution. At various times following injection, mice were killed by cervical dislocation 
and underwent peritoneal lavage. The body was sprayed with 75% ethanol prior to blunt 
dissection of peritoneum skin and a 19G needle was used to lavage the peritoneum with 
5ml sterile PBS. Generally, ~4ml lavage fluid was recovered per mouse. Cells were 
recovered by centrifugation of lavage fluid at 300g (Labofuge 400R Centrifuge, 
Heraeus, Essex, UK) for 5min at 4ºC, washed in 5ml PBS, re-suspended in 1ml PBS and 
counted using a haemocytometer (Neubauer).    
 
 
2.3.2. Cell culture  
Unless otherwise stated, basic culture medium used was Dulbeco’s modified Eagle’s 
medium (DMEM) with 10% v/v heat inactivated fetal calf serum (FCS), 1% 
penicillin/streptomycin. Cells were counted using a haemocytometer. 
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2.3.3. Enrichment of peritoneal mast cells  
Following peritoneal lavage (with 5ml sterile PBS), cells were washed once with PBS 
and re-suspended in 80µl medium (as above but containing 2% FCS) per 107 cells. In 
order to magnetically label cells for enrichment of mast cells (MC), 20µl of CD117 (c-
kit) beads (Miltenyi Biotec, Surrey, UK) were added per 107 cells and incubated for 
15min at 4ºC. Cells were then washed with 1ml medium (containing 2% FCS) and re-
suspended in 500µl of the same medium. A MACS magnet and LS columns (Miltenyi 
Biotec) were used to recover labeled cells (according to manufacturer’s instructions). 
First, the unlabelled cells were allowed to pass through the magnetic column (while the 
labeled cells attached to the magnet), then once the column was removed from the 
magnet the magnetically labeled cells were flushed through and collected. Purification 
was tested microscopically on cytospins or by flow cytometry. 
 
 
2.3.4. Bone marrow derived macrophages (BMD-M) 
Following Schedule 1 killing, the femur bone was carefully extracted from the body and 
remaining muscle and connective tissue were removed. In a sterile hood, both epiphyses 
were cut away with a scalpel. By inserting a 23G needle into the diaphysis compartment 
and forcing fluid through it, cells were flushed with 5ml medium supplemented with 
L929 conditioned supernatant, which contains M colony stimulating factor (M-CSF), 
into a sterile Teflon pot (Roland Vetter Laborbedarf, Ammerbuch, Germany) (1 femur 
per pot). The process was repeated with the other end of the femur. The total cell 
suspension was gently aspirated 10 times through a 19G needle to disrupt cell clumps. 
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Teflon pots were incubated at 37ºC, in CO2 (5%). On alternate days 25% of the medium 
was replenished. Cells were harvested on 7d.  
 
 
2.3.5. Bone marrow derived mast cells (BMD-MC) 
BM was retrieved from mouse femurs as described above (2.3.4). The volume of the 
total cell suspension was made up to 50ml in a Falcon tube with warm basic culture 
medium, and 10µl was used to count cells. Cells were then centrifuged at 230g for 
7min and the supernatant was discarded. The cell pellet was re-suspended in basic 
culture medium supplemented with recombinant mouse IL-3 and SCF (both from 
PeproTech EC, Ltd. 20µg/ml IL-3 stock and 1mg/ml SCF stock, using 10µl of each per 
200ml of medium). Cells were placed in 162cm2 culture flasks at 5x105cells/ml and 
incubated at 37ºC, 5% CO2. Cells were checked daily for contamination and allowed to 
mature for 3 weeks. Half the medium was replaced on Mondays, Wednesdays and 
Fridays with fresh MC-differentiating medium. 
 
 
2.3.6. Measurement of 11β-HSD1 activity 
 
2.3.6.1. Preparation of [3H] 11-dehydrocorticosterone 
[3H]-11-Dehydrocorticosterone was prepared as previously described (Low et al., 1994). 
Briefly, 120µl (5nM) of [3H]-corticosterone was added to 200µl of 25mM NAD+, 300µl 
of rat placental homogenate (gift from Ms Lynne Ramage) and 4.45ml of C buffer, and 
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gently shaken at 37°C for at least 3h. Next, 4ml of ethyl acetate was added; the solution 
was then vortexed and centrifuged (Labofuge 400R Centrifuge) at 2,000rpm for 5min. 
The organic (upper) layer containing the steroid was transferred into a clean tube and re-
centrifuged. The organic layer was then dried under air, approximately 800µl at a time in 
HPLC tube. Once dry, the steroid was reconstituted in 200µl of 100% ethanol. 
Recovery, purity and specific activity were assessed in a 1µl aliquot by thin layer 
chromatography (TLC) (Methods 2.3.6.3.) and counted in scintillation fluid (Pico-fluor 
40, Canberra Packard, Berkshire, UK) in a β-counter (Wallac 1450 Microbeta Plus 
liquid scintillation counter, Milton Keynes, UK). The prepared [3H]-11-
dehydrocorticosterone was stored at -20°C for future use. 
 
2.3.6.2. 11β-reductase/dehydrogenase assay 
11β-HSD1 activity was measured in intact cells as previously reported (Low et al., 
1994). Conversion of [3H]-corticosterone to [3H]-11-dehydrocorticosterone (11β-
dehydrogenase activity) or [3H]-11-dehydrocorticosterone to [3H]-corticosterone (11β-
reductase activity) was measured in intact primary cells. Normally, 106 cells were 
seeded per well of a 24-well plate in 1ml of medium and incubated at 37ºC for the 
duration of the experiment (1h to 24h). A trace amount of tritiated steroid (normally 
5nM) was diluted with unlabelled steroid and added to the cell medium to give a final 
concentration of 200nM steroid. Aliquots of medium (200µl) were collected at various 
times after addition of [3H]-11-dehydrocorticosterone or [3H]-corticosterone. Steroids 
were extracted with >4x vol ethyl acetate and dried in HPLC tubes as above. [3H]-
Cortisone conversion to cortisol was measured in experiments with human neutrophils. 
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2.3.6.3. Thin Layer Chromatography (TLC) 
Dried steroids were re-suspended in 40µl of 100% ethanol containing unlabelled 
corticosterone and 11-dehydrocorticosterone (each at 5mg/ml) to aid visualization under 
UV light on the developed TLC plate (aluminium sheets, 20x20cm, silica gel, VWR). 
Samples were spotted onto the plates at 8µl at a time. Chromatography was carried out 
in 100ml methanol:chloroform (92:8, v/v), until the solvent almost reached the top of the 
plate. TLC plates were exposed to 3H phosphorimager screens (Fuji; Raytek, Sheffield, 
UK) for 3-5d. 3H-steroids were visualised using a phosphorimager (Fuji FLA-2000) and 
quantitated using Aida software (Raytek; Sheffield, UK). Results are expressed as % 
conversion of substrate ([3H]-11-dehydrocorticosterone) into product ([3H]-
corticosterone). Alternatively, steroids from 11β-HSD1 activity assay were measured by 




2.3.7. Models of experimental arthritis  
 
2.3.7.1. Collagen-Induced Arthritis (CIA) 
Responsiveness to CIA is linked to the major histocompatibility complex (MHC) class II 
H-2 haplotype, with H-2q haplotype having the highest response rate and H-2b, the 
lowest (Wooley et al., 1981). C57BL/6 mice bear H-2b and thus, tend to be resistant to 
CIA, unlike other strains, such as DBA/1 mice, where arthritis symptoms generally 
develop between 28d to 40d after initial immunization (personal communication, Dr 
Mohini Gray). A modified immunization protocol, where the collagen is mixed with 
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complete Freund’s adjuvant (CFA), and in which 60-70% of C57BL/6 mice developed 
arthritis, has been previously described (Campbell et al., 2000). Briefly, to induce 
arthritis using collagen type II in complete Freund’s adjuvant (CII-CFA), a solution of 
2mg/ml of chicken sternal collagen type II (Sigma) in 10mM sterile acetic acid was 
emulsified in an equal volume of complete Freund’s adjuvant (Incomplete Freund’s 
Adjuvant (Sigma) mixed with 5mg/ml of Mycobacterium tuberculosi (Difco 
Laboratories)). Using a 100µl Hamilton glass syringe, Hsd11b1-/- or Hsd11b1+/+ male 
mice (n=10/group) were immunized (between 8am and 10am) intradermally at the base 
of the tail with 100µl of freshly prepared CII-CFA solution on d0 and again, 21d later. In 




2.3.7.2. KxB/N serum transfer model 
 
2.3.7.2.1 The K/BxN model of inflammatory arthritis 
The K/BxN serum transfer model of arthritis, applicable to most strains of mice (Ji et al., 
2001), has proved to be a useful experimental model in examining the mechanisms that 
underlie inflammatory arthritis (Matsumoto et al., 1999). K/BxN TCR transgenic mice 
spontaneously develop auto-antibodies to glucose-6-phosphate isomerase (G-6-PI), 
resulting in onset of severe arthritis by ~3 weeks of age (Kouskoff et al., 1996). Injection 
of serum or purified G-6-PI antibodies from arthritic K/BxN mice into healthy recipient 
mice rapidly (by 24-48h) and reproducibly induces an inflammatory arthritis which is 
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progressive, symmetric and is characterized by synovitis, periarticular inflammation, 
pannus formation, and destruction of cartilage and bone (Matsumoto et al., 1999; 
Matsumoto et al., 2002).  The arthritis is self-resolving by 21d (as the G-6-PI antibody is 
cleared from the system), although it can be perpetuated with repeated injections of 
K/BxN serum. Myeloid cells, and particularily MC (Lee et al., 2002), are implicated in 
K/BxN arthritis (Ji et al., 2002). Lymphocytes are not required (Korganow et al., 1999) 
since arthritis progression is normal in RAG-1 knockout mice, which lack mature T and 
B cells (Mombaerts et al., 1992; Shultz et al., 2000). Thus, by injecting K/BxN 
arthritogenic serum, the lymphocyte-dependent induction phase of arthritis is bypassed, 
allowing examination of the inflammatory ‘effector’ stage of disease (Ji et al., 2001).  
 
KxB/N arthritis was induced in Hsd11b1-/- and Hsd11b1+/+ male mice by either a single 
i.p. injection of K/BxN serum (5.6µl/g body weight) (gift from Dr Mohini Gray) on d0 
or 2 injections of 7.5µl/g body weight on d0 and d2. All injections occurred between 
8am and 10am.  
 
 
2.3.7.2.2 Assessment of inflammatory arthritis 
Daily monitoring of disease development and progression included visual examination 
of carpal and hock joints for redness/swelling. Clinical scoring was carried out according 
to a clinical index based on redness and swelling of the affected joints. Two methods of 
clinical scoring were used. For Method 1, each paw was given a score of 0-3 (maximum 
score of 12) depending on severity of inflammation; 0 indicated no evidence of 
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inflammation, 1 indicated subtle inflammation (metatarsal phalanges joints, individual 
phalanx, or localized oedema), 2 indicated more obvious swelling localized to dorsal or 
ventral surface of paw, and 3 involved swelling of the entire paw (Lee et al., 2002). For 
Method 2, each red paw was assigned 0.5 point and for each swollen paw 1 point was 
assigned, resulting in a maximum score of 4 per mouse (Ji et al., 2002).  During the 
maximal dose experiment, ankle thickness was measured using a calliper (Kroeplin 
POCO-2T, Wessex Metrology, UK). Right tarsal joint swelling was defined as the 
difference in width (mm) from that measured at d0. 
 
 
2.3.7.2.3 Histological assessment 
Arthritic joints (carpal and hock) from acute and chronic experiments were dissected and 
fixed in 10% formalin, followed by decalcification in 10% EDTA in neutral buffered 
formalin at room temperature (RT). The decalcification lasted at least 4 weeks. Sections 
were stained with haematoxylin and eosin (H&E) to assess pathology, while remaining 
sections were used for immunohistochemistry (IHC) (Section 2.3.13). Sectioning was 
carried out by the core Pathology Service, Edinburgh University. The H&E sections 
were examined by Dr David Brownstein and by Dr Donald Salter. The objective was to 
determine whether there were differences in inflammation within and around the 
arthritic joint cavity between Hsd11b1-/- and control mice at the onset of inflammation or 
whether the degree of bone and cartilage erosion and destruction differed between 
genotypes following resolution.  
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2.3.8. Tail nick blood collection 
For measurement of basal plasma corticosterone levels, peripheral blood was collected 
under non-stressed conditions via tail nick between 0730h and 0830h. Briefly, one 
mouse at a time was quickly lifted from its cage and a small cut was made at the base of 
tail with a sterile scalpel. Approximately 25µl of blood was then collected into EDTA 
coated microvettes (Sarstedt Inc., UK) and placed on ice. Samples were centrifuged at 
4˚C for 10min at 12,000rpm and plasma stored at -20ºC until further analysis.    
 
 
2.3.9. Corticosterone radioimmunoassay 
Plasma corticosterone levels were measured by radioimmunoassay. Plasma samples 
were diluted 1:10 in borate buffer, heated for 30min at 75˚C then centrifuged (Labofuge 
400R Centrifuge) for 2min at 13,000rpm at RT. In a 96-well plate, 20µl of each sample 
was added to 50µl borate buffer containing [3H]-corticosterone (10,000cpm per sample) 
and corticosterone antibody was added. The rabbit-anti-rat corticosterone antiserum 
(kindly provided by Dr Chris Kenyon) was added at 1:10,000 dilution in borate buffer. 
This mix was incubated at RT for 1h. Next, 50µl of anti-rabbit scintillation proximity 
assay (SPA) beads were added to each well and incubated for 24h at RT before using a 
β-scintillation counter. The corticosterone concentration in each sample was determined 
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2.3.10. Carrageenan-induced pleurisy  
Carrageenan-induced pleurisy is a well-established model of acute inflammation. 
(Cuzzocrea et al., 1999; Frode-Saleh & Calixto, 2000; Salvemini et al., 2001) 
Carrageenan is an Irish sea-moss and injection of it into the pleural cavity induces 
neutrophilia at the injection site and development of biphasic sub-pleural inflammation 
(Vinegar et al., 1976). The mechanism leading to influx of neutrophils into the pleural 
cavity is uncertain. This cavity model of inflammation is self limiting and usually 
resolves within 48h. It is a similar model to sterile peritonitis, allowing straightforward 
extraction of inflammatory cells from the pleural cavity by lavage. The model is 
characterized by recruitment of phagocytic cells to the intra-pleural cavity, commencing 
with a rapid influx of neutrophils (initiated at 1h after injection of carrageenan (Vinegar 
et al., 1976), followed by monophasic monocyte mobilization.  
 
2.3.10.1. Induction of pleurisy 
Carrageenan-induced pleurisy was induced as previously described (Vinegar et al., 
1976; Vinegar et al., 1982; Gilroy et al., 1999) by Dr Deborah Sawatzky or Mr Michael 
(Spike) Clay (both from MRC Centre for Inflammation Research). Briefly, male mice 
were anesthetized with i.p injection of isoflurane and a small incision was made between 
the 6th and 8th intercostal muscles, 100µl of 0.1% λ-carrageenan (Marine Colloids Inc, 
USA) in PBS was injected using a blunted needle and the wound was closed using the 
autoclip system. All injections occurred between 8am and 10am. Mice were killed and 
cells and tissues were collected at various time points (4h, 24h, 48h and 72h following 
intra-pleural injection) by lavaging the intra-pleural cavity using 1ml of PBS. Entire 
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thorax, or lung tissue only, was dissected and fixed in 10% formalin for subsequent 
histology. The process of pleural lavage is invasive and occasionally results in samples 
contaminated with blood. Red blood cell contamination affects the measurement of the 
recruited leukocyte number. Accordingly, bloody pleural lavages were excluded from 
cell counts for this reason. 
 
 
2.3.10.2. Assessment of pleural inflammation 
Comparative assessment of inflammation between Hsd11b1-/- and Hsd11b1+/+ mice was 
achieved by measuring exudate volume, and total cell number (by haemocytometer). 
Greater infiltration of cells was used to infer greater inflammation. Flow cytometry was 
used to quantify percent of apoptotic and necrotic cells as well as cell types (using 
inflammatory cell markers described in Section 2.3.16.). In addition, cytospins (Section 
2.3.12.) were prepared to confirm cell identification and ratio. Histological assessment 
of lungs was performed by Dr David Brownstein to identify the degree of tissue damage 
at various stages of disease (Section 2.3.10.3.). 
 
2.3.10.3. Cytokine measurements (ELISA and CBA kit) 
Cytokine levels were determined using a cytometric bead assay (CBA) mouse 
inflammation kit (BD Biosciences, Oxford, UK) which simultaneously measures IL-6, 
IL-10, IL-12p70, MCP-1, IFN-γ and TNF-α. Samples were diluted in assay diluent 
(supplied with the kit), mixed thoroughly and transferred into assay tubes containing 
50µl mixed capture beads and 50µl of the Mouse Inflammation PE Detection Reagent 
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(supplied with the kit). Samples were then incubated in the dark for 2h at RT, washed 
with wash buffer (supplied with the kit) and the supernatant discarded. The bead pellet 
was re-suspended in 300µl of wash buffer and samples were analyzed by flow cytometry 
(BD FACArray Bioanalyser) and analysis was performed using BD FACSComp 
Software. Using the provided standards, the concentration of each cytokine was 
calculated from a standard curve for each protein, this covered a defined set of 
concentrations from 20 – 5000pg/ml). 
 
A general protocol for DuoSet ELISA kit (R&D Systems, Abingdon, UK) was used to 
measure cytokines individually. Briefly, a 96-well plate was coated overnight with 
capture antibody (diluted according to manufacturer’s instructions), washed and 
incubated with 300µl block solution (PBS with 1% BSA and 5% sucrose) for a 
minimum of 1h at RT. 100µl of provided standards or samples were added to wells and 
incubated at RT for 2h. Plates were then washed with PBS (containing 0.05% Tween20) 
and the detection antibody (diluted according to manufacturer’s instructions) was added 
and incubation carried out at RT for a further 2h. The plates were washed again and 
incubated with 100µl of streptavidin horseradish peroxidase (HRP) (diluted according to 
manufacturer’s instructions) for 20min at RT in the dark. After a final wash, 100µl of 
peroxidase substrate solution (SureBlue Reserve, KPL, Gaithersburg, MD, USA) was 
added to each well and incubated for another 20min in the dark. The reaction was 
stopped by adding 100µl of stop solution (0.6M H2SO4) to each well and absorbance at 
450nm was determined using a microplate reader. 
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2.3.10.4. Histological assessment 
For lung histology, previously fixed thorax (in 10% formalin) from each mouse was 
washed in 15ml 5% nitric acid for 3h at RT to decalcify the ribs. Each sample was then 
placed with the dorsal side of the thorax face down in cryostat cassettes and embedded 
in hot wax. 3-5µm sections were cut from embedded samples using a microtome and 
mounted on glass slides. Alternatively, isolated lungs fixed in 10% formalin were 
paraffin-embedded and sectioned without the process of decalcification. Sections were 




2.3.11. RNA Extraction and Analysis 
 
2.3.11.1. RNA extraction 
Only autoclaved glassware and tubes were used and all equipment was treated with 
RNaseZap to protect RNA samples from contamination and degradation by nucleases. 
Solutions were made with DEPC H2O or were used from previously unopened nuclease-
free stocks. To isolate RNA from cells in suspension, the cells were centrifuged (300g at 
4C, 5min) (Labofuge 400R Centrifuge) and the pellet re-suspended in TRIzol 
(Invitrogen) at 5x106 cells/ml. TRIzol reagent allows one-step isolation of RNA based 
on a modified Chomczynski and Sacchi method of RNA extraction using guanidium 
thiocyanate (Chomczynski & Sacchi, 1987). 200µl of chloroform was added per 1ml of 
TRIZOL and vortexed. Following centrifugation (7,500g at 4C, 5min) to separate the 
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phases, the aqueous phase was carefully removed so as not to disturb the DNA-
containing interface or the lower protein-containing phenol-choloform phase and 
transferred to a fresh tube. 500µl of isopropanol was added and left for 10min at RT. 
RNA was recovered by centrifugation and the RNA pellet was washed in 80% ethanol 
by vortexing and centrifugation (7,500g at 4C, 5min). After heating at 70ºC for 2-3min 
the pellet was dissolved in 30µl DEPC H2O. 1µl was removed for quantification and the 
remaining sample was stored at 80C until required. 1l RNA solution diluted in 99l 
DEPC H2O was used to assess RNA purity and concentration by UV absorbance at 
wavelengths of 260nM and 280nM using the GeneQuant RNA/DNA calculator 
(Pharmacia Biotech, UK). A ratio of >1.8 indicated RNA free of protein and not de-
purinated. 
  
2.3.11.2. Reverse transcription  
Reverse transcriptase was used to produce single-stranded cDNA from total RNA. Using 
Invitrogen’s Superscript III reverse transcriptase system (Invitrogen), 20l reactions 
were prepared containing 0.5g total RNA, 1l 10mM dNTPs, 1l Random Primers 
(Promega Corporation, Wisconsin, USA). Using a thermal cycler (Genius, Techne) 
reactions were incubated for 5min at 65C then immediately placed on ice for ≥1min. 
The contents were collected by brief centrifugation and 4l of 5x First-Strand Buffer 
(supplied with the kit), 1l 0.1M DTT, 1l 1U/l RNasin (ribonuclease inhibitor) and 
1l 200U/l SuperScript III reverse transcriptase were added before the samples were 
incubated at 25C for 5min then 50C for 1h. Finally, the reaction was heated at 70C 
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for 15min to inactivate the reverse transcriptase and then rapidly cooled to 4C. 
Negative controls contained DEPC H2O instead of either reverse transcriptase or total 
RNA and were performed in parallel. 
 
2.3.11.3. Polymerase Chain Reaction (PCR) 
GoTaq DNA Polymerase kit (Promega Corporation) was used to amplify cDNA by 
PCR. The following components were combined in a 0.5ml PCR reaction tube in H2O 
for a total vol of 50l per single reaction; 1l cDNA (product of reverse transcription 
reaction obtained as described above), 5l 5X DNA polymerase reaction buffer 
(supplied with the kit) containing 1.5mM MgCl2, 0.5l of 10mM dNTP and 1l of each 
primer (see bellow). Finally, 0.25l of GoTaq DNA polymerase (supplied with the kit) 
enzyme was added. Negative controls contained H2O instead of cDNA. 
 
The PCR conditions were: 95°C for 5min for an initial denaturation, then 95°C for 30s, 
60°C for 30s, 72°C for 1.5min for a total of 35 cycles. The cycles were followed by 
7min extension at 72°C and then were held at 4°C until retrieval. The products were 
mixed with 1l of loading buffer and electrophoresis was carried out on a standard 1% 
Agarose/TBE gel containing 0.005% ethidium bromide (EtBr) at 100-150V for 30-
45min. DNA size markers were included to confirm the size of amplified products. The 
gel was viewed on a transilluminator at 260nm. 
 
 






11β-HSD1 PCR reactions used a common reverse primer complementary to exon 6, 
868P 5'-AGGATCCAG/AAGCAAACTTGCTTGCA-3' (Rajan et al., 1995),  and one of 
the following forward primers:  
 
869P in exon 3 (Rajan et al., 1995), common to all 11β-HSD1 transcripts:  
869P 5'-AAAGCTTGTCACA/TGGGGCCAGCAAA-3'   (469bp) 
 
OR one of the 3 forward primers for one of the 3 promoters: 
 
P1, 5'-GGAGCCGCACTTATCTGAA-3'   (627bp) 
 
P2, 5'-GGAGGTTGTAGAAAGCTCTG-3'   (647bp) 
 
P3, 5'-GTATGGAAAGCAAGACAAGG-3'   (542bp) 
 
11β-HSD2  forward 5'-CTGAAGCTGCTGCAGATTGGAT- 3'  
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2.3.12. Centrifugation of cells 
Samples of freshly isolated primary cells or cultured cells (2x105) were suspended in 
120µl PBS containing 10% FCS, then centrifuged for 3min at 300rpm onto SuperFrost 
plus slides (VWR International) using a Cytocentrifuge (Shandon 3, UK). Slides were 
then allowed to air dry and were fixed in freshly prepared 90% acetone/10% methanol 
(v/v) for 10min at RT. Alternatively, dried slides were stained in a 3-stage process; 1) 
slides were dipped in methanol for 2min, then 2) slides were placed in Dade Diff-Quick 
Red (Dade Diagnostica, Siemens Healthcare Diagnostics, New York, USA) for 1min, 
and lastly 3) slides were dipped for 30s in Reastain Diff-Quick Blue (Dade Diagnostica) 
then rinsed in H2O.  
 
 
2.3.13. Immunohistochemistry (IHC) 
All IHC procedures were carried out at RT and PBS supplemented with 0.05% Tween20 
was used as wash buffer unless otherwise stated. Sections of tissues embedded in 
paraffin were de-waxed prior to staining by double immersion in xylene for 1min and 
5min, then in ethanol (100%, 95%, 85% and 75% for 1min each), and finally in H2O. 
Generally, for HRP staining, slides were soaked first in peroxidase block (2% H2O2 in 
100% methanol) for 10min then briefly washed in a bath of PBS. Slides were then 
loaded into a Sequenza unit in PBS, and each slide was incubated with 3 drops of Vector 
Avidin/Biotin block (Vector, Burlingame, CA, USA) for 10min each and washed with 
PBS (2x 5min). 125µl protein block (Dako Cytomation, Cambridgeshire, UK) was 
added for 10min, followed by primary antibody diluted in Dako diluent (Dako 
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Cytomation) (125µl total volume) for 1h at RT or overnight at 4ºC. Slides were then 
washed twice with PBS and secondary antibody, appropriately diluted in Dako diluent 
(125µl total volume), was applied for 30min at RT. Slides were again washed twice with 
PBS and incubated with 3 drops of Vector ABC RTU (Vector, Burlingame, CA, USA) 
for 30min, washed again and incubated with 125µl diaminobenzidine (DAB) colour 
reagent (Dako Cytomation) for 5min in the dark. Finally, slides were washed, transfered 
to a staining rack, counterstained in haematoxylin (10s to 30s, then washed in Scots 
H2O) and mounted with cover slip (Chance Propper Ltd., Warley, UK). 
 
For 11β-HSD1 HRP staining the primary antibodies used were: a) polyclonal rabbit-anti-
11β-HSD1 (Cayman Chemical Company, Ann Arbor, MI, USA) (used at 1:100) or b) 
polyclonal sheep-anti-11β-HSD1 (gift from Dr Scott Webster) (1:1000). Secondary 
antibodies were: a) polyclonal goat-anti-rabbit (Dako) (1:400) and b) rabbit-anti-sheep 
(Upstate Cell Signaling Solutions, New York, USA) (1:1000). Sheep IgG and rabbit IgG 
isotype controls (gift from Dr Jeremy Brown) were used at 1:1000. 
 
For immunofluorescent staining, slides were soaked first in PBS for 5min and then 
loaded into a Sequenza unit and blocked with PBS (containing 0.05% Tween and 10% 
mouse serum) for 15-30min at RT. 125µl primary antibody, at the dilution given above 
for 11β-HSD1 or with MC markers antibodies (mMCP-2, 1:500; or mMCP-6/7, 1:100) 
(gift from Dr Jeremy Brown) for 1h at RT or overnight at 4ºC. Sheep-anti-mouse IgG 
and rabbit-anti-mouse IgG isotype controls were used at 1:1000. Slides were washed 
twice with PBS and 125µl secondary antibody was added: fluorescein isothiocyanate 
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(FITC) conjugated donkey-anti-sheep (1:100) or rhodamine red-x conjugated donkey-
anti-rabbit (1:200) (both from Jackson Immuno Research Laboratories, Inc., USA). 
Tissue sections were dehydrated following staining by brief soaking in 95% then 100% 
ethanol, cleared in xylene and mounted with a cover slip using resinous mounting 
medium. 
 
2.3.13.1. In-house 11β-HSD1 antibody  
Total protein from liver, lung and kidney from Hsd11b1-/- and Hsd11b1+/+ mice was 
used in western blot analysis (Section 2.3.13.2.) of 11β-HSD1 expression. Using the in-
house, sheep derived antibody (generated by Dr Scot Webster and purified by Dr Sophie 
Turban and Mr Fu Yang) a band of the size expected for 11β-HSD1 (34kDa) was clearly 
detected in samples from the Hsd11b1+/+ mice. However, only a faint band was seen for 
the Hsd11b1-/- mice, in lung only (Figure 2.1.). The intensity of the 11β-HSD1 band (in 
liver samples from Hsd11b1+/+ mice) was reduced when the antibody was pre-incubated 
overnight with the mouse recombinant protein against which the antibody was raised 

















    
 
Figure 2.1 In-house 11β-HSD1 antibody detects 11β-HSD1 protein in control mice.  
Western blot technique was used to detect 11β-HSD1 protein expression in liver, lung 
and kidney tissue from untreated Hsd11b1-/-(-/-) and Hsd11b1+/+ (+/+) mice using sheep-
anti-mouse 11β-HSD1 antibody (primary antibody used at 1:1000 dilution, HRP 
conjugated secondary anti-sheep antibody used at 1:2000 dilution). 24µg of total protein 
was loaded per well. 1a shows the 34kDa protein band, which is likely to be a doubly-
glycosylated protein, whilst 1b is likely to be mono-glycosylated protein, which is most 
visible in the Hsd11b1+/+ liver samples. Samples were prepared by homogenization of 
tissues from two separate Hsd11b1-/- and Hsd11b1+/+ mice (shown side by side for each 
genotype, per tissue). Overnight pre-incubation with the 11β-HSD1 recombinant protein, 
against which the antibody was raised, significantly reduced the antibody signal (A2) in 
liver samples from two Hsd11b1+/+ mice in comparison to the same liver samples 
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2.3.13.2. Western Blot   
Frozen tissues were homogenized on ice using cold buffer (100g glycerol, 300mg Tris, 
186mg EDTA, and 7.7mg DTT made up to 500ml in H20, pH to 7.5). Total protein 
concentration was determined using BioRad protein assay (BioRad Laboratories, UK) 
and 24µg of total protein was loaded per well. SeeBlue Plus2 pre-stained standards 
(Invitrogen) were used as size markers. Invitrogen’s XCell II Blot Module was used to 
separate and transfer the proteins using NuPAGE Novex Bis-Tris gel according to 
manufacturer’s instructions. Briefly, the gel was run at 200V for ~45min in NuPAGE 
MES running buffer and transferred in NuPAGE transfer buffer on to a nitrocellulose 
membrane (Invitrogen) at 30V for ~1h. Immediately after protein transfer, the 
membrane was placed in 20 ml of blocking solution (5% non-fat dry milk in PBS) and 
incubated with gentle shaking for 1-2h at RT. Incubation with primary antibody was 
performed overnight at 4C. Following incubation with the primary antibody, the 
membrane was washed 3 times at RT with wash buffer (PBS + 0.1% Tween-20) for 
15min per wash. The membrane was incubated with the secondary antibody in blocking 
solution with gentle shaking for 1-2h at RT. Following incubation with the secondary 
antibody, the membrane was washed 4 times at RT with wash buffer (same as above) for 
15min per wash. The membrane was developed using chemiluminescence detection kit 
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2.3.14. Toluidine blue staining  
Toluidine blue (which stains sulfated polysacharides purple) results in metachromatic 
staining of MC, while staining the remaining background (orthochromatic staining) light 
blue. Deparaffinized, re-hydrated sections (Section 2.3.13.) were stained in toluidine 
blue working solution (listed in materials) for 2-3min at RT, then washed three times in 
H2O. Stained slides were dehydrated by briefly dipping slides in 95% and 100% ethanol, 




2.3.15. Bone marrow transplantation (BMT) 
BMT experiment was carried out by Ms Kay Samuel. 7d prior to irradiation, the H2O 
supply of recipient mice was supplemented with antibiotics (Baytril and Borgal 24% 
(trimethoprim-sulpha), provided by BRF, WGH). Mice were lethally irradiated using a 
γ-Cell 40 irradiator (MDS Nordian GammaCell 40E, 137Cs source) using a dose of 
1050R (10.50Gy) for 10min. A single cell suspension of donor BM (107 cells in 200µl 
PBS) was prepared for intra-venus (i.v.) injection into recipient mice in a 1ml syringe 
fitted with a 25G needle (collection of BM was the same as in Section 2.3.4.). Following 
the irradiation, recipient mice were warmed in a ‘hot box’ (37ºC) for 10-15min to dilate 
the tail vein prior to injection. A physical restraint (plastic tube) was required to hold the 
mouse still during injection. Antibiotics were discontinued 28d later and mice were used 
for arthritis experiments after 56d, when the reconstitution of recipient mice should be 
complete.  
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2.3.16. Flow cytometry 
Prior to flow cytometric analysis, cells in polystyrene tubes were incubated on ice for 
30min in PBS with 10% mouse serum (to block non-specific binding). In general, 
conjugated antibodies were added to the cells at concentrations suggested by the supplier 
and incubated on ice for 30min in the dark. The cells were washed in 2ml PBS and 
recovered by centrifugation at 300g for 5min with 400l PBS prior to analysis. Specific 
and non-specific fluorescence was determined by processing ≥5000 cells/sample through 
a FACScan or FACScalibur (Becton Dickinson, Oxford, UK) machine, using Cellquest 
software (Becton Dickinson). The following antibodies were used at 1:100 dilution 
(eBiosciences, UK unless otherwise stated): CD11b conjugated to FITC, GR-1 
phycoerythrin (PE), c-kit PE, B220 (mouse CD45R) PE, F4/80 allophycocyanin (APC) 
and F4/80 PE (Caltag, UK). Data analysis was performed using CellQuest (Becton 
Dickinson, UK) as well as FlowJo software (Treestar, Oregon, USA). Antibody 
specificity and reactivity can vary and the assessment of cell number is dependent upon 
the positioning of the gates. For this reason, the same gates were used for each sample in 
order to minimize variation due to this potentially confounding issue (shown in Chapter 
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2.3.17. Assessment of vascular permeability with Evan’s Blue Dye 
A preliminary experiment was conducted using C57BL/6 mice in order to determine 
whether an i.v. injection of 200µl of 1% Evan’s Blue was measurable in peritoneal 
lavages, and whether the concentration of dye in the peritoneum changed over the course 
of peritonitis. A sample of blood was also collected (via cardiac puncture following 
Schedule 1 cull) in order to measure Evan’s Blue concentration in the circulation. 
Circulating Evan’s Blue levels were used as a marker of total Evan’s Blue injected per 
animal to standardize all data. Based on results from 4 mice (n=1 per time point) Evan’s 
Blue was detectable (absorbance of 620nm) following i.p. injection of PBS only (optical 
density (OD) 0.022) and increased in concentration at 4h (OD 0.048), 1d (OD 0.049) 
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2.3.18. Mast cell degranulation 
 
Total peritoneal cells were obtained by peritoneal lavage (as described above, Section 
2.3.1.) from Hsd11b1-/- and Hsd11b1+/+ male and female mice. Cell pellets (containing 
2x10^6 cells per sample) were re-suspend in 50µl of Tyrode’s buffer (10 mM Hepes 
buffer (pH 7.4), 130mM NaCl, 5mM KCl, 1.4mM CaCl2, 1mM MgCl2, 5.6mM glucose, 
0.1% BSA) alone or with K/BxN serum or other secretagory peptides, and incubated for 
15min at 37°C. The release of the granule enzyme β-hexosaminidase was measured as 
previously described (Razin et al 1984). Briefly, following incubation the samples were 
centrifuged at 5000rpm for 3min and 5µl aliquots of the supernatant were transferred to 
wells (96-well plate) in triplicate. The remaining supernatant was carefully removed and 
the cell pellets were solubilized with 50µl Tyrode’s buffer + 0.5% Triton X-100. 
Following solubilization of the pellet 5µl aliquots were transferred into wells in 
triplicate. Next, 50µl of substrate solution (1.3 mg ml-1 p-nitrophenyl-N -acetyl-b-D-
glucosamine (Sigma) in 0.1M sodium citrate, pH 4.5.) was added to each well and 
incubated for 40min at 37°C. To stop the reaction 50µl of stop solution (0.2M glycine, 






% degranulation =             OD supernatant                            X 100 
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2.3.19. Statistics 
Statistical analysis was performed using GraphPad Prism 4.00 software with P≤0.05 as 
the criterion for statistical significance. All data are expressed as mean ± standard error 
of mean (SEM). Data were analysed by Student’s t-tests, Analysis of Variance 
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3.1. Introduction 
Previous experiments using a model of sterile peritonitis suggested a more severe 
inflammatory response in Hsd11b1-/- mice, with greater recruitment of inflammatory 
cells than in control (Hsd11b1+/+) mice (Gilmour, 2002). However, inflammation 
resolved at a similar time in both Hsd11b1-/- and Hsd11b1+/+ mice. Carrageenan-induced 
pleurisy represents an alternative, and perhaps more physiologically relevant 
experimental model of inflammation than thioglycollate-induced peritonitis (Chapter 2, 
Section 2.3.1.). As in peritonitis, this model allows for isolation and analysis of recruited 
inflammatory cells at the onset, peak and resolution stages of inflammation. However, 
unlike the peritonitis model, the pleurisy model also allows histological analysis of lung 
tissue following induction of inflammation. Injection of carrageenan induces a single, 
monophasic mobilization of neutrophils and monocytes during the acute phase of 
inflammation which normally resolves, or at least starts to clear, by 48h. The 
experiments described in this chapter were carried out in collaboration with Dr Deborah 
Sawatzky, who helped with the methods and analysis of the first experiment (Study 1) 
and Mr Michael (Spike) Clay, who performed the intra-pleural injections and assisted 











3.2.1. More inflammatory cells are recruited in Hsd11b1-/- mice than in Hsd11b1+/+ 
mice during carrageenan-induced pleurisy 
 
Study 1 
Intra-pleural lavages (with 1ml sterile PBS) were carried out on Hsd11b1-/- and 
Hsd11b1+/+ mice at 4h, 24h and 48h following injection of carrageenan. Significantly 
more inflammatory cells were recruited in Hsd11b1-/- mice than in Hsd11b1+/+ mice 
both at the early stage (4h) and peak stage (24h) of inflammation (Figure 3.1). No 
difference was seen at 48h between genotypes. Oedema was assessed by weighing the 
collected lavages. There was no difference in lavage volume between Hsd11b1-/- and 
control mice at any time point: 4h (Hsd11b1-/-; 1.06±0.04ml versus Hsd11b1+/+; 
0.97±0.07ml, p>0.05), 24h (Hsd11b1-/-; 1.01±0.02ml versus Hsd11b1+/+; 0.93±0.05ml, 
p>0.05) or 48h (Hsd11b1-/-; 1.0±0.03ml versus Hsd11b1+/+; 1.0±0.06ml, p>0.05).  
 
Because inflammation had failed to resolve as expected at 48h (in both genotypes), a 
subsequent time point (72h) was examined in a separate experiment. However, at 72h 
more cells were recovered from both Hsd11b1-/- and control mice than were recovered at 
any time point in the initial experiment, and similar to the earlier time points, there were 
significantly more cells present in lavages from Hsd11b1-/- than those from Hsd11b1+/+ 
mice (Figure 3.2). The lavage volume was similar between the genotypes (Hsd11b1-/-; 
0.8±0.06ml versus Hsd11b1+/+; 0.83±0.06ml). A subsequent health report revealed the 
presence of Pasteurella pneumotropica in the animal facility (Western General Hospital, 
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Edinburgh) at this time, providing a likely explanation for the exaggerated inflammatory 
response at 72h in both genotypes of mice (see Discussion below). Accordingly, no 
further analysis was carried out on the 72h time point. 
 
Study 2 
To address whether the differences seen between genotypes at 4h and 24h, and the lack 
of signs of resolution at 48h were confounded by an underlying sub-clinical lung 
infection, a second study was carried out at a later date in a separate animal facility 
(New Royal Infirmary, Edinburgh). Unfortunately, lavages from 4h and 48h following 
carrageenan injection contained too many red blood cells (RBC) to properly assess cell 
numbers microscopically, and it was only possible to count cells from the 24h time 
point, confirmed greater cell recruitment in Hsd11b1-/- than in Hsd11b1+/+ mice 
(Hsd11b1-/-; 3.0±0.4x107 versus Hsd11b1+/+;1.9±0.3x107, p<0.05). Nonetheless, the 
cells from all three time points in the second experiment were used for flow cytometry 







































Figure 3.1 Hsd11b1-/- mice show a more severe inflammatory response during the 
acute and peak stages of carrageenan-induced pleurisy.  
In Study 1, following intra-pleural injection of carrageenan (100µl of 0.1% 
carrageenan), significantly more inflammatory cells (expressed per ml) were recovered 
from Hsd11b1-/- (white bars) than Hsd11b1+/+ mice (black bars) at 4h, and 24h 
(n=7/genotype). Similar numbers of cells were recruited in both genotypes at 48h 































Figure 3.2 Hsd11b1-/- mice show a more severe inflammatory response at 72h 
following injection of carrageenan.  
In Study 1, 72h following intra-pleural injection of carrageenan (100µl of 0.1% 
carrageenan) mice of both genotypes had elevated numbers of inflammatory cells 
(expressed per ml), with significantly more cells in Hsd11b1-/- (white bar) than 
Hsd11b1+/+ mice (black bar) (n=6/group). Values shown are mean ± SEM. * p<0.05, 
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3.2.2. Assessment of phenotype of intra-pleural inflammatory cells 
Study 1 
Differential cell counts were carried out on cells recovered from lavage fluid. Based on 
microscopic observation of Quick-Diff stained cytocentrifuged cells, there was no 
difference between genotypes in the proportion of cell types (neutrophils, monocytes 
and M) elicited into the intra-pleural cavity 4h following carrageenan injection (Figure 
3.3). Cytocentrifuged cells from later time points (24h and 48h) contained clumps 
making distinction of individual cells, and counting, extremely difficult and inaccurate 
(data not shown).  
 
Study 2 
In the second carrageenan experiment, flow cytometry (Chapter 2, Section 2.3.16.) was 
used to quantitate and characterize recruited cells using antibodies (anti-F4/80 and anti-
Gr-1) which should label the vast majority of these cells (neutrophils, monocytes and 
M. This additionally had the advantage of obtaining specific counts despite a large 
number of RBC being present. At 4h and 24h, Hsd11b1-/- mice had more Gr-1+/F4/80+ 
cells than Hsd11b1+/+ mice (Figure 3.4.A). Whilst no difference between genotypes was 
found in the Gr-1+/F4/80+ subpopulation at 48h, Hsd11b1-/- mice showed a higher 
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Figure 3.3 Similar inflammatory cell types were recruited in Hsd11b1-/- and 
Hsd11b1+/+ mice at 4h after carrageenan injection.  
(A) Relative numbers of cell types were assessed microscopically (blind to genotype), 
by counting Diff-Quick stained cytocentrifuged cells prepared from Hsd11b1+/+ and 
Hsd11b1-/- mice from Study 1. (B) Two-way ANOVA did not reveal differences in cell 
types recruited between Hsd11b1-/- (white bars) and Hsd11b1+/+ (black bars) mice. 


























4h 48h24h  






























Figure 3.4 Greater Gr-1+ F4/80+ sub-population of intra-pleural cells extracted 
from Hsd11b1-/- than Hsd11b1+/+ mice at 4h and 24h.  
(A) In Study 2, flow cytometry revealed more Gr-1+/F4/80+ cells in intra-pleural lavages 
from Hsd11b1-/- (white bars) than Hsd11b1+/+ mice (black bars) at 4h and 24h after 
carrageenan injection. At 48h, Hsd11b1-/- mice had more Gr-1+ F4/80- cells than 
Hsd11b1+/+ mice (B), but no difference was seen in the Gr-1+ F4/80+ population at this 
time. Values shown are mean ± SEM. * p<0.05 when compared by Two-way ANOVA 
(A) or unpaired Student’s t-test (B). Analysis was based on gating using unstained cell 
samples (C). (D) Representative image of dot plot from 4h lavage from Hsd11b1-/- 








Chapter 3. Carrageenan-Induced Pleurisy 
 79
3.2.3. Altered viability of  intra-pleural inflammatory cells from Hsd11b1-/- mice  
Study 1 
Viability of intra-pleural inflammatory cells was assessed by flow cytometry. Following 
recovery from lavages, cells were labeled with annexin V to detect apoptotic cells and 
propidium iodide (PI) which stains necrotic cells. The proportion of cells undergoing 
apoptosis 4h and 48h after injection of carrageenan was lower in Hsd11b1-/- mice 
compared to Hsd11b1+/+ mice (Figure 3.5.A). The proportion of cells which were 
apoptotic did not differ between genotypes at 24h. Hsd11b1-/- mice also had a lower 
proportion of cells that were necrotic at 4h (Figure 3.5.B). As a result the proportion of 
viable cells was greater in Hsd11b1-/- mice at 4h and 48h (Figure 3.4.C). Because the 
total number of cells was greater in Hsd11b1-/- mice at 4h and 24h, the number of viable 
























































Figure 3.5 In study 1, more viable inflammatory cells were recovered from intra-
pleural lavages of Hsd11b1-/- mice than of Hsd11b1+/+ mice at 4h and 24h.   
Proportion of apoptotic (A) and necrotic (B) cells recovered at 4h, 24h, and 48h after 
injection of carrageenan, resulting in greater percent of viable cells (C) (at 4h and 48h), 
contributing to an overall greater number of cells (D) in lavages collected from 
Hsd11b1-/- (white bars) than Hsd11b1+/+ mice (black bars) (n=7/genotype/time point). 
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Study 2 
Cell viability was measured in sub-populations of cells which were determined by flow 
cytometry using Gr-1 and F4/80 cell markers. Thus, PI and Annexin V were analyzed in 
individually gated sub-populations (Figure 3.6). At 4h and 48h there was no difference 
in cell viability between the genotypes when comparing the total cell population (gating 
around all cells in sample), and only at 24h were there more viable cells (actual number) 
in Hsd11b1-/- than in Hsd11b1+/+ mice (Hsd11b1-/-; 2.7x107±0.4 vs Hsd11b1+/+; 
1.7x107±0.3). However, for all time points there was a significantly higher proportion 
(Figure 3.7.A) and number (Figure 3.7.B) of viable cells in the Gr-1+ F4/80+ sub-
population of intra-pleural cells in Hsd11b1-/- than in Hsd11b1+/+ mice. No differences 
in cell viability between genotypes were noted at any time point in the Gr-1- F4/80- sub-
population (data not shown). Taken together, results from both pleurisy studies suggest a 
higher number of viable inflammatory cells, present in the lavages from Hsd11b1-/- mice 







Figure 3.6 PI and Annexin V staining of pleural inflammatory cells.  
Representative flow cytometry plots showing PI (y axis) and Annexin V (x axis) 
analysis of unstained cells (left), Hsd11b1+/+ mice (middle) and Hsd11b1-/- mice (right). 
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Figure 3.7 In study 2, more viable Gr-1+ F4/80+ cells were present in lavages from 
Hsd11b1-/- mice than from Hsd11b1+/+ mice at all time points during pleurisy.  
Hsd11b1-/- mice (white bars) had higher percent (A) and total number (B) of viable Gr-
1+ F4/80+ cells than Hsd11b1+/+ mice (black bars) at 4h, 24h, and 48h following 
injection of carrageenan. (n=7/genotype/time point). Values shown are mean ± SEM. 
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3.2.4. Resolution of lung inflammation is altered in Hsd11b1-/- mice  
 
Histological assessment of lungs from untreated mice or mice sacrificed 4h, 24h, or 48h 
following intra-pleural injection of carrageenan (Study 1 and 2) was performed blind to 
genotype by an expert rodent pathologist, Dr David Brownstein. There were no 
differences in lung histology between untreated Hsd11b1+/+ and Hsd11b1-/- mice (data 
not shown). At 4h following injection of carrageenan, there was noticeable inflammation 
in both genotypes with thickened visceral pleura (due to enlarged and/or activated 
mesothelial cells) and infiltration of inflammatory cells (dominated by neutrophils) 
(Figure 3.8). There was substantial histological variability within groups at 4h, and 
accordingly it was not possible to ascertain any difference in severity of inflammation 
between the genotypes. Although by 24h inflammation had worsened compared to 4h, in 
both genotypes, there was variability within groups with no clear qualitative or 
quantitative difference between genotypes. The visceral pleura were thicker and 
lymphoid aggregates (comprised of plasma cells, lymphocytes, neutrophils and M) 
were apparent within the mediastinum to a similar extent in both genotypes (Figure 3.9). 
Interestingly, while at 24h the lymphoid aggregates appeared similar between both 
genotypes (Figure 3.10, A and B), inflammation began to resolve in Hsd11b1+/+ mice 
48h after injection of carrageenan, yet was still in progress in Hsd11b1-/- mice (Figure 
3.10, C and D). The ongoing inflammation in Hsd11b1-/- mice was not only evident by 
the continued presence of lymphoid aggregates (Figure 3.10) which had largely 
disappeared in Hsd11b1+/+ mice, but also by continued thickened peri-oesophageal 
mediastinum (Figure 3.11) and visceral pleura (Figure 3.12). Importantly, adhesion of 
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lung lobes was observed only in Hsd11b1-/- mice at 48h, a qualitative difference between 






























Figure 3.8 4h following injection of carrageenan inflammation is noticeable in both 
genotypes with thickened visceral pleura and enlarged mesothelial cells.  
Representative histology images showing lungs from a control Hsd11b1+/+ mouse (A, 5x 
original magnification) and mesothelial cells (B, 100x original magnification) at 0h and 
4h following intra-pleural injection of carrageenan (100µl of 0.1% carrageenan). Lung 
sections from 0h were similar in both genotypes. At 4h, both genotypes exhibited similar 
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Figure 3.9 Lymphoid aggregates in lung sections at 24h following injection of 
carrageenan in mice from both genotypes.  
Representative image of lung section from a Hsd11b1+/+ mouse at 24h (A, 5x original 
magnification) following intra-pleural injection of carrageenan (100µl of 0.1% 
carrageenan). The thickening of visceral pleura (B, 100x original magnification) and 
formation of lymphoid aggregates (C; arrows indicate lymphoid aggregates, 50x original 
magnification) in the mediastinum was similar in the two genotypes. The lymphoid 
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Figure 3.10 Ongoing inflammation in Hsd11b1-/- mice at 48h following carrageenan 
injection.  
Intensity of lymphoid aggregates is similar in Hsd11b1+/+ mice (A) and Hsd11b1-/- mice 
(B), 24h following intra-pleural injection of carrageenan (upper panels). At 48h (lower 
panels), more evidence of resolution of inflammation is seen in the Hsd11b1+/+ mice (C) 






















Figure 3.11 Greater peri-oesophageal mediastinum thickening with worse 
inflammation in Hsd11b1-/- mice.  
Representative histology image of lungs from Hsd11b1+/+ (A and C, ) and Hsd11b1-/- (B 
and D) mice 48h following intra-pleural injection of carrageenan. There is persistence of 
peri-oesophageal mediastinum thickening with worse inflammation in Hsd11b1-/- (D) 




















Figure 3.12 Persistent thickening in visceral pleura in Hsd11b1-/- mice.  
Representative images of visceral pleura at 48h following intra-pleural injection of 
carrageenan. There is persistent thickening in visceral pleura in Hsd11b1-/- mice (B) that 
is not seen in the controls (A). Images are 50x original magnification. Arrow heads 
indicate mesothelial cells that line the pleura. 
 
 











Figure 3.13 Adhesion of lung lobes 48h following intra-pleural injection of 
carrageenan in Hsd11b1-/- mice. 
Representative images of lung section from Hsd11b1-/- mice (images from sections taken 
from 2 separate Hsd11b1-/- mice) showing adhesion of lung lobes 48h following intra-
pleural injection of carrageenan. Adhesion of lung lobes was seen uniquely in Hsd11b1-/- 
mice (A and B) and not in the controls (not shown). Images are 50x original 
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3.2.5. Lung cytokine profiles during carrageenan-induced pleurisy 
Previously, differences in cytokine release have been shown between Hsd11b1-/- and 
Hsd11b1+/+ mice (Gilmour et al., 2006; Zhang & Daynes, 2007). Therefore, to determine 
whether cytokine responses to carrageenan-induced pleurisy differed between 
Hsd11b1+/+ and Hsd11b1-/- mice, IL-6, IL-10, IL-12p70, MCP-1, IFN-γ and TNF-α 
cytokine levels were measured in pleural exudates from Study 1 using a cytometric bead 
assay (CBA) mouse inflammation kit. In both genotypes, TNF-α levels were highest at 
4h and although there was a trend for TNF-α to be higher in Hsd11b1-/- mice, it did not 
reach statistical significance (Figure 3.14). Similarly, IL-6 levels were highest at 4h, 
with much lower levels at 24h and undetectable levels at 48h and 72h and did not differ 
between genotypes at any time point (Figure 3.14). INFγ, IL-12p70 and IL-10 all peaked 
at 24h, and whilst INFγ and IL-10 did not differ between genotypes, peak levels of IL-
12p70 at 24h after carrageenan injection, were lower in Hsd11b1-/- than in Hsd11b1+/+ 
mice (Figure 3.14). Levels of MCP-1 were high for the first 48h following carrageenan 
injection and were similar in both genotypes at 4h and 24h (although at both time points 
MCP-1 reached the maximum limit detection of the assay in many of the samples) 













Figure 3.14 Study 1, altered cytokine levels in Hsd11b1-/- versus Hsd11b1+/+ mice 
following intra-pleural injection of carrageenan.  
Results based on CBA mouse inflammation kit which was used to simultaneously 
measure IL-6, IL-10, IL-12p70, MCP-1, IFN-γ and TNF-α levels in pleural exudates at 
the indicated times following injection of carrageenan. Peak levels (24h) of IL-12p70 
(top left panel) were lower in lavages from Hsd11b1-/- mice (white bars) than in lavages 
from Hsd11b1+/+ mice (black bars). There was a trend (p=0.09) for higher peak levels (at 
4h) of TNF-α in Hsd11b1-/- mice. Values shown are mean ± SEM. * p<0.05 represents a 
significant difference between genotypes (n=6-7/genotype/time) when compared by 
























































































































































































The comparative assessment of carrageenan-induced lung inflammation described in this 
Chapter is consistent with a role for 11β-HSD1 in limiting acute inflammation. These 
results suggest that, compared to control mice, Hsd11b1-/- mice show an exaggerated 
inflammatory response to carrageenan injection and possibly impaired resolution. 
Despite similar lavage volumes, more cells were recovered from the pleural cavity of 
Hsd11b1-/- mice than from controls following intra-pleural injection of carrageenan. The 
recruitment of more inflammatory cells in Hsd11b1-/- mice is indicative of a greater 
inflammatory response.  
 
Based on previous characterization of this model, the increased number of recovered 
cells seen in Hsd11b1-/- mice at 4h following injection of carrageenan is likely to be due 
to an influx of neutrophils with the increase at 24h likely to be due to increased numbers 
of monocytes (Vinegar et al., 1982a). Microscopic examination of cytocentrifuged cells 
was consistent with this conclusion, and is consistent with previous data showing 
increased numbers of recruited inflammatory cells in TG-induced peritonitis but no 
difference in the population recruited (Gilmour, 2002; Gilmour et al., 2006). However, 
further assessment by flow cytometry revealed that a sub-population of cells expressing 
F4/80 and Gr-1 cell markers differed between the two genotypes, suggesting that the 
recruited cells may differ in phenotype. In addition, the level of cell death in recruited 
inflammatory cells was lower at the onset of inflammation in Hsd11b1-/- than in 
Hsd11b1+/+ mice. Resolution of inflammation is dependent on the successful removal of 
Chapter 3. Carrageenan-Induced Pleurisy 
 94
inflammatory cells (by migration or phagocytosis) and pro-inflammatory stimuli they 
produce, as well as cessation of recruitment of viable cells. Thus, ongoing influx of 
viable cells, such as neutrophils, and their continued release of pro-inflammatory 
mediators, will prolong the inflammatory response.  
 
Measurement of cytokine concentrations in exudates suggested differences in levels of 
inflammatory mediators between the two genotypes. Unfortunately, the CBA assay was 
not sufficiently sensitive for all the cytokines measured and levels in some samples were 
outside the range of the assay. Nonetheless, peak levels of IL-12p70, which plays a 
major role in driving the T cell response towards a Th1 pattern of cytokine secretion 
(Trinchieri et al., 2003; Trinchieri, 2003), was lower in lavage fluid from Hsd11b1-/- 
than in Hsd11b1+/+ mice, 24h following intra-pleural injection of carrageenan. Pro-
inflammatory functions of IL-12 include induction of IFN-(Trinchieri et al., 2003). 
However, IFN- levels were similar between genotypes at all times following injection. 
In addition, although not significant, levels of TNF-α, an early pro-inflammatory 
cytokine, were increased in Hsd11b1-/- mice at 4h after injection. Level of MCP-1, a 
chemoattractant for monocytes, was increased in Hsd11b1-/- mice at 48h after injection 
(although all Hsd11b1-/- samples were above assay detection limit and therefore 
statistical analysis was not possible for these samples). This is intriguing as MCP-1 may 
be of key importance in the recruitment of monocytes in pulmonary infections, whilst 
11β-HSD1 inhibitor decreases MCP-1 levels in aorta of apoe-/- mice (Hermanowski-
Vosatka et al., 2005).  
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Normally, carrageenan-induced pleurisy involves a monophasic mobilization of 
neutrophils followed by monocytes (Vinegar et al., 1982b). Resolution in this model is 
usually observed by 48h. However, this was not seen. Although a direct comparison 
between the 72h experiment and the other time points (4h, 24h and 48h) in Study 1 is 
not possible since the experiments were completed separately, the elevated levels of 
recruited inflammatory cells at 72h (above levels at 24h and 48h) were surprising and 
difficult to explain. During routine health monitoring at the animal facility (Western 
General Hospital, Edinburgh), where all the carrageenan-induced pleurisy experiments 
were carried out, Pasteurella pneumotropica infections were found in sentinel animals 
(January 2005 report) at the time of the experiments. This opportunistic organism is 
found in many research colonies of rodents and in the presence of primary pathogens 
can potentiate the severity of disease (Brennan et al., 1965). Therefore, although the 
groups of mice were well matched between the experiments it is possible that infection 
with Pasteurella pneumotropica confounded some or all of these experiments, 
accounting for the failure to fully resolve inflammation at 48h and for the unexpectedly 
high cellularity in the separate experiment at 72h. Indeed, although the cellularity was 
greatly increased at 72h, cytokine levels had returned to basal at this time, suggesting 
cessation of pro-inflammatory mediators.   
 
Histological assessment did not reveal any differences between lungs of untreated 
Hsd11b1-/- and Hsd11b1+/+ mice, suggesting that any differences observed following 
inflammation are not due to an underlying pathology, but are due to the inflammatory 
stimulus itself. During the onset and peak of inflammation, both genotypes showed 
Chapter 3. Carrageenan-Induced Pleurisy 
 96
progressively worse inflammation. At 48h, control mice showed signs of resolution with 
less inflamed pleura and fewer aggregates, whereas most Hsd11b1-/- mice had ongoing 
inflammation. Uniquely, Hsd11b1-/- mice exhibited adhesions on lung lobes suggesting 
possible fibrosis development if left for longer duration. This raises the possibility that 
worse tissue damage (scarring) will ultimately occur in Hsd11b1-/- mice. The fibrous 
adhesions might be a direct reaction to the greater influx of inflammatory cells in 
Hsd11b1-/- mice. However, given the qualitative nature of the differences between 
genotypes it is perhaps likely due to a greater reaction of the non-leukocyte cells (eg. 
resident fibroblast and mesothelial cells) to the pro-inflammatory environment. During 
pleural inflammation, mesothelial cells secrete chemokines (including IL-8, MIP-1 and 
MCP-1) to recruit neutrophils and monocytes (Antony et al., 1995; Mohammed et al., 
1998; Mohammed et al., 1999). Fibroblasts exist in the interstitial stroma beneath 
mesothelial cells and also contribute to leukocyte recruitment during serosal 
inflammation (Faull, 2000; Witowski et al., 2001; Loghmani et al., 2002). 
 
In summary, this Chapter corroborates previous findings in TG-peritonitis experiments 
(Gilmour, 2002), suggesting that Hsd11b1-/- mice exhibit an altered course of  acute 
inflammation. Importantly, this model demonstrated that the worse acute inflammatory 
response seen in Hsd11b1-/- mice is not limited to sterile peritonitis. The findings in the 
carrageenan-induced pleurisy model are novel but remain preliminary. However, they 
provide a basis for further investigation. Future experiments using this model should 
focus on identifying exactly which cells in lung (both resident and inflammatory) 
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express 11β-HSD1 and how the levels of expression are altered by inflammation during 
the onset, peak and resolution phases. Histology data implies that Hsd11b1-/- mice are 
not only slower to resolve inflammation but also that they might be at higher risk for 
fibrotic disease. Finally, corticosterone levels are high (350-400ng/ml) in pleural 
exudates at the acute phase, but return to normal 24h after carrageenan injection (Gilroy 
et al., 2004). In future experiments, it will be important to measure corticosterone levels 
in both plasma and pleural exudate (not completed in these experiments) to determine if 
the HPA response and tissue corticosterone penetration during caraggeenan-induced 




































Chapter 4. Experimental Arthritis 
 99
4.1. Introduction 
Since GC are commonly and successfully used to treat inflammatory arthritis in humans 
a model of experimental arthritis was also used to further investigate whether and how 
11β-HSD1 deficiency confers an inflammatory phenotype. There are many experimental 
models of arthritis, but none fully address the complexity of human rheumatoid arthritis. 
In addition, considerable heterogeneity exists between mouse strains in susceptibility to 
different models of experimental arthritis. Hence, the initial aim was to select a model 
suited for C57BL/6 mice and which allowed for assessment of inflammation during 
onset, peak and resolution of disease, providing opportunity for histological assessment. 
Two separate and previously established models were tested. Type II collagen-induced 
arthritis with complete Freund’s adjuvant (CIA-CFA) (reviewed in Chapter 2, Section 
2.3.7.1.) is widely used and well characterized in rodents. However, not all mouse 
strains respond to this model of arthritis. The second model was the more recently 
described K/BxN serum transfer model (Kouskoff et al., 1996). Injection of serum or 
purified G-6-PI antibodies from arthritic K/BxN mice into healthy recipient mice rapidly 
and reproducibly induces an inflammatory arthritis which is self-resolving (as the 
antibody is cleared), bypassing the lymphocyte-dependent induction phase of arthritis 










4.2.1. C57BL/6 mice are resistant to arthritis in the CIA-CFA model  
Despite previous reports of successful induction of arthritis using the CIA-CFA model in 
C57BL/6 mice (Campbell et al, 2000), inoculation with CIA-CFA failed to produce 
arthritis in C57BL/6 (control) mice. Clinical assessment of redness and swelling of limbs 
(as described in Chapter 2, Section 2.3.7.2.3) was carried out to determine disease onset 
and severity. Only intermittent symptoms (eg. redness of skin around carpal joints 
without swelling) were observed and only in 1 (of 10) Hsd11b1-/- mice after 60d of 
observation (data not shown). No signs were observed in the control mice. 
 
Accordingly, this model was not used further to investigate the course of arthritis in 
Hsd11b1-/- mice. During the course of this experiment, it was noted that following sub- 
dermal injection of emulsion containing collagen with CFA, mice developed temporary, 
self-resolving ulcers at the site of injection, at the base of the tail. Ulceration was more 
severe, with more bleeding in Hsd11b1-/- mice than the control mice (Figure 4.1). In 
addition, there was delayed healing of the wounds in Hsd11b1-/- mice compared to 



























































Figure 4.1 A greater proportion of Hsd11b1-/- mice developed dermal ulcers 
following CIA-CFA immunization than Hsd11b1+/+ mice. 
Hsd11b1-/- (white bars; n=10) and Hsd11b1+/+ mice (black bars; n=9) received sub-
dermal injection of 100µl CIA-CFA on d0 and d21. Mice were observed for 61d 
following initial injection, and ulcer formation was recorded. Values represent % of 
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4.2.2. Earlier onset of arthritis and delayed resolution following K/BxN serum 
transfer in Hsd11b1-/- mice: Experiment 1, standard dose of K/BxN serum 
 
The standard dose (i.p. injections of 7.5l K/BxN serum/g body weight administered on 
0d and 2d) previously reported in the literature was initially chosen as it has been shown 
to cause arthritis in C57BL/6 mice (Ji et al., 2002). Administration of K/BxN serum 
produced symmetrical (in all 4 limbs) arthritis in both Hsd11b1-/- and Hsd11b1+/+ 
control mice (Figure 4.2). Clinical score was monitored until the arthritis had resolved in 
the control mice (at 21d). Inoculation with the standard dose of serum resulted in an 
earlier onset of symptoms in Hsd11b1-/- mice, with significantly higher clinical scores 
than the controls until 4d (Figure 4.3.A.). However, by 5d, the clinical score for both 
groups reached maximum, and remained high until approximately 12d. Although the 
peak score was similar between the 2 genotypes, the area under the curve (AUC), based 
on 21d observation, was significantly greater in the Hsd11b1-/- than the Hsd11b1+/+ mice 
(Figure 4.3.B.). Consistent with worse clinical score, the AUC for caliper measurement 
of ankle (right tarsal joint) diameter was significantly greater in Hsd11b1-/- compared to 
Hsd11b1+/+ mice (Figure 4.3.C). Inflammation in both groups started to resolve by 16d 
(Figure 4.3.A.). However, the improvement in clinical score for Hsd11b1-/- mice lagged 













Figure 4.2 I.p. injection of K/BxN serum results in joint swelling.  
The appearance of a normal hind limb of a C57BL/6 Hsd11b1+/+ mouse (A and B), in 
contrast to the appearance (C and D) 10d following injection of the standard dose (2 i.p. 
injections of 7.5l/g body weight on 0d and 2d) of K/BxN serum. In all K/BxN arthritis 
experiments mice were injected with serum between 8am and 10am. The representative 
arthritic paws shown were assigned the maximal clinical score of 3 (Clinical scoring 
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Figure 4.3 Earlier onset of arthritis and delayed resolution following K/BxN serum 
transfer in Hsd11b1-/- mice.  
(A) Standard dose (i.p. injections of 7.5l/g body weight on 0d and 2d) of K/BxN serum 
showing daily clinical scores (characterized by oedema and redness of carpal and hock 
joints) over 21d. Two-way mixed ANOVA showed significant interaction between 
genotype (p<0.01). (B) AUC for Hsd11b1-/- mice (white bar) compared to Hsd11b1+/+ 
mice (black bar) (n=5/group), and (C) AUC for caliper measurement of ankle (right 
tarsal joint) diameter was also greater in Hsd11b1-/- compared to Hsd11b1+/+ mice. 
Clinical scoring in this experiment was performed together with Dr Mohini Gray.                    
* p<0.05 when compared by unpaired Student’s t-test. Values shown represent mean ± 
SEM.  
B C 
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4.2.2.1. Pathology analysis after 21d of K/BxN arthritis 
Histological analysis (carried out by Dr D. Brownstein, CCVS) of H&E sections of 
joints after 21d of arthritis showed periarticular inflammation in the bones and tendons 
leading towards the joint for both genotypes (Figure 4.4). However, no qualitative 
differences were found between the two genotypes. In addition, both genotypes showed 
little evidence of exudate volume, panus (none in carpal, possibly some in tarsal joints) 
or erosion at 21d, and any intra-articular inflammation had resolved by this time. 
Fibroblast proliferation around the joint, new cartilage and bone, and thickening of 
tendon sheath was found in both genotypes, but no striking observable difference 
between genotypes was noted. Additionally, there was strong evidence of periarticular 




















Figure 4.4 Pathology does not differ between the genotypes after 21d of standard 
dose K/BxN serum transfer arthritis.  
Joints were collected 21d following experimental arthritis (i.p. injections of 7.5l 
K/BxN serum/g body weight on d0 and d2) (n=5/group). Representative images of H&E 
sections, showing carpal joints, from Hsd11b1-/- (A and B) and Hsd11b1+/+ mice (C and 
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4.2.2.2. Effects of K/BxN arthritis on anthropometric measurements 
Anthropometric differences were observed between the genotypes in response to K/BxN 
arthritis. The body weight of the Hsd11b1-/- mice was significantly greater at both the 
start (Hsd11b1+/+; 29.0±0.7g versus Hsd11b1-/-; 32.0±0.5g, p<0.01), despite Hsd11b1+/+ 
control mice being age matched, and end of the experiment (Hsd11b1+/+; 29.2±0.8g 
versus Hsd11b1-/-; 33.8±0.5g, p<0.01). Thymus weight, expressed as percent of body 
mass, was significantly lower in Hsd11b1-/- than in Hsd11b1+/+ mice (Figure 4.5.A). 
Although the right adrenal was significantly heavier in Hsd11b1-/- than in Hsd11b1+/+ 
mice (with a trend for larger left adrenal), this did not reach significance when expressed 
as percent body weight (data not shown). Overall, Hsd11b1-/- mice had a significantly 
lower thymus:adrenal ratio (corrected for body weight) than Hsd11b1+/+ mice (Figure 
4.5.B). These changes were not observed in Hsd11b1-/- mice following arthritis induced 
by a lower dose of K/BxN serum (Experiment 2, discussed below), indicating that the 





















































Figure 4.5 Anthropometric differences between Hsd11b1-/- and Hsd11b1+/+ mice in 
response to K/BxN serum transfer arthritis.  
Thymus weight, expressed as % body mass, and thymus:adrenal ratio were significantly 
lower in Hsd11b1-/- (white bar) than in Hsd11b1+/+ mice (black bar) 21d following 
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4.2.3. Earlier onset of arthritis and delayed resolution in Hsd11b1-/- mice: 
Experiment 2, reduced dose of K/BxN serum 
 
The standard dose of K/BxN serum (described above) produced severe arthritis with 
maximum clinical scores (maximum score=12) in Hsd11b1+/+ as well as Hsd11b1-/- 
mice. In order to detect greater severity of inflammation in Hsd11b1-/- than in 
Hsd11b1+/+ mice (the predicted hypothesis), it was therefore necessary to cause a sub-
maximal arthritis in Hsd11b1+/+ mice. Accordingly, the inoculum of K/BxN serum was 
reduced to a single injection of 5.6µl/g body weight on 0d. Administration of the 
reduced dose resulted in the development of a milder arthritis in both genotypes (Figure 
4.6).  
 
Similar to the standard dose experiment, inoculation with the reduced dose of K/BxN 
serum resulted in an earlier onset of symptoms in Hsd11b1-/- mice with clinical scores 
remaining above those of Hsd11b1+/+ mice for the duration of the experiment (Figure 
4.6.A). The reduced inoculum resulted in a significantly higher AUC in Hsd11b1-/- mice 
than in Hsd11b1+/+ mice (Figure 4.6.B). As with the standard dose, resolution of clinical 
symptoms in Hsd11b1-/- mice was delayed ~1d compared to Hsd11b1+/+ mice (Figure 
4.6.A), with ~50% reduction in clinical scoring at ~16d in Hsd11b1-/- compared to ~11d 
in Hsd11b1+/+ mice (Figure 4.6.A). Furthermore, the more aggressive onset of 
inflammation was reflected in the greater number of joints with higher clinical scores in 
Hsd11b1-/- than in Hsd11b1+/+ mice (Figure 4.7). 
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Figure 4.6 Earlier onset and delayed resolution of arthritis in Hsd11b1-/- mice with 
reduced dose of K/BxN serum.  
Higher clinical scores (A) over 21d of arthritis, and greater AUC (B) following reduced 
dose (single injection of 5.6µl/g body weight on d0) of K/BxN serum transfer in 
Hsd11b1-/- mice (white) compared to Hsd11b1+/+ mice (black) (n=5/genotype). Clinical 
scoring was performed blind to genotype. Values shown are mean ± SEM. Two-way 
ANOVA showed significant interaction (p<0.01). For AUC, * p<0.05 when compared 







































Figure 4.7 The total number of joints, with more severe clinical scores, was higher 
in Hsd11b1-/- than in the Hsd11b1+/+ mice.  
More aggressive onset of inflammation, reflected by higher number of paws with higher 
clinical score in the Hsd11b1-/- (white bars) than in the Hsd11b1+/+ mice (black bars) 
following reduced dose (single injection of 5.6µl/g body weight on d0) of K/BxN serum 
transfer. Chi Square analysis showed a significant difference (p<0.05) between 
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Inoculation with a reduced dose resulted in a less symmetric arthritis with high 
variability in both genotypes. The asymmetrical pattern of arthritis made it difficult to 
obtain reproducible measurements of paw swelling with the caliper. As a result, 
significant differences could not be detected between genotypes with caliper 
measurements of the ankle (right tarsal joint) diameter (data not shown).  
 
4.2.3.1. Pathology analysis after 21d of K/BxN arthritis 
Histological assessment of joint sections (21d post injection) from the reduced dose 
experiment revealed that Hsd11b1-/- mice had a more reactive bone phenotype and 
intense periarticular inflammation with more severe exostosis and collagen deposition. 
Uniquely, ganglion cyst formation was observed in Hsd11b1-/- mice but not in 
Hsd11b1+/+ mice (Figure 4.8).  
 
4.2.3.2. Plasma corticosterone levels remained elevated in Hsd11b1-/- mice during the  
resolution stage of arthritis 
 
Plasma was collected at the nadir of corticosterone secretion (0800h) under stress-free 
conditions for measurement of corticosterone levels at d2 and d21. At d2, the acute stage 
of disease, both genotypes had elevated plasma corticosterone levels (Figure 4.9). 
However, at d21, a time point at which mice of both genotypes showed significant levels 
of recovery (based on clinical scoring), corticosterone remained elevated in Hsd11b1-/- 
mice (Figure 4.9), consistent with an ongoing stress response. In contrast, corticosterone 
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levels in Hsd11b1+/+ mice were significantly lower at d21 in comparison to d2 (Figure 
4.9).   
 
4.2.3.1.Effects of K/BxN arthritis on anthropometric measurements 
Following the reduced dose of K/BxN serum, all mice lost body weight by 21d (Figure 
4.10.A). At the end of the experiment there was no difference in thymus weight 
(expressed as % body mass) between the 2 genotypes (Figure 4.10.B). Although the 
right adrenal mass (% body mass) was larger in Hsd11b1-/- compared to Hsd11b1+/+ 
mice (Figure 4.10.C), there was no difference in the left adrenal as well as total adrenal 
weight (% body mass), and the thymus:adrenal ratio was similar between the genotypes 


































Figure 4.8 Histological assessment showed a more reactive bone phenotype and 
intense periarticular inflammation with severe exostosis and ganglion cyst 
formation in Hsd11b1-/- mice.  
Joints were collected 21d following induction of experimental arthritis with K/BxN 
serum (single injection of 5.6µl/g body weight on d0) (n=5/genotype). Representative 
images of H&E sections, showing left carpus, from Hsd11b1+/+ (A) and Hsd11b1-/- mice 





















Figure 4.9 High circulating corticosterone levels in Hsd11b1-/- mice at 21d after 
K/BxN serum injection.  
Morning circulating corticosterone levels 2d and 21d post arthritis challenge (single 
injection of 5.6µl/g body weight on d0) in Hsd11b1-/- (white) and Hsd11b1+/+ mice 
(black) (n=5/group). Values shown are mean ± SEM. Two-way ANOVA showed a 
significant interaction (p<0.05). * p<0.05 indicates significant difference between 






















































































































Figure 4.10 Anthropometric effects of 11β-HSD1 deficiency following K/BxN 
arthritis.  
Body weight (A) was measured on d0 and d21 during K/BxN arthritis with reduced dose 
(single injection of 5.6µl/g body weight on d0) in Hsd11b1-/- (white) and Hsd11b1+/+ 
mice (black) (n=5/group). Thymus (B) and adrenals (C) were collected and weighed on 
d21, from which thymus:adrenal ratio was determined (D). All tissue weights are 
expressed as % body weight. Values shown are mean ± SEM. * p<0.05 and ** p<0.01 
indicate significant difference between genotypes at 21d when compared by unpaired 
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4.2.4. K/BxN arthritis: acute phase 
The most pronounced difference in clinical symptoms between the genotypes occurred 
at the acute phase of arthritis, with a more rapid onset of inflammation in the Hsd11b1-/- 
mice (Figure 4.3 and 4.6). As a result, an acute experiment was carried out using 5.6µl 
K/BxN serum/g body weight in order to observe histological differences, with mice 
killed 2d following injection of serum. Similarly to the previous experiments, Hsd11b1-/- 
mice showed a more rapid onset of inflammation with higher clinical scores, reflecting 
greater redness and swelling of the joints, than Hsd11b1+/+ mice, 2d following injection 
of serum (Figure 4.11).   
 
Histological examination (Prof Donald Salter) of 2d arthritic joint sections showed a 
severe inflammatory response in mice from both genotypes (data not shown). However, 
no qualitative differences were detected between genotypes, despite the earlier onset of 
inflammation in Hsd11b1-/- mice. Exudate within the joint space and inflammation 
(based on influx of acute inflammatory cells into the joint synovium) was apparent 

































Figure 4.11 More aggressive onset of inflammation in Hsd11b1-/- mice 2d after of 
K/BxN serum injection.  
(A) Higher clinical scores following a single injection of 5.6µl of K/BxN serum/g body 
weight on d0 in Hsd11b1-/- mice (white circles) compared to controls (black squares). 
Two-way ANOVA showed a significant interaction (p<0.01). (B) More joints with 
higher clinical score in Hsd11b1-/- mice (white bars) compared to Hsd11b1+/+ (black 
bars). Chi square analysis showed a significant difference (p<0.05) between genotypes. 
Clinical scoring was performed blind to genotype (n=5/genotype).Values shown are 
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4.2.5. Micro-CT scanning reveals altered bone micro-architecture in Hsd11b1-/- mice 
following K/BxN arthritis 
 
 
Femurs, taken from mice 2d or 21d following a single injection of 5.6µl K/BxN serum/g 
body weight on d0, were subjected to micro-CT scanning (this was carried out by Dr 
Rob van 't Hof). The scans suggested that bone micro-architecture in Hsd11b1-/- mice 
differed from that in Hsd11b1+/+ mice following 21d (discussed below), but not 2d of 
arthritis (Table 4.1). Lack of differences at the early stages of arthritis suggests that any 
differences seen at the later time point cannot be attributed to innate differences between 
the genotypes. This is in accordance with a previously published observation that under 
normal conditions (untreated) Hsd11b1-/- mice maintain normal bone formation 
(Justesen et al., 2004). 
 
Trabecular bone (cancellous or spongy bone) differed between Hsd11b1-/- and 
Hsd11b1+/+ mice following 21d of K/BxN arthritis (Table 4.2). Although trabecular 
bone volume did not significantly differ between the genotypes, trabecular separation 
and thickness were greater in Hsd11b1-/- mice, and the trabecular number was lower, in 
comparison to the Hsd11b1+/+ mice. Structure Model Index (SMI), measuring level of 
weakness, and Trabecular Pattern Factor (TPF), a measure of connectedness, were both 
higher in the Hsd11b1-/- than the Hsd11b1+/+ mice (Figure 4.12.). Cortical bone 
measurements showed that, overall, after arthritis Hsd11b1-/- mice had smaller femur 
bones, based mainly on smaller tissue volume, while cortical thickness remained similar 
between the two groups (Table 4.3). 
 





Table 4.1 Histomorphometric parameters for trabecular bone from 
Micro-CT scanning of femur bones 2d after injection of K/BxN 
serum 
 
Parameter  Hsd11b1+/+ Hsd11b1-/- T-test 
 
Tissue volume 2.11 1.92 p>0.05 
 
Bone volume 0.36 0.34 p>0.05 
 
Percent bone volume 16.8 17.3 p>0.05 
 
Trabecular thickness 0.045 0.054 p>0.05 
 
Trabecular separation 0.17 0.18 p>0.05 
 
Trabecular number 3.72 3.21 p>0.05 
 
Trabecular pattern factor 17.23 17.21 p>0.05 
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Table 4.2 Histomorphometric parameters for trabecular bone from 
Micro-CT scanning of femur bones 21d after injection of K/BxN 
serum 
 
Parameter  Hsd11b1+/+ Hsd11b1-/- T-test 
Tissue volume 2.7x109 2.6x109 p>0.05 
Bone volume 5x108 4.1x108 p<0.01 
Percent bone volume 1.9x101 1.6x101 p>0.05 
Tissue surface 1.4x107 1.3x107 p>0.05 
Bone surface 3.5x107 2.6x107 p<0.01 
Bone surface / volume ratio 7.1x10-2 6.3x10-2 p<0.01 
Bone surface density 1.3x10-2 1x10-2 p<0.01 
Trabecular thickness 5x101 5.3x101 p<0.01 
Trabecular separation 2x102 2.3x102 p<0.01 
Trabecular number 3.7x10-3 2.9x10-3 p<0.01 
 
Table 4.3 Histomorphometric parameters for cortical bone from 
Micro-CT scanning of femur bones 21d after injection of K/BxN 
serum 
 
Parameter  Hsd11b1+/+ Hsd11b1-/- T-test 
Tissue volume 1.7x109 1.5x109 p<0.01 
Bone volume 5.4x108 5x108 p<0.01 
Percent bone volume 3.2x101 3.4x101 p>0.05 
Tissue surface 1.3x107 1x107 p>0.05 
Bone surface 1.1x107 9.6x106 p<0.01 
Bone surface / volume 
ratio 2x10-2 1.9x10-2 p>0.05 
Bone surface density 6.3x10-3 6.5x10-3 p>0.05 
Cortical thickness: 1.6x102 1.6x102 p>0.05 
   major axis 2.8x103 2.6x103 p<0.05 
   minor axis 1.4x103 1.3x103 p<0.05 
   axis ratio 2 2.1 p>0.05 
 




















Figure 4.12 Weaker and less connected trabecular bone in femurs of Hsd11b1-/- 
mice than Hsd11b1+/+ mice following 21d of K/BxN arthritis.  
Higher Structure Model Index (SMI), measuring level of “weakness”, and Trabecular 
Pattern Factor (TPF), measuring bone connectedness, in Hsd11b1-/- mice (open circles) 
and Hsd11b1+/+ mice (black squares) 21d following a single injection of 5.6µl of K/BxN 
serum/g body weight on d0. Values represent individual mice. * p<0.05 indicates 









The aim of the experiments described in this Chapter was to establish a suitable model 
of arthritis to evaluate disease course in Hsd11b1-/- mice for comparison to Hsd11b1+/+ 
mice. The CIA-CFA arthritis model was tried first. C57BL/6 mice are resistant to CIA 
(see Chapter 2, Section 2.3.7.1.). However, Campbell et al. (2000) have described a 
modified immunization protocol (used here), where the collagen is mixed with complete 
Feund’s adjuvant (CFA), and in which 60-70% of C57BL/6 mice developed arthritis. 
Unfortunately, this model failed to produce arthritis in either genotype, with none of the 
control mice showing any signs of arthritis and only one Hsd11b1-/- mouse showing 
intermittent symptoms. Since the CIA-CFA did not produce arthritis in any of the mice, 
this model was not pursued. However, an interesting observation was made suggesting 
an altered immune reaction to CFA in Hsd11b1-/- mice. During the experiment most 
mice developed ulcers, following the injection, but with greater frequency and prolonged 
bleeding in Hsd11b1-/- mice.  
 
The alternative model tried, K/BxN serum transfer, produced arthritis in all mice. 
Importantly, there was a highly reproducible earlier onset of symptoms in Hsd11b1-/- 
mice irrespective of the dose of K/BxN serum used to initiate arthritis. In all 
experiments, the peak clinical score of inflammation did not differ. The shape of the 
curves for clinical scoring within each experiment was similar for both genotypes. 
However, scores for Hsd11b1-/- mice always remained above the controls for the 
duration of the experiments (except in the standard dose experiment where both 
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genotypes peaked at the same level). Unlike the standard protocol, in the reduced serum 
protocol the joints of the recipient mice were not uniformly affected. With reduced dose 
the disease progressed at a variable rate and other limbs could become involved at later 
intervals. Whilst an asymmetrical pattern of arthritis is more representative of human 
rheumatoid arthritis, it made it difficult to obtain reproducible measurements of paw 
swelling with caliper. Resolution occurred at approximately the same time in both 21d 
experiments, which probably reflects the half life of antibody (stable arthritis being the 
“plateau” and resolution occurring rapidly as the antibody is cleared), but interestingly, 
Hsd11b1-/- mice were slower to recover. The slower resolution may be related to the 
earlier onset; however, it may reflect a separate mechanism. 
 
Consistent with more severe inflammation, Hsd11b1-/- mice had a more reactive bone 
phenotype and greater periarticular inflammation than the controls, characterized by 
exostosis and ganglion cyst formation. In humans, ganglion cysts (previously 
undescribed in rodents) may be early signs of arthritis and are suggestive of worse 
inflammation (personal communication with Dr David Brownstein), whilst exostosis is a 
reaction of bone to inflammation in the overlying tendon sheath. It remains unexplained 
however, why no pathological differences between genotypes were detected at the onset 
of arthritis (2d after injection of K/BxN serum), when differences in oedema were 
obvious. One possible explanation is that vasopermeability and/ or vasodilation in 
response to the K/BxN serum differs between the genotypes. A possible mechanism for 
increased blood vessel leakiness is addressed more fully in Chapter 5. Excessive 
angiogenesis contributes to the pathology of rheumatoid arthritis and GC have been 
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shown to inhibit angiogenesis (Folkman et al. 1983). Moreover, a role for endogenous 
GC by 11β-HSD1 in repair angiogenesis has been demonstrated, and not surprisingly, 
Hsd11b1-/- mice show increased angiogenesis (Small et al. 2005) suggesting an 
alteration in blood vessels of Hsd11b1-/- mice. It will be interesting to determine if the 
vascular bed within the joints differs between genotypes before and after arthritis. To 
date, there is no suggestion that developmental angiogenesis differs in Hsd11b1-/- mice. 
 
Bone deformation and severe exostosis may occur in cyclical episodes of bone necrosis 
and repair, as is the case with chronic inflammation. The literature suggests a cyclic 
response during inflammation involving necrosis, resorption, inflammation, and 
proliferation of bone tissue. Arthritis-induced persistent inflammation caused bone 
remodeling that was more severe in Hsd11b1-/- mice than in the controls. In addition to 
greater exostosis in carpal bones around the affected joints (local response) in Hsd11b1-/- 
mice, micro-CT scanning of femur bones revealed that following K/BxN arthritis, the 
micro-architecture of the femur bone, away from the joint (therefore a systemic 
response), was also altered. By indicating that the injection of K/BxN serum also has a 
systemic effect, affecting bone away from the joints, the micro CT scanning data 
provides additional information on the K/BxN model of arthritis which, unlike its effects 
within the synovial joint, is not discussed broadly in the literature. 
 
The micro-architecture determines stability of bone and can be described more 
specifically by histomorphometric parameters; TPF, which provides assessment of the 
connectedness of bone tissue, and SMI which reflects the level of weakness (personal 
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communication with Dr Rob van 't Hof). Higher levels of TPF and SMI were measured 
in bones from Hsd11b1-/- mice, indicating thinner and less well connected bones than the 
in controls following arthritis. GC have profound effects on bone (Chiodini et al., 1998; 
Dalle et al., 2001) and the presence of functional 11β-HSD1 in bone (Justesen et al., 
2004) suggests that it too plays a role in bone metabolism. Previous in vitro data showed 
that over-expression of 11β-HSD1 in osteoblasts reduced cellular proliferation and 
increased cellular differentiation (Eyre et al., 2001). Interestingly, differences between 
genotypes were only seen following 21d of arthritis and not at the early stages (2d). This 
suggests normal structure of bones in untreated Hsd11b1-/- mice. This would be in 
accordance with previous reports on bone assessment of Hsd11b1-/- mice showing that 
deficiency of 11β-HSD1 did not affect bone mass or bone turnover (Justesen et al., 
2004). However, to better explain the bone related findings of this chapter, in the future 
bone histomorphometry and assessment of osteoclast and osteoblast numbers should be 
made in both genotypes prior to and following inflammatory arthritis.  
 
Finally, under normal conditions Hsd11b1-/- mice, on their original MF1/129 genetic 
background, have elevated plasma GC levels, both basally and following acute stress (10 
min restraint stress) (Harris et al., 2001). However, Hsd11b1-/- mice on C57BL/6 
background show normal plasma corticosterone levels (Yau et al., 2007). Plasma 
corticosterone levels were elevated to a similar extent in Hsd11b1-/- and control mice 2d 
following a single injection of K/BxN serum, indicating that differential HPA axis 
activation between the genotypes does not underlie this acute inflammatory phenotype. 
Interestingly, plasma corticosterone levels failed to return to normal in Hsd11b1-/- mice 
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during the resolution stage (d21) indicating a greater and prolonged stress in these mice 
in response to arthritis. Taken together, these data suggest that any differences in HPA 
response to stress between genotypes are influenced by the type of stimulus and its 
duration. It will be important to further investigate this in the future. 
  
In summary, mice deficient in 11β-HSD1 exhibit an exaggerated response in the K/BxN 
serum transfer model of arthritis. These experiments are consistent with the original 
observations by Gilmour (2002), demonstrating worse acute inflammation in Hsd11b1-/- 
mice, with greater recruitment of inflammatory cells following TG-induced sterile 
peritonitis. However, in contrast to the TG-induced peritonitis model, where resolution 
occurred simultaneously in both genotypes, here, the resolution of arthritis (judged by 
clinical scoring of inflamed joints and supported by histology at 21d) was delayed in 
Hsd11b1-/- mice. This finding is in agreement with the data from carrageenan-induced 
pleurisy described in Chapter 4, where resolution of pleural inflammation was altered in 
Hsd11b1-/- mice. These findings strongly support a role for 11β-HSD1 as an endogenous 
modulator of inflammation. Future experiments using the K/BxN model should be 
aimed at the onset and resolution phases specifically to determine if they are regulated 
by a single mechanism or two separate factors. Also, it will be of critical importance to 
establish which cells (resident and inflammatory immune cells or non-immune cells) are 
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5.1. Introduction 
Compared to the metabolically protective aspects of 11β-HSD1-deficiency, much less is 
known regarding inflammatory/immune consequences, and only relatively recently has 
interest in the role of 11β-HSD1 in immune cells arisen. Although some older studies 
examined the 11β-HSD ‘shuttle’ in immune cells and organs (Hennebold et al., 1996), 
they predated the realization that 11β-HSD comprises two distinct enzymes and it is only 
relatively recently that this has been re-examined in the context of two separate 
isozymes (reviewed in Chapman et al., 2006, 2008). MC play an early role during the 
inflammatory response and are essential for K/BxN arthritis (Lee et al., 2002). The 
results in this chapter focus on characterisation of 11β-HSD1 in MC, as well as the 
consequences of 11β-HSD1-deficiency in these cells. MC function was assessed in 
Hsd11b1-/- mice to investigate a possible mechanism for the altered inflammatory 
response, with earlier onset of oedema, during arthritis challenge in these mice (Chapter 
4). In addition to assessment of MC number and morphology in Hsd11b1-/- mice, in vitro 
MC degranulation experiments, using peritoneal MC retrieved from both genotypes, 












5.2.1. Immunohistochemical staining of 11β-HSD1 in peritoneal cells 
 
Peritoneal cells exhibit 11β-reductase activity, which increases rapidly and markedly 
following TG injection (Gilmour et al., 2006). To determine whether peritoneal MC 
express 11β-HSD1, cytocentrifuge preparations of resident peritoneal cells from 
Hsd11b1+/+ mice were first stained with a commercially available rabbit-anti-mouse 
11β-HSD1 antibody (from Cayman) and a sheep-anti-mouse tryptase (mMCP-6/7) 
antibody (gift from Dr Jeremy Brown), specific for mouse MC. Strong staining for 11β-
HSD1 was seen in a subset of peritoneal cells, all of which also stained with mMCP-6/7 
antibody, suggesting high 11β-HSD1 expression in peritoneal MC (Figure 5.1.A). 
Staining of other peritoneal cells was much lower, with background level in resident 
M. Unfortunately, this antibody proved to be non-specific as even greater staining was 
detected in resident peritoneal cells from Hsd11b1-/- mice (Figure 5.1.B). Therefore, the 
Cayman antibody must recognize an epitope other than 11β-HSD1, and was not used in 













Figure 5.1 Immunofluorescent detection of 11β-HSD1 in tryptase-positive 
peritoneal MC.  
Co-staining of peritoneal MC with a commercially available rabbit-anti-mouse 11β-
HSD1 antibody (Cayman) (1:100) and sheep-anti-mouse tryptase (mMCP-6/7) antibody 
(1:100) carried out on cytospins of resident peritoneal cells from Hsd11b1+/+ mice (A), 
or Hsd11b1-/- mice (B). Sheep-anti-mouse IgG and rabbit-anti-mouse IgG isotype 
controls were used at 1:1000. Secondary antibodies were FITC conjugated rat-anti-sheep 
(green) (1:100) and Rhodamine red-conjugated rat-anti-rabbit (red) (1:200). Scale bar 
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Accordingly, HRP IHC was repeated using a purified in-house sheep-anti-mouse 11β-
HSD1 antibody (raised against recombinant mouse 11β-HSD1 protein), which was 
confirmed to be specific for 11β-HSD1 (see Chapter 2, Section 2.3.13.1.). IHC on 
cytocentrifuge preparations from resident peritoneal cells with the in-house 11β-HSD1 
antibody and a tryptase (mMCP-6/7) antibody showed 11β-HSD1 was localized in cells 
with the characteristic morphology of MC (Figure 5.2.). However, co-staining with both 
antibodies was not possible due to the identical origin of both antibodies (both raised in 
sheep). Nonetheless, the distinct morphology of MC allows for relatively easy 
identification of MC on cytospins.   
 
5.2.2. 11β-HSD1 activity in BMD-MC 
To measure 11β-HSD activity in MC, highly pure population of BMD-MC (Chapter 2, 
Section 2.3.5.) from Hsd11b1+/+ mice was assayed for dehydrogenase and reductase 
activity over 2h, 5h, and 24h. Only 11β-reductase activity was detected, with no 
dehydrogenase activity, suggesting the presence of 11β-HSD1 and not 11β-HSD2 in 
BMD-MC (Figure 5.3.). Cultured BMD-MC were used due to the difficulty of obtaining 
sufficient numbers of pure, un-stimulated peritoneal MC. 11β-HSD activity was also 
measured in BMD-M cultured from the same BM cells (data not shown). As previously 
reported (Gilmour, 2002; Gilmour et al., 2006), BMD-M showed only 11β-reductase 
activity (12pmol corticosterone/h/106 cells), with levels comparable to activity measured 
in BMD-MC (Figure 5.3.).  
 




Figure 5.2 11β-HSD1 staining of resident peritoneal MC from Hsd11b1+/+ mice.  
HRP IHC was performed on cytocentrifuge preparations of peritoneal cells from 
untreated Hsd11b1+/+ mice by incubation of slides with primary antibodies; sheep-anti-
mouse 11β-HSD1 (A), tryptase antibody (B) or sheep IgG control (D), followed by 
incubation with secondary HPR conjugated anti-sheep antibody (1:1000). No primary 
antibody control (C) was incubated with secondary antibody only. Colour was 
developed using DAB without nickel as the chromogen. Original images were taken at 















Figure 5.3 11β-HSD1 activity in BMD-MC.  
11β-HSD1 reductase and dehydrogenase activities in BMD-MC were measured by 
adding 3H-substrate to the medium, removing aliquots at various times up to 24h and 
calculating conversion of substrate to product. Data are expressed as % conversion of 
200nM substrate by 2x106 cells, over time. Solid lines/square symbols, reductase 
activity (conversion of 11-dehydrocorticosterone to corticosterone); dashed lines/open 
symbols, dehydrogenase activity (conversion of corticosterone to 11-
dehydrocorticosterone). The level of 11β-reductase activity was 16.9±1.1pmol 
corticosterone/h/106 cells. Values are mean ± SEM of 3 independent assays carried out 
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5.2.3. 11β-HSD1 mRNA is expressed in BMD-MC 
11β-HSD1 mRNA expression was demonstrated in BMD-MC by reverse transcription-
PCR (Figure 5.4). Similar to other immune cells (mouse thymocytes, spleen B and T 
cells, and T cells isolated from lymph nodes, as well as BMD-M), no PCR product was 
observed using primers specific for 11β-HSD2 (Figure 5.4). To determine which 
promoter of Hsd11b1 was utilized in MC, total BMD-MC mRNA was subject to reverse 
transcription-PCR using primers specific for each of the 3 different promoters of 
Hsd11b1; P1 used in lung and kidney; P2 widely used including in liver and adipose 
tissue and P3, used in kidney (for details see Chapter 1, Section 1.6.5. and Chapter 2, 
Section 2.3.11.3.). Control reverse transcription-PCR reactions from liver and kidney 
mRNA served as positive controls for the transcription of Hsd11b1 from the P2 and P3 
promoters, respectively. BMD-MC utilized only the P1 promoter of the Hsd11b1 gene 
(Figure 5.5). No PCR product was produced with the P2 or P3 primers (Figure 5.5). As 
an additional control, mRNA from BMD-MC prepared in a separate laboratory (supplied 



































Figure 5.4 Hsd11b1 mRNA in BMD-MC and other immune cells.  
(A) BMD-MC express 11β-HSD1 mRNA (469bp reverse transcription-PCR product 
with primers 868P and 869P) but not 11β-HSD2 mRNA (B) (400bp reverse 
transcription-PCR product). Positive controls were liver mRNA (positive control for 
11β-HSD1) and kidney mRNA (positive control for 11β-HSD2). Reverse transcription-
PCR products for BMD-MC are from 2 independent BMD-MC RNA samples. 0 RT 
lane contains a reaction without reverse transcriptase (but with BMD-MC RNA) and 0 
PCR reaction contains water instead of cDNA. Lane 1 contains a 100bp ladder. BMD-


























Figure 5.5 BMD-MC transcribe Hsd11b1 from the P1 promoter.   
MC transcribe Hsd11b1 from the P1 promoter (upper panel), whereas M use the P2 
promoter (lower panel, image provided by Mr Fu Yang). Upper panel; reverse 
transcription-PCR products from 3 independent BMD-MC RNA samples showing the 
627bp reverse transcription-PCR product from transcripts initiated at the P1 promoter 
(lanes 4-6), but not the P2 (predicted product of 647bp, lanes 7-9) or P3 promoters 
(predicted product of 542bp, lanes 10-12) of 11β-HSD1. Total 11β-HSD1 mRNA was 
detected using primers common to all transcripts (lanes 13-15, 587bp product with 
primers ex2 and 868P). Lower panel; reverse transcription-PCR products from BMD-
M RNA showing the 647bp reverse transcription-PCR product arising from 
transcription initiated at the P2 promoter (lane 3), but not the P1 (lane 2) or P3 
promoters (lane 4) of 11β-HSD1. Total 11β-HSD1 mRNA (T) was detected using 868P 
and 869P primers, common to all transcripts (lanes 5, 6; 469bp product). Lane 1 in both 
panels contains a 1kb ladder. Lanes marked (0) contain water instead of cDNA and lanes 
marked (-) show reverse transcription-PCR reactions from which the reverse 
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5.2.4. MC number is not altered in peritoneum or joints of Hsd11b1-/- mice 
Since MC are known to accumulate in tissues during inflammation, play a key role in 
K/BxN arthritis, and Hsd11b1-/- mice exhibit worse onset of inflammation using this 
model (Chapter 4), MC number was quantified in carpal joints collected 2d following 
injection of the arthritic serum (5.6µl/g of body weight). Paraffin embedded joint 
sections were stained with Toluidine blue (Figure 5.6.A) and MC were counted 
microscopically in randomly chosen fields. The number of Toluidine blue stained MC 
was similar in Hsd11b1-/- and Hsd11b1+/+ mice (Figure 5.6.B).  
 
Peritoneal MC number also did not differ between genotypes. Flow cytometry analysis 
showed no difference in the total number or proportion of c-kit+ cells within the 
peritoneum (range between 2% and 3% of total peritoneal cells in both Hsd11b1-/- and 
Hsd11b1+/+ mice in multiple comparisons between genotypes) or bone marrow 
(Hsd11b1-/- 3.6x107±0.6 versus Hsd11b1+/+ 4.8x107±0.7 cells). Similarly, there was no 
difference in peritoneal MC number based on differential cell counts from Diff-Quick 
stained cytocentrifuge preparations of peritoneal cells (Figure 5.9). 
 
























Figure 5.6 Toluidine blue staining of MC in joints showed MC number did not 
differ between Hsd11b1-/- and Hsd11b1+/+ mice, 2d following 5.6µl/g injection of 
K/BxN serum.  
(A) Representative images of deparaffinized and hydrated joint sections from 
Hsd11b1+/+ (+/+) and Hsd11b1-/- (-/-) mice stained with Toluidine blue (arrow heads 
indicate stained MC). Original images were taken at 100x (left panels) and 400x (right 
panels) magnification. (B) MC were counted using a 100µm2 reticule. Fields were 
chosen at random for counting (n=5/genotype). Data are expressed as mean ± SEM. 
A 
B 
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5.2.5. Enhanced MC degranulation in Hsd11b1-/- mice 
To investigate whether 11β-HSD1-deficiency alters MC degranulation following 
stimulus, cell degranulation was measured in total peritoneal cells from naïve Hsd11b1-/- 
and Hsd11b1+/+ mice using an in vitro assay of β-hexosaminidase, released from MC 
granules. Initial experiments using peritoneal cells from control mice were performed to 
establish the appropriate concentration of cells and stimulus, as well as the timing of 
assay. Ionomycin causes MC degranulation in a dose dependent manner, and therefore 
was used as a positive control in MC degranulation assays (Figure 5.7.A). CRH is a 
known stimulus of MC degranulation (Theoharides et al., 1998; Donelan et al., 2006). 
However, it did not result in degranulation above background levels (Figure 5.7.A), and 
thus was not used in further experiments. K/BxN serum has been shown to cause MC 
degranulation both in vivo (Lee et al., 2002; Binstadt et al., 2006) and in vitro (Binstadt 
et al., 2006). Diluted 1:2 in Tyrode’s buffer, K/BxN serum caused maximal 
degranulation, comparable to the response of MC to 10µM ionomycin (Figure 5.7.A). 
When peritoneal cells from Hsd11b1-/- and control mice were compared, there was no 
difference between genotypes in β-hexosaminidase release in response to increasing 
concentrations of ionomycin (0.5µM, 2µM and 10µM), (Figure 5.7.B), and no difference 
in un-stimulated cells (not shown), suggesting that degranulation in response to Ca2+ 
ionophore is normal in Hsd11b1-/- MC cells.  
 
Crucially, when a sub-maximal dilution of K/BxN serum was added to peritoneal cells, 
degranulation was significantly higher in Hsd11b1-/- cells than in cells from Hsd11b1+/+ 
mice after 15min incubation with 1:8 dilution of K/BxN serum (Figure 5.8.A). In 
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contrast, a 1:2 dilution of serum caused similar degranulation in cells of both genotypes 
(Figure 5.8.A). Cytokine measurements using ELISA kits (VEGF and TNF-α) were 
attempted on the remaining supernatant from the degranulation assay experiments. 
However, cytokine levels were below the detection limits of the assays. Degranulation in 
response to K/BxN serum was also observed microscopically using an enriched 
population of CD117+ peritoneal cells (50-70% MC purified with MACS columns, 
Chapter 2, Section 2.3.3.), incubated with or without 1:8 dilution of K/BxN serum. After 
21h, cells were photographed. Control cells from Hsd11b1+/+ mice showed little effect of 
incubation with K/BxN serum, whereas Hsd11b1-/- cells showed significant 

















































































Figure 5.7 Effect of ionomycin, CRH and K/BxN serum on MC degranulation 
measured by β-hexosaminidase release.  
(A) Release of β-hexosaminidase from total peritoneal cells (2x106) from control mice in 
response to 15min incubation with Tyrode’s buffer alone (0), ionomycin (0.1-10 µM), 
0.1µM CRH, or K/BxN serum (diluted 1:2 in Tyrode’s buffer). (B) Net release of β-
hexosaminidase from peritoneal cells (2x106) from Hsd11b1+/+ (black bars) and 
Hsd11b1-/- mice (white bars) was measured following 15min incubation with ionomycin 
(0.5µM, 2µM, or 10µM in Tyrode’s buffer). Data are expressed as mean % 
degranulation ± SEM; assay completed in triplicate (n=4/genotype). CRH, 
corticotrophin releasing hormone. 
A 
B 
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Figure 5.8 Compared to control MC, 11β-HSD1-deficient peritoneal MC show 
greater degranulation induced by K/BxN serum.  
(A) Net degranulation was measured by release of β-hexosaminidase from peritoneal 
cells (2x106) from Hsd11b1-/- (white bars) or Hsd11b1+/+ (black bars) mice following 15 
min incubation with K/BxN serum (diluted 1:8 or 1:2 in Tyrode’s buffer). Data are 
expressed as mean ± SEM; n=12-13, *p<0.05 when compared by Two-way ANOVA. 
(B) Representative micrographs of enriched peritoneal CD117+ cells from Hsd11b1+/+ 
(left panels) or Hsd11b1-/- mice (right panels) following 21h incubation with buffer (top 
panels) or K/BxN serum (1:8 dilution) (lower panels). Arrow indicates degranulated 
MC. Original images were taken at 400x magnification. 
 
* 
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5.2.6. Hsd11b1-/-  mice have an altered MC phenotype 
Histochemical staining and flow cytometry analysis were performed to investigate if 
Hsd11b1-/- MC showed an altered cell phenotype. Staining of cytocentrifuge 
preparations of naïve peritoneal cells with Alcian blue or Safranin O, did not reveal any 
obvious histochemical differences between MC from the two genotypes (Figure 5.9). In 
contrast, flow cytometry analysis of peritoneal cells revealed a greater proportion of 
CD117+ (or c-kit+) cells which also expressed CD11b and F4/80 cell markers in 
Hsd11b1-/- mice compared to Hsd11b1+/+ mice (Figure 5.9). In addition, comparison of 
SSC (side scatter, measurement of cell granularity) histogram patterns from both 
genotypes, showing distribution of cells according to granularity, indicated that CD117+ 
cell distribution was altered in the Hsd11b1-/- mice (Figure 5.10.A and B). Analysis of 
side scatter histograms revealed that CD117+ peritoneal cells from Hsd11b1-/- mice were 
more granular than cells from the controls (Hsd11b1-/- mice, 45.3±5.1% vs Hsd11b1+/+ 
mice, 28.2±6.8%). Finally, there was no difference in cell size between the two 
genotypes based on indirect assessment of FSC (forward scatter, measurement of cell 

















Figure 5.9 Comparable histochemical staining of peritoneal MC from Hsd11b1-/- 
and Hsd11b1+/+ mice.  
Representative images of Diff-Quick, Alcian blue and Safranin O staining of freshly 
prepared cytocentrifuge preparations of cells from peritoneal lavages showing similar 
histochemical characteristics of MC from both Hsd11b1-/- (-/-) and Hsd11b1+/+ (+/+) 
mice (cells from 5 mice per genotype were examined). Arrow heads indicate MC. 
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B  
Figure 5.10 A greater proportion of CD117+ peritoneal cells from Hsd11b1-/- mice 
express CD11b and F4/80 than in Hsd11b1+/+ mice.  
Staining was performed in freshly isolated peritoneal cells (5x105) incubated with 
CD117, CD11b and F4/80 antibodies or the appropriate isotype controls. (A) 
Representative flow cytometry dot plot of CD11b and F4/80 staining of CD117+ cells 
from Hsd11b1-/- mice (-/-) and CD117+ cells from Hsd11b1+/+ (+/+) mice. (B) Gating on 
CD117+ peritoneal cells, Hsd11b1-/- mice (white bars) contained a significantly greater 
proportion of CD11b and F4/80 positive cells then Hsd11b1+/+ mice (black bars). Data 
are expressed as mean ± SEM, n=6/genotype, *p<0.05, **p<0.01 when compared by 
Two-way ANOVA. 










Figure 5.11 Flow cytometric analysis of size and granularity of CD117+ peritoneal 
cells shows altered phenotype in Hsd11b1-/- mice.  
Freshly isolated peritoneal cells (5x105) from Hsd11b1-/- (grey) and Hsd11b1+/+ (black) 
mice were analysed by flow cytometry. Representative histograms showing SSC (side 
scatter; representing cell granularity), in individual mice (A), or mean SSC for each 
genotype (B). Unlike SSC, FSC (forward scatter; representing cell size) did not differ 
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5.2.7. Assessment of vascular leakage in skin  
To test the hypothesis that increased MC degranulation in response to K/BxN serum 
resulted in worse oedema and acute inflammation in Hsd11b1-/- mice, vascular leakage 
was measured in skin of Hsd11b1-/- and Hsd11b1+/+ mice. An assay of MC-induced 
vascular leakage in skin has been previously described (Donelan et al., 2006). In this 
assay, Evan’s Blue dye is injected into the tail vein 1h prior to intra-dermal injection of 
potent inducers of MC degranulation into the skin; 1µM SP, 1µM neurotensin (NT), 
0.1µM CRH, and 1µM Compound 48/80 (C48/80, a synthetic MC secretagogue used as 
a positive control). K/BxN serum was also tested (Figure 5.12.A). Sterile PBS was used 
as a negative control. However, this method proved technically difficult to perform, and 
vascular leakage (visualized as blue patches on the inside of the skin) was extremely 
variable between mice of the same genotype and even within a single mouse (Figure 
5.12.B and data not shown). In addition, other confounding factors, such as an irregular 
pattern of blood vessels (the location and the size of vessels) as well as skin blemishes 
and pigmentation present on the underside of the dermal layer, prevented accurate 
delivery and assessment of vascular leakage by this technique. Accordingly, an 















Figure 5.12 Assessment of vascular leakage in skin using MC secretagogues and 
Evan’s Blue dye.  
Anaesthetized mice received iv injection of 200µl Evan’s Blue dye followed by 50µl 
intra-dermal injection of various MC degranulation triggers (clockwise starting from 
top: 1µM SP, 0.1µM CRH, 1µM NT, 1:2 dilution K/BxN serum, 1µg/ml C48/80 or 
PBS, as a negative control). After 30min mice were euthanized and skin was removed 
for examination. (A) Representative image from Hsd11b1-/- mouse. (B) Two 
representative skin samples from Hsd11b1-/- (-/-) and Hsd11b1+/+ (+/+) mice. SP, 
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5.2.8. Assessment of vascular leakage in the peritoneum 
A second assay was tried to measure vasopermeability in Hsd11b1-/- and Hsd11b1+/+ 
mice during inflammation, this time in a model of sterile peritonitis (Chapter 2, Section 
2.3.1.). Evan’s Blue dye was injected i.v. 1h prior to i.p. injection of 10% TG (0.5ml). 
Vascular leakage was then measured by the appearance of blue dye in the peritoneum. 
Based on preliminary experiments in C57BL/6 mice, a time point of 4h after TG was 
chosen for quantification of Evan’s blue dye in peritoneal lavage fluid (Chapter 2, 
Section 2.3.17.). Subsequent experiments included mice from both genotypes and 
vascular leakiness was assessed at 4h following TG injection. Using this assay, no 
differences were seen between Hsd11b1-/- and Hsd11b1+/+ mice (Figure 5.13). However, 
during the course of the experiment, it was noted that the amount of dye in the lavage 
fluid was strongly dependent on the conditions in which it was collected (eg. the length 



























































Figure 5.13 Vascular leakage was not different between genotypes 4h following 
induction of TG-peritonitis and was highly variable within each genotype group. 
Concentration of Evan’s Blue dye in peritoneal lavages 4h following TG injection in 
Hsd11b1-/- (white bar) and Hsd11b1+/+ mice (black bar) (n=8/genotype). Absorbance at 
620nm was measured in peritoneal lavages (corrected for by levels of Evan’s Blue in 














Chapter 5. 11β-HSD1 in Mast Cells 
 152 
5.3. Discussion 
The data contained in this chapter show unequivocally that MC express functional 11β-
HSD1 and suggest that, in its absence, MC function is altered. Initial observations were 
made with IHC staining of 11β-HSD1 in resident peritoneal MC from untreated 
Hsd11b1+/+  mice which showed MC to have high 11β-HSD1 expression compared to 
the other resident cells. However, due to the difficulty of obtaining sufficient numbers of 
relatively pure and un-stimulated peritoneal MC. BMD-MC, previously shown to have 
‘connective’ tissue-like properties when cultured under appropriate conditions, were 
used for RNA and enzyme activity measurements. Highly pure BMD-MC, differentiated 
in vitro expressed 11β-HSD1 mRNA and activity, but not 11β-HSD2 mRNA, a pattern 
which was also seen in other immune cells (discussed in Chapter 6). Reductase activity 
in BMD-MC was higher than in T lymphocytes (<0.1pmol/h/106 cells; (Zhang et al., 
2005)) and BMD-DC (7pmol/h/106 cells; (Freeman et al., 2005)) and comparable with 
levels in BMD-M  
 
Interestingly, Hsd11b1 gene transcription in BMD-MC initiates at the upstream P1 
promoter (Bruley et al., 2006), with little or no transcription from the downstream P2 
(Bruley et al., 2006) and P3 (Moisan et al., 1992) promoters. This contrasts with BMD-
M in which the Hsd11b1 gene is transcribed from the P2 promoter, and suggests a 
distinct regulation in MC compared with most other cell types (eg. liver, adipose tissue, 
and neurons) which utilize the P2 promoter. Intriguingly, expression of C/EBP, a 
potent activator of the P2 promoter of the Hsd11b1 gene transcription (Bruley et al., 
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2006), is not compatible with MC differentiation (Arinobu et al., 2005) possibly 
explaining the use of P1 in this cell type.  
 
The functional role of 11β-HSD1 in MC was addressed both in vitro and in vivo. MC 
accumulate at sites of chronic inflammation, including rheumatoid arthritis (Gelbmann 
et al., 1999; Kassel & Cato, 2002; Woolley, 2003). However, MC number was not 
altered in peritoneum or in joints of Hsd11b1-/- mice compared to the control mice (albeit 
2d after the induction of arthritis) and therefore could not underlie the phenotypic 
difference. However, peritoneal MC from Hsd11b1-/- mice, showed a decreased 
threshold for degranulation induced by K/BxN serum immune complexes. This 
increased sensitivity, at least in part, is likely to contribute to the earlier onset of 
inflammation seen in Hsd11b1-/- mice.  
 
Hsd11b1-/- mice had more CD117+ cells which were also positive for CD11b and F4/80, 
than Hsd11b1+/+ mice, suggesting an increase in a subpopulation of MC in Hsd11b1-/- 
mice. CD11b is not normally considered a MC marker. It is preferentially expressed on 
neutrophils, monocytes, and M while F4/80 is a classical M marker. However, 
CD11b and F4/80 have been described on MC, and their expression on MC is associated 
with monocyte-like morphology (Nishiyama et al., 2004), although the relevance of this 
is unclear at present. It has been suggested that CD11b is expressed on immature MC 
and is involved in emigration of MC precursors into tissues (Rosenkranz et al., 1998). 
Following diptheria toxin treatment of mice expressing the human diptheria toxin 
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receptor under the control of the CD11b promoter, MC were depleted >90% (although 
with a later time course than M)(Cailhier et al., 2006), consistent with expression of 
CD11b on MC as well as M. Moreover, over-expression of PU.1 (the master 
haematopoietic regulator) in MC progenitors induces CD11b, F4/80 and c-kit 
(Nishiyama et al., 2004). Interestingly, GC receptor and PU.1 exert mutually 
antagonistic effects in some haematopoietic cell precursors (Gauthier et al., 1993), yet in 
monocytes they functionally co-operate (Aittomaki et al., 2000). Thus, it is possible that 
GC regeneration via 11β-HSD1 regulates the differentiation, phenotype, or function of 
MC (and other leukocytes), depending upon the availability of enzyme substrate. It will 
of great interest to determine whether haematopoietic cell differentiation is affected in 
Hsd11b1-/- mice. 
 
Injection of K/BxN arthritic serum into mice induces a rapid vascular leak localized to 
peripheral extremities (Binstadt et al., 2006). Attempts were made to measure vascular 
leakiness in Hsd11b1-/- mice. The methods used here have previously been used to show 
differences in vasodilation between C57BL/6 mice and W/Wv mice (which are 
completely deficient in MC) (Donelan et al., 2006). However, these experiments were 
unsuccessful largely due to technical difficulties. In the future it will be important to 
establish whether Hsd11b1-/- exhibit increased vascular leakage. Interestingly,    
Hsd11b1-/- mice show increased angiogenesis following injury (Small et al., 2005), 
indicating susceptibility of vascular regulation by 11β-HSD1, at least during tissue 
repair. Since MC occur in highly vascular tissues, where they are found next to blood 
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vessels, it will be of interest to establish whether MC play a role in this phenotype of 
Hsd11b1-/- mice. 
 
Although 11β-HSD1-deficiency in MC provides an intriguing mechanism that may 
contribute to the worsened inflammatory response in Hsd11b1-/- mice, it remains unclear 
whether it is the 11β-HSD1-deficiency in resident cells or the recruited inflammatory 
cells that are responsible for the altered inflammatory response in Hsd11b1-/- mice.  
 
 











Assessment of the immune system and its contribution to the 
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6.1. Introduction 
Expression of 11β-HSD1 has previously been reported in M (Thieringer et al., 2001, 
Gilmour et al., 2006), CD4+, CD8+, and B220+ lymphocytes (Zhang et al., 2005), as well 
as DC (Freeman et al., 2005). It is important to note, however, that 11β-HSD1 is also 
expressed in various non-immune cells which play a role during an inflammatory 
response. Therefore, the inflammatory phenotype of Hsd11b1-/- mice may be due to 11β-
HSD1-deficiency in recruited immune cells (eg. monocytes, neutrophils, eosinophils), 
resident immune cells (such as MC and M), local tissue microenvironment (eg. blood 
vessels), or a combination of these factors. A BM transfer (BMT) experiment (Chapter 
2, Section 2.3.15.) was carried out in an attempt to determine the relative contributions 
of 11β-HSD1 in tissues versus recruited immune cells to the anti-inflammatory 
phenotype. However, it was also important to establish whether BM cells in Hsd11b1-/- 
were normal. Therefore, to determine whether 11β-HSD1-deficiency alters immune cell 
sub-populations, cells from BM, spleen, thymus, peritoneum, as well as peripheral blood 
were isolated from untreated Hsd11b1-/- mice and Hsd11b1+/+ mice, for quantification of 
total cell numbers and cell types by flow cytometric measurement of standard cell 
markers. The BMT experiment described in this chapter was carried out in collaboration 
with Kay Samuel, who performed the irradiation and tail vain injections as well as 








6.2.1. Effects of 11β-HSD1-deficiency on number of immune cells 
The number of cells collected from BM, spleen, thymus, peritoneum, as well as 
peripheral blood cells, did not differ between genotypes (Figure 6.1). This finding was 
consistent with results from Chapter 5, where both Hsd11b1-/- and Hsd11b1+/+ mice 
exhibited a similar number of MC in peritoneum and joints (Chapter 5, Section 5.2.5).  
 
6.2.2. Flow cytometric analysis of immune cells from Hsd11b1-/- and Hsd11b1+/+mice 
 
Flow cytometric analysis (Chapter 2, Section 2.3.16.), using antibodies against c-kit, 
B220, Thy-1, Gr-1, CD45, Lin and Sca-1 (see Table 6.1 for details) was used to 
characterize cells obtained from both Hsd11b1-/- and Hsd11b1+/+ mice. The ratio of 
CD4+/CD8+ T-cells was measured only in the thymus. For analysis of peritoneal, spleen 
and BM cells, antibodies were combined as follows: CD45/Thy-1/B220 to stain T and 
B-cells, CD45/CD11b/Gr-1 to stain monocytes/granulocytes, CD45/LIN/c-kit and 
CD45/Sca-1/c-kit to stain MC. Data were analysed in dot plots and histograms (Figure 





             
 






































































































Figure 6.1 Total cell number in immune organs and leukocyte number in 
peripheral blood did not differ between Hsd11b1-/- and Hsd11b1+/+ mice.  
Cell counts (determined microscopically using haemocytometer) of peritoneal cells (A), 
spleenocytes (B), thymocytes (C), total BM cells from both femurs (D) and peripheral 
blood leukocytes (E) revealed no differences in cell numbers between Hsd11b1+/+ (black 
bars) and Hsd11b1-/- mice (white bars). Data represent total number of cells per 
compartment per mouse and are expressed as mean ± SEM; n=5/genotype. No 
significant differences were detected between the genotypes when compared by 
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Table 6.1 Overview of antibodies used for the flow cytometric assessment of 
inflammatory cell phenotype in Hsd11b1-/- mice.   
 
Antibody Main Target  Comments Other names 
B220  B lymphocytes Also found on activated T 
cells, subset of DC and 




CD11b Monocytes, Mand 
granulocytes, not 
lymphocytes 





CD4 T helper cells Co-receptor in MHC II-
restricted antigen induced 
T cell activation 
Ly-4,L3T4 
CD8 T cell suppressor / 
cytotoxic cells 
MHC I-restricted receptor Ly-2 
CD45 All hematopoietic cells, 
except mature 
erythrocytes and platelets 
Essential regulator of T 






CD117 Hematopoietic stem cells 
and mature MC 
Important for 




Gr-1 Granulocytes Also found on M and 
transiently expressed on 
differentiating monocytes 
Ly6G, and  
includes Ly6C 
Lin Monoclonal antibody 
cocktail   
Containing: CD2, CD3, 
CD4, CD5, CD8, NK1.1, 




Sca-1 Immature hematopoietic Found on early 
hematopoietic progenitor 
cells that can populate BM 
Ly6A/E or Ly6D 
CD90  T lymphocytes and 
thymocytes 
Also found on neural 













Figure 6.2 Representative dot plots and histograms used for flow cytometric 
analysis of immune cells from naïve Hsd11b1-/- and Hsd11b1+/+ mice.  
(A) Dot plots showing unstained cells (upper panel) and cells stained for CD11b (PE; x-
axis) and Gr-1 (APC; y-axis) (lower panel) from Hsd11b1-/- (-/-) and Hsd11b1+/+ (+/+) 
mice. (B) Histograms of unstained cells (upper panel) and Thy-1 positive cells (lower 
panel) showing 3 gates (M1; unstained cells, M2; Thy-1 low, and M3; Thy- high). The 
same templates (dot plots and histograms) were used for assessment of cells from whole 




+/+   -/- 
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6.2.3. Effects of 11β-HSD1-deficiency on immune cell populations 
Comparison of cells recovered from untreated Hsd11b1-/- and Hsd11b1+/+ mice revealed 
differences in cell populations between genotypes, in peritoneum and BM (Figure 6.3, 
Figure 6.4 and Table 6.2). Peritoneal cells from Hsd11b1-/- mice contained a higher 
proportion of Thy-1+ cells, and a lower proportion of Gr-1-/CD11b+ cells and Gr-
1+/CD11b+ cells than Hsd11b1+/+ mice (Figure 6.3). In BM, compared to Hsd11b1+/+ 
mice, Hsd11b1-/- mice had a greater proportion of B cells (B220+) and lower proportion 
of Gr-1+ cells (Figure 6.4). No differences were seen between the genotypes in cell 





































































































































Figure 6.3 Hsd11b1-/- mice have more T cells but fewer granulocytes in the 
peritoneum than Hsd11b1+/+ mice.  
Flow cytometry analysis of peritoneal cells from Hsd11b1+/+ (black bars) and Hsd11b1-/- 
mice (white bars) showed a greater proportion of Thy-1+ cells (A), and a lower 
proportion of Gr-1-/CD11b+ (B) and Gr-1+/CD11b+ cells (C) in the peritoneum of 
Hsd11b1-/- mice. Data are mean ± SEM; n=5/genotype. ** p<0.01 when compared by 
unpaired Student’s t-test.    
 




















































Figure 6.4 Altered distributions of B cells and granulocytes in the BM of untreated 
Hsd11b1-/- mice.  
Flow cytometry analysis of BM cells revealed that in comparison to Hsd11b1+/+ mice 
(black bars), Hsd11b1-/- mice (white bars) had a greater proportion of B220+ cells (A) 
and fewer Gr-1+ cells (B). Data represent mean ± SEM; n=5/genotype. * p<0.05 when 
compared by unpaired Student’s t-test.   
 
 




Table 6.2 Flow cytometric comparison of peripheral blood cells from untreated 
Hsd11b1-/- and Hsd11b1+/+ mice. 
 
 
Blood Cells Hsd11b1+/+  (n=5) Hsd11b1-/-  (n=5) T-test 
B220+/Thy-1- 25.7±5.1 21.2±3.7 p>0.05 
 
B220+/Thy-1+ 2.1±0.3 2.7±0.2 p>0.05 
 
B220-/Thy-1- 49.3±3.4 44.5±3.7 p>0.05 
 
B220-/Thy-1+ 22.9±6.7 31.6±4.2 p>0.05 
 
B220+/Gr-1- 26.7±5.4 21.1±3.7 p>0.05 
 
B220+/Gr-1+ 2.4±1.1 3.9±1.2 p>0.05 
 
B220-/Gr-1- 54.5±7.6 49.5±1.6 p>0.05 
 




























Thymocytes Hsd11b1+/+  (n=5) Hsd11b1-/-  (n=5) T-test 
 
B220+/Thy-1- 0±0 0±0 p>0.05 
 
B220+/Thy-1+ 0.022±0.01 0.014±0.01 p>0.05 
 
B220-/Thy-1- 22.57±5.51 25.84±5.91 p>0.05 
 
B220-/Thy-1+ 76.324±5.15 74.234±5.94 p>0.05 
 
B220+/Gr-1- 0±0 0±0 p>0.05 
 
B220+/Gr-1+ 0.022±0.02 0.022±0.02 p>0.05 
 
B220-/Gr-1- 98.742±0.69 99.95±0.02 p>0.05 
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Table 6.4 Flow cytometric comparison of spleenocytes from untreated Hsd11b1-/- 
and Hsd11b1+/+ mice. 
 
Spleenocytes Hsd11b1+/+  (n=5) Hsd11b1-/-  (n=5) T-test 
 
B220+/Thy-1- 56.4±1.5 55.8±2.6 p>0.05 
 
 B220+/Thy-1+ 7.7±0.4 7.4±0.4 p>0.05 
 
B220-/Thy-1- 15.4±1.4 12.7±5.5 p>0.05 
 
 B220-/Thy-1+ 20.6±2.0 20.7±1.1 p>0.05 
     
    B220+/Gr-1- 63.21±1.0 62.5±2.3 p>0.05 
 
B220+/Gr-1+ 0.9±0.2 0.8±0 p>0.05 
 
B220-/Gr-1- 34.6±1.4 35.7±2.4 p>0.05 
 
B220-/Gr-1+ 1.3±0.3 1.1±0.1 p>0.05 
 
B220+/c-kit- 59.5±2.6 63.8±2.7 p>0.05 
 
B220+/c-kit+ 0.1±0 0.1±0.03 p>0.05 
 
B220-/c-kit- 40.5±2.6 36.0±2.7 p>0.05 
 
B220-/c-kit+ 0.03±0.01 0.03±0 p>0.05 
   
  Gr-1+/CD11b- 1.0±0.1 1.0±0.2 p>0.05 
 
  Gr-1+/CD11b+ 6.0±1.0 4.7±0.9 p>0.05 
 
 Gr-1-/CD11b- 78.8±2.1 80.7±1.9 p>0.05 
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6.2.4. Bone marrow cell transfer between Hsd11b1-/-and Hsd11b1+/+ mice 
Following lethal gamma irradiation (described in Chapter 2, Section 2.3.15.), Hsd11b1-/- 
mice were reconstituted with 107 BM cells from Hsd11b1+/+ mice via tail vein injection; 
designated KO(WT) mice. Conversely, irradiated Hsd11b1+/+ mice were reconstituted 
with BM from Hsd11b1-/- mice; designated WT(KO) mice. Unfortunately, survival was 
low following irradiation and BMT, with ~half of the mice dying ~12d following the 
procedure. A second BMT procedure was performed in order to generate sufficient mice 
for an arthritis experiment. Due to a lag in time (~2 weeks) between the two BMT 
procedures, two separate BMT-arthritis experiments were carried out and data were 
pooled as presented below.   
 
6.2.5. Induction of K/BxN serum transfer arthritis  following BMT 
After 56d of recovery, BMT recipient mice, as well as non-irradiated (non-BMT) 
Hsd11b1-/- and Hsd11b1+/+ mice were subjected to K/BxN arthritis (Figure 6.5). The 
time course of arthritis onset in non-BMT Hsd11b1-/- and Hsd11b1+/+ mice was similar 
to previous experiments (Figure 6.6, compare with Figure 4.6), demonstrating that the 
serum batch used for this experiment had a similar potency to previous batches. 
Following in vivo reconstitution of BM in lethally irradiated mice, recovery and the 
subsequent injection of K/BxN serum, all mice developed disease. However, unlike 
previous arthritis experiments using non-BMT mice, the disease course in BMT mice 
showed very large within-group variability (Figure 6.7), resulting in overlap of the group 
means (Figure 6.8). The area under the curve for clinical scores was not statistically 
different between groups (data not shown). Nonetheless, at all but 3 of the time points, 
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the mean clinical score was higher for KO(WT) than for WT(KO) mice, although this 





























Figure 6.5 Experimental design for BMT-arthritis.  
(A) Antibiotics were initiated 7d prior to commencement of BMT-arthritis experiment. 
Irradiation of mice and reconstitution with 107 donor cells via tail vein injection 
occurred on d0. After 56d of recovery arthritis was induced with a single injection of 
K/BxN serum (5.6l/g body weight). After 21d of arthritis (d77), mice from all 
experimental groups were culled and tissues were collected for analysis. (B) List of 
experimental groups; KO(WT) indicates Hsd11b1-/-  mice which were reconstituted with 
BM cells from Hsd11b1+/+ mice, whilst WT(KO) indicates Hsd11b1+/+ mice which 
were reconstituted with BM cells from Hsd11b1-/-  mice. Checkmark indicates whether 
BMT and/or arthritis were performed. n indicates number of mice in each group.  
 
Groups BMT arthritis n 
 
WT(KO)   7 
 
KO(WT)   5 
 
Hsd11b1-/-    3 
 
Hsd11b1+/+    3 
 





   
2 
 
-7d 0d 28d 56d 77d 
K/BxN arthritis (21d) 
Injection 
of serum Tissue collection  




































Figure 6.6 Time course of arthritis in non-BMT mice is similar to that observed 
previously.  
Clinical score over 21d following a single injection of 5.6l/g body weight of K/BxN 
serum on 0d. Hsd11b1-/- mice (white circles, dashed line) are compared to Hsd11b1+/+ 
mice (black squares, solid line) (n=3/genotype). Clinical scoring was preformed blind to 











Figure 6.7 High variability in clinical scoring following injection of K/BxN serum in 
individual BMT-mice.  
Clinical score following a single injection of K/BxN serum (5.6l/g body weight) on d0 
in KO(WT) (n=5) (A) and in WT(KO) (B) (n=7) mice. Values shown are for individual 










































































Figure 6.8 Similar clinical scores for WT(KO) and KO(WT) mice following 
injection of K/BxN serum.  
Clinical scores (pooled data from both BMT-arthritis experiments) showing KO(WT) 
mice (white diamonds, dashed line) (n=5) compared to WT(KO) (black triangles, solid 
line) (n=7). Values shown are mean ± SEM. Two-way ANOVA did not show 
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6.2.6. Assessment of immune cells following BMT and K/BxN arthritis 
Following arthritis, cells were recovered from the peritoneum, thymus, spleen and BM 
(as described above for untreated mice, Section 6.2.1) for total cell counts (Figure 6.9 
and Figure 6.10). In contrast to untreated mice, following arthritis, Hsd11b1-/- mice 
without BMT had higher number of total spleenocytes and BM cells than Hsd11b1+/+ 
mice, without BMT (Figure 6.9, compared with Figure 6.1). The number of thymocytes 
and peritoneal cells remained similar in both genotypes (Figure 6.9).  
 
Following both BMT and arthritis, there were no differences in cell counts between the 
KO(WT) and WT(KO) groups (Figure 6.10). However, BMT-mice, compared to non-
BMT groups, lost the most weight, appeared sickly and failed to show symptoms of 
arthritis following injection of K/BxN serum (77d following BMT) (data not shown). 
This was similar in both the KO(WT) and WT(KO) mice. Interestingly, there was a 
positive correlation between the area under the curve of the clinical score (indicating the 
severity of arthritis) and the number of BM cells (including total cell number from both 
femurs/mouse) (Figure 6.11.A). In addition, there was a positive correlation between the 
number of BM cells and spleenocytes (Figure 6.11.B), as well as BM cells and 
thymocytes (Figure 6.11.C).  
 
Finally, flow cytometric analysis was performed on cells following BMT and K/BxN 
arthritis. However, due to the high mortality rate following irradiation and sub-optimal 
health of surviving BMT mice it is difficult to draw reliable conclusions from these data. 
The results have been included in Appendix I. 
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Figure 6.9 Following arthritis, Hsd11b1-/- mice had more spleenocytes and BM cells, 
but a similar number of peritoneal cells and thymocytes as Hsd11b1+/+ mice.  
Cell counts (determined microscopically using haemocytometer) of peritoneal cells (A), 
thymus (B), and spleen (C) and BM (D) from Hsd11b1-/- and Hsd11b1+/+ mice with 
arthritis (n=3/group). Values shown are mean ± SEM. * p<0.05 when compared by 





















































































Figure 6.10 Similar number of immune cells in WT(KO) and KO(WT) mice with or 
without arthritis.  
Cell counts (determined microscopically using haemocytometer) of cells from 
peritoneum (A), thymus (B), spleen (C) and BM (D) from KO(WT) with arthritis (n=5), 
WT(KO) with arthritis (n=7), KO(WT) without arthritis (n=2) and WT(KO) without 
arthritis (n=2). Values shown are mean ± SEM. No statistical differences were detected 
in groups with arthritis (unpaired Student’s t-test). Statistical tests were not performed 
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Figure 6.11 Severity of arthritis was positively associated with BM cells, 
irrespective of genotype.  
(A) There was a positive correlation between the clinical score AUC (arbitrary units) 
and the number of reconstituted cells in BM (r2=0.55, p<0.01). (B) There was a positive 
correlation between the number of BM cells (total cells collected from both femurs) and 
spleenocytes (r2=0.35, p<0.05), as well as (C) BM cells and thymocytes (r2=0.46, 
p<0.01). Each point corresponds to a single mouse (n=13). 
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6.3 Discussion 
11β-HSD1 expression has been shown in immune cells, including lymphocytes and cells 
of the myeloid lineage, and recent work has shown that the phenotype of these cells is 
altered by 11β-HSD1-deficiency (reviewed in (Chapman et al., 2006)).  The experiments 
described in this Chapter were designed to dissect the relative contributions of ‘resident’ 
immune cells (such as MC and M) and non-immune cells that form the local 
microenvironment (such as smooth muscle cells and fibroblasts, which also express 11β-
HSD1) which are radio-resistant and the radio-sensitive ‘recruited’ inflammatory cells to 
the altered inflammatory response in Hsd11b1-/- mice. First, however, flow cytometric 
analysis was performed on leukocytes and their progenitors from untreated Hsd11b1-/- 
and control mice, to determine the consequences of 11β-HSD1-deficiency on the 
undisturbed immune system. Although no differences were found in total cell numbers 
between the genotypes, Hsd11b1-/- mice showed abnormalities in the proportions of 
lymphocytes and granulocytes in peritoneal and BM cells, compared to Hsd11b1+/+ 
mice. These data warrant more experiments to fully assess the role of 11β-HSD1 in the 
regulation of haematopoietic differentiation programmes. 
 
The reconstitution of immune cells in recipient mice, during the BMT-arthritis 
experiment, may have been sub-optimal. The high mortality rate (~50%) at ~12d 
following irradiation, while mice were supplemented with antibiotics, was probably a 
result of insufficient reconstitution of immune cells (personal communication, Ms Kay 
Samuel), and post mortem observations showed gastrointestinal problems. Furthermore, 
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upon examination of BM cell counts in surviving mice, it appeared that mice with lower 
cell counts (suggesting poor reconstitution) inversely correlated with severity of arthritis 
in both BMT groups; KO(WT) and WT(KO). The positive correlation between number 
of BM cells and clinical scores in the recipient mice suggested that in order to be 
susceptible to K/BxN arthritis, mice had to have a fairly healthy and intact immune 
system to begin with. Nonetheless, the preliminary BMT-arthritis experiment hinted at 
the contribution of the host (thus non-immune or resident immune cells) in worsening 
arthritis. Although not significant, KO(WT) mice appeared to have impaired resolution 
compared to WT(KO) mice. 
 
Amendments to the experimental protocol may be used to improve the outcome of future 
BMT experiments aimed to determine the relative contributions of 11β-HSD1 in resident 
versus recruited immune cells to the inflammatory phenotype. For example, transfer of 
spleenocytes from donor mice to the host, in addition to i.v. injection of BM cells, will 
provide short term immunity and aid in post-operative recovery, ultimately reducing 
mortality. Importantly, it will be essential to determine the success of BM reconstitution 
and health of recipient mice prior to continuation of further experimental procedures. 
This can be achieved by using C57BL/6J mice carrying the CD45.1 marker as “WT” 
mice. Normal C57BL/6J mice (as well as the congenic Hsd11b1-/- mice used in all 
experiments) carry the antigenically distinct CD45.2 allele. Thus, flow cytometry 
analysis of leukocytes can be used to detect presence or absence of the CD45.1/CD45.2 
antigens to confirm normal numbers and origin of leukocytes, in spleen and BM cells 
during the recovery period. Alternatively, the relative levels of 11β-HSD1 alleles in 
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circulating leukocytes, in Hsd11b1-/- and Hsd11b1+/+ mice, can be determined to assess 
the success of reconstitution following irradiation. The BMT experiment established that 
Hsd11b1+/+ mice can be reconstituted with BM cells from Hsd11b1-/- mice (and vice 
versa). However, additional control groups; Hsd11b1-/- reconstituted with BM cells from 
Hsd11b1-/- mice and control mice reconstituted with BM cells from control mice, should 
also be included. 
 
Finally, the question of whether the inflammatory phenotype of Hsd11b1-/- mice is 
driven by MC, or is dependent upon the hormonal (GC) or tissue (eg. vasculature) 
environment can be addressed in the future using KitW-sh/W-sh mice (available from 
Jackson labs), which are deficient in MC (Grimbaldeston et al., 2005). For example, 
mature MC populations can be reconstituted in non-irradiated KitW-sh/W-sh mice by 
transfer of BMD-MC (cultured from Hsd11b1-/- or Hsd11b1+/+ mice). Alternatively, 
KitW-sh/W-sh mice can be crossed with Hsd11b1-/- mice to generate KitW-sh/W-sh Hsd11b1-/- 
doubly mutant mice (achieved in F2 mice as the Kit and Hsd11b1 genes are on different 
chromosomes), which can then be reconstituted with BMD-MC from either Hsd11b1-/- 
or Hsd11b1+/+ mice. Importantly, these experiments will enhance our understanding of 
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7.1 Summary 
Pharmacologically, GC exert powerful immunosuppressive and anti-inflammatory 
effects, but long term therapy is limited by the adverse metabolic side effects. The aim 
of this thesis was to investigate whether amplification of intracellular GC levels by 11β-
HSD1 represents an important endogenous mechanism in limiting inflammation. Recent 
evidence (reviewed in (Chapman et al., 2006)), including work described in this thesis, 
suggests that 11β-HSD1 forms part of an endogenous anti-inflammatory mechanism 
engaged early during an inflammatory response that may program subsequent resolution. 
The contribution of 11β-HSD1 during an inflammatory response was examined using 
Hsd11b1-/- mice and Hsd11b1+/+ control mice. Both the carrageenan-induced pleurisy 
model (described in Chapter 3), as well as the K/BxN model of self-resolving 
experimental arthritis (described in Chapter 4), were found to be suitable in vivo 
experimental models of inflammation, revealing worse inflammation in Hsd11b1-/- mice 
compared to Hsd11b1+/+ mice. These data support the original findings, which 
suggested an anti-inflammatory function for 11β-HSD1 in a model of TG-induced 
peritonitis (Gilmour, 2002; Gilmour et al., 2006), and importantly, emphasize a role for 
11β-HSD1 in restraining acute inflammation. Furthermore, in contrast to the TG-
induced peritonitis model, where resolution occurred simultaneously in both genotypes, 
these data suggests that the resolution of inflammation seen both in arthritis (judged by 
clinical scoring of inflamed joints and supported by histology at 21d) and pleurisy 
(based on histological examination at 48h) was delayed in Hsd11b1-/- mice, suggesting 
that 11β-HSD1 may also promote resolution. It is possible however, that the altered 
resolution may be a consequence of the greater initial inflammatory response.  
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In this thesis, it was demonstrated that MC express functional 11β-HSD1 enzyme 
(described in Chapter 5). Crucially, 11β-HSD1-deficient mast cells show a reduced 
threshold for MC degranulation induced in vitro by K/BxN arthritogenic serum, a 
finding that has implications for not only inflammatory arthritis, but also infection, 
allergy and tolerance. This finding also provides a mechanistic insight into how 11β-
HSD1 may modulate the early immune response. The studies presented in this thesis, 
consistently, and in more than one model, demonstrate that the phenotype of Hsd11b1-/- 
mice is consistent with a more rapid onset of inflammation and/or greater initial severity, 
with adverse downstream consequences. An altered MC phenotype is likely to underlie 
at least part of this phenotype. These studies have provided a basis for future 
experiments to tease apart the role and regulation of 11β-HSD1 in inflammation. Thus, 
further investigations are warranted and better understanding of the immune-regulated 





These findings raise intriguing questions about the importance of local modulation of 
GC by 11β-HSD1, with particular relevance to MC, and provide a basis for further 
investigation. The locus of the anti-inflammatory effect of 11β-HSD1 remains a central 
question. Although recently 11β-HSD1 has been identified in immune cells (reviewed in 
(Chapman et al., 2006)), it will be important to clearly identify which of these cells are 
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involved in the mechanism responsible for the acute anti-inflammatory effects of 11β-
HSD1.  
Previously it has been shown that 11β-HSD1 activity is rapidly induced in peritoneal 
cells following TG injection and the cell type responsible for this remains to be 
identified (Gilmour et al., 2006). Future experiments should focus on identifying and 
phenotyping the cell populations elicited to the peritoneum during acute TG-induced 
peritonitis. However, it is important to remember that the variation in 11β-HSD1 activity 
(measured in resident versus elicited cells) may reflect differences in the activation state 
of these cells rather than their source. Therefore, a direct comparison of 11β-HSD1 
activity in resident and elicited peritoneal cells following their activation ex vivo is also 
necessary. 
 
Additionally, following TG injection more cells were elicited to the peritoneum in 
Hsd11b1-/- than in Hsd11b1+/+ mice (Coutinho et al, to be submitted). Thus, in parallel 
to the investigations suggested above, it will be important to establish the mechanisms 
responsible for the greater influx of cells seen in Hsd11b1-/- mice during an 
inflammatory response. The number of immune cells isolated from peritoneum, spleen, 
thymus, BM and peripheral circulation from untreated mice was similar between 
Hsd11b1-/- and Hsd11b1+/+ mice (described in Chapter 6). Two possible mechanisms 
responsible for the greater recruitment of inflammatory cells during peritonitis are; first, 
cytokine and chemokine regulation of the inflammatory response involving the resident 
immune cells as well as non-immune cells and/or incoming inflammatory cells, and 
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secondly, the regulation of vascular permeability. Attempts were made (described in 
Chapter 5) to evaluate vascular permeability in the skin and peritoneum of Hsd11b1-/- 
and Hsd11b1+/+ mice. However, due to technical difficulties no conclusions could be 
drawn and thus this question remains to be addressed.  
 
Chapter 6 described the BMT-arthritis experiment which was designed to examine the 
relative contribution of recruited inflammatory cells versus host tissue to the 
inflammatory phenotype of the Hsd11b1-/- mice. Unfortunately, due to technical 
difficulties and large variability in the response of mice to the BMT, clear conclusions 
could not be made. However, despite its shortcomings, this preliminary experiment 
hinted that overall worse inflammation tracked with the host tissue. With hindsight, 
additional checkpoints and controls in the experimental design (described in the 
discussion section of Chapter 6) would have perhaps ensured a more successful 
reconstitution of the immune system and allowed for a more indepth interpretation of the 
data. To further address which type of cells are responsible for the phenotype of the 
Hsd11b1-/- mice, BMT should be repeated with these additional controls. It is likely that 
both compartments (immune/non-immune resident cells and recruited inflammatory 
cells) play a role and a separate set of experiments must to be designed to look 
individually at the contribution of specific sub-types of cells, for example MC, 
fibroblasts, M, vascular tissue or mesothelial cells.  
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The focus of Chapter 5 was to compare the phenotype of MC from Hsd11b1-/- and 
Hsd11b1+/+ mice since 11β-HSD1 has not been characterized in MC previously. 
Although the number of MC was normal, the phenotype was altered in Hsd11b1-/- mice, 
particularly IgG-mediated degranulation, which was higher in Hsd11b1-/- than 
Hsd11b1+/+ mice following exposure to 1/8 dilution of K/BxN serum. Therefore, future 
experiments should investigate the contribution of 11β-HSD1 in MC to the phenotype of 
Hsd11b1-/- mice to determine if it limits acute oedema and inflammation.  
 
Since the function of 11β-HSD1 is dependent upon its substrate (inactive GC) much of 
the physiological function seen in vivo may not be apparent in an in vitro environment. 
This is an important factor to consider when planning experiments which are aimed at 
establishing whether 11β-HSD1 may regulate the differentiation of MC as well as the 
phenotype and function of mature MC, especially since these cells complete their 
development under influence of the local environment. Therefore, it will be of great 
importance to establish an appropriate MC population to use, preferably one 
differentiated in vivo (in the presence of endogenous GC). Perhaps peritoneal MC, albeit 
a very small cell population (3-5% of the total peritoneal population), serve as the ideal 
cell source in which to carry out further experiments. Recently, Malbec et al (2007) have 
proposed a method of culturing peritoneal MC to generate highly pure MC populations 
with large number of mature serosal-type mouse MC which retain most of the 
morphological, phenotypic, and functional features of peritoneal MC. It will be 
interesting to apply this culture method in further comparisons of Hsd11b1-/- and 
Hsd11b1+/+ MC, particularly for degranulation experiments (with various stimuli, eg. 
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IgE mediated degranulation) and preparation of MC mRNA for microarray analysis of 
gene expression programmes.  
 
A key question arising from this thesis is whether a single or separate mechanism(s) are 
responsible for 11β-HSD1 limiting inflammation at the acute versus the resolution stage. 
Evidence in the literature points to a crucial role for MC in initiating inflammation, 
acting prior to M and playing a major role in neutrophil recruitment (reviewed in 
(Nigrovic & Lee, 2005)). However, there is evidence that MC are also involved in tissue 
repair and remodeling processes following chronic inflammation (reviewed in (Marshall 
& Jawdat, 2004)). Thus, it is possible that MC may be a contributing factor, not only to 
the onset of arthritis, but also to the delay in resolution seen in the Hsd11b1-/- mice 
during arthritis. However, the mechanisms by which GC promote resolution are not well 
understood and MC 11β-HSD1 is only one possible mechanism in a system which is 
complex and more than likely to be dependent on multiple cells and pathways.  
 
Tissue remodeling was altered in Hsd11b1-/- mice in both the pleurisy model (adhesion 
of lung lobes seen only in Hsd11b1-/- mice) and in arthritis (worse exostosis and 
ganglion cyst formation, seen only in Hsd11b1-/- mice). Additionally, data obtained from 
the micro-CT scanning of femur bones (described in Chapter 4) showed arthritis-induced 
abnormal remodeling of bone micro-architecture in Hsd11b1-/- mice, but only after 21d 
of arthritis and not after 2d (shown in Chapter 4) or in untreated mice (Justesen et al., 
2004). To better understand the mechanism behind these skeletal changes, further 
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examination of histomorphometric parameters, including assessment of osteoclasts and 
osteoblasts, in Hsd11b1-/- mice are warranted.  
 
Finally, in addition to the immune cells, the HPA axis plays a key role in the response to 
inflammatory stimuli. Plasma corticosterone levels were measured at the start and 
conclusion of arthritis (described in Chapter 4), with greater plasma corticosterone levels 
in Hsd11b1-/- mice during resolution than in Hsd11b1+/+ mice. Intracellular GC 
concentrations can differ markedly from blood levels due to metabolism by 11β-HSD. 
Thus, it will be important to verify the circulating levels of both corticosterone and 11-
DHC in untreated and experimental mice (at varying stages of inflammation) in order to 
establish the available level of substrate for 11β-HSD1. This type of experiment may 
explain why, despite greater activation of HPA axis during resolution, Hsd11b1-/- mice 
have worse inflammation than Hsd11b1+/+ mice. 
 
In this thesis, Hsd11b1-/- mice were examined during acute inflammation which resolved 
over days or weeks. The stimulus or irritant in each case was a sudden assault on the 
host immune system (eg. i.p. injection of K/BxN serum) resulting in an acute response 
of the immune system and recruitment of inflammatory cells. This is in contrast to the 
low grade inflammatory response described for obesity and the metabolic syndrome (not 
addressed in this thesis, but reviewed elsewhere (Hotamisligil, 2006)). Intriguingly, 
Hsd11b1-/- mice are protected from symptoms of the metabolic syndrome (Morton et al., 
2001; Morton et al., 2004). In this context, during low grade chronic inflammation, 11β-
HSD1-deficiency is protective. This paradox highlights the complexity both of GC 
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regulation by 11β-HSD1, but also the effect of GC on the immune system. Much more 
work is required to truly appreciate the differences in inflammatory response during 
acute, high-impact versus low-grade and chronic inflammation, and how GC mediate the 
immune responses in each case.  
 
In conclusion, the experiments described in this thesis support an anti-inflammatory role 
for 11β-HSD1 during an inflammatory response (in at least the models described here) 
and begin to address the underlying mechanisms for the altered inflammatory phenotype 
of Hsd11b1-/- mice. Most importantly, these data provide an exciting foundation to 
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Appendix I 1.1 Flow cytometric analysis of immune cells following BMT and K/BxN 
arthritis 
  
At the end of the BMT-arthritis experiment, cells recovered from the thymus, 
peritoneum, spleen and BM were assessed by flow cytometry (described for untreated 
mice in Chapter 6, Section 6.2.3), using similar antibody panel (listed in Chapter 6, 
Section 6.2.2.). In the thymus, there was no difference in the ratio of CD4+ and CD8+ 
cells in any of the groups (Appendix I, Table 1). Flow cytometric analysis did reveal 
some differences in cell staining between various groups as described bellow: 
 
In normal Hsd11b1-/- and Hsd11b1+/+ mice, subjected to arthritis, differences were noted 
in spleen (particularly severe deficiency in CD45+ cells in Hsd11b1-/- in comparison to 
Hsd11b1+/+ mice) and BM cell distribution (Appendix I, Table 2). However, due to 
small group sizes (n=3/genotype) definite conclusions cannot be made. No differences 
were found in peritoneal cells (data not shown) between Hsd11b1-/- and Hsd11b1+/+ 
mice following arthritis, although, large within-group variability and small group size 
prevented conclusive results.  
 
In mice subjected to BMT but not arthritis, flow cytometric analysis did not reveal 
significant differences between WT(KO) and KO(WT) groups in any of the tissues (data 
not shown), although there appeared to be a higher percent of c-kit+ BM cells in 
KO(WT) (3.6%±0.1) than in WT(KO) mice (2.6%±0.2) (p=0.05), with very small 
variability within-groups. However, as there were only two mice per group, definite 
conclusions cannot be made.  
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Flow cytometry assessment of cells from mice in the BMT-arthritis groups showed most 
differences in staining between mice in WT(KO) and KO(WT) groups in cells from BM;  
WT(KO) mice had a lower percent of CD45+ cells, and a higher percent of Lin+ and c-
kit+ cells in the BM than KO(WT) mice (Appendix I, Figure 1.1). No differences 
between the two groups were seen in cells isolated from the peritoneum or spleen 













Appendix I, Figure 1.1 Altered cell markers in cells from BM in BMT-arthritis 
mice.   
Flow cytometry analysis showed less CD45+ cells (A) and more Lin+ cells (B) and c-kit+ 
(C) cells in BM of KO(WT) (grey bars; n=5) than WT(KO) (hatched lines; n=7) mice. 









































































Appendix I, Table 1. Flow cytometry analysis of CD4+ and CD8+ cells in the 
thymus from all BMT/arthritis experimental groups. 
 
 
Thymocytes             Group  Mean  T-test 
WT(KO) + arthritis, n=7 2.8 ± 0.6 CD8+/CD4- 
KO(WT) + arthritis, n=5 3.3 ± 1.1 
p>0.05 
WT(KO) + arthritis, n=7 86.2 ± 1.3 CD8+/CD4+ 
KO(WT) + arthritis, n=5 76.8 ± 13.3 
p>0.05 
WT(KO) + arthritis, n=7 2.0 ± 0.5 CD8-/CD4- 
KO(WT) + arthritis, n=5 5.0 ± 3.4 
p>0.05 
WT(KO) + arthritis, n=7 9.0 ± 0.4 CD8-/CD4+ 
KO(WT) + arthritis, n=5 14.9 ± 9.1 
p>0.05 
     
    
 
Thymocytes             Group  Mean   T-test 
Hsd11b1-/- + arthritis, n=3 5.4 ± 0.8 CD8+/CD4- 
Hsd11b1+/+ + arthritis, n=3 5.7 ± 0.8 
p>0.05 
Hsd11b1-/- + arthritis, n=3 71.3 ± 1.5 CD8+/CD4+ 
Hsd11b1+/+ + arthritis, n=3 72.8 ± 4.7 
p>0.05 
Hsd11b1-/- + arthritis, n=3 11.9 ± 0.9 CD8-/CD4- 
Hsd11b1+/+ + arthritis, n=3 10.6 ± 4.1 
p>0.05 
Hsd11b1-/- + arthritis, n=3 11.4 ± 0.5 CD8-/CD4+ 
Hsd11b1+/+ + arthritis, n=3 10.9 ± 0.5 
p>0.05 
      
      
Thymocytes            Group  Mean  T-test 
WT(KO), n=2 9.78 ± 5.91 CD8+/CD4- 
KO(WT), n=2 2.07 ± 0.83 
p>0.05 
WT(KO), n=2 46.40 ± 33.28 CD8+/CD4+ 
KO(WT), n=2 83.25 ± 2.75 
p>0.05 
WT(KO), n=2 8.80 ± 5.86 CD8-/CD4- 
KO(WT), n=2 2.72 ± 1.46 
p>0.05 
WT(KO), n=2 35.03 ± 21.53 CD8-/CD4+ 







Appendix I, Table 2. Flow cytometry analysis of spleenocytes and BM cells 
from Hsd11b1-/- and Hsd11b+/+ mice subjected to 21d of K/BxN arthritis. 
 
Spleenocytes                 Group Mean T-test 
Hsd11b1+/+ + arthritis, n=3 42.20 ± 1.99 Lin+ 
Hsd11b1-/- + arthritis, n=3 36.20 ± 1.21 
p<0.05 
Hsd11b1+/+ + arthritis, n=3 65.19 ± 9.39 CD45+ 
Hsd11b1-/- + arthritis, n=3 2.61 ± 1.44 
p<0.01 
Hsd11b1+/+ + arthritis, n=3 1.40 ± 0.20 p<0.01 CD45+/c-kit+ 
Hsd11b1-/- + arthritis, n=3 0.61 ± 0.14   
Hsd11b1+/+ + arthritis, n=3 59.94 ± 18.47 CD45+/c-kit+ 
excluding Lin+ Hsd11b1-/- + arthritis, n=3 2.12 ± 0.68 
p<0.01 
Hsd11b1+/+ + arthritis, n=3 2.23 ± 0.29 c-kit+  
Hsd11b1-/- + arthritis, n=3 2.28 ± 0.79 
p>0.05 
Hsd11b1+/+ + arthritis, n=3 58.65 ± 0.59 p<0.01 B220+/Thy-1- 
Hsd11b1-/- + arthritis, n=3 53.70 ± 0.86   
Hsd11b1+/+ + arthritis, n=3 24.73 ± 0.10 B220-/Thy-1+ 
Hsd11b1-/- + arthritis, n=3 22.43 ± 2.15 
p>0.05 
Hsd11b1+/+ + arthritis, n=3 1.12 ± 0.69 CD11b-/Gr-1+ 
Hsd11b1-/- + arthritis, n=3 0.45 ± 0.09 
p>0.05 
Hsd11b1+/+ + arthritis, n=3 2.71 ± 0.14 CD11b+/Gr-1+ 
Hsd11b1-/- + arthritis, n=3 3.76 ± 0.15 
p<0.01 
Hsd11b1+/+ + arthritis, n=3 5.97 ± 1.74 CD11b+/Gr-1- 
Hsd11b1-/- + arthritis, n=3 3.56 ± 1.45 
p>0.05 
      
BM Cells                            Group Mean T-test 
Hsd11b1+/+ + arthritis, n=3 21.55 ± 1.68 Lin+ 
Hsd11b1-/- + arthritis, n=3 18.24 ± 1.15 
p>0.05 
Hsd11b1+/+ + arthritis, n=3 2.00 ± 0.07 p<0.01 c-kit+  
Hsd11b1-/- + arthritis, n=3 3.07 ± 0.10   
Hsd11b1+/+ + arthritis, n=3 17.35 ± 2.27 p<0.01 B220+/Thy-1- 
Hsd11b1-/- + arthritis, n=3 26.50 ± 2.86   
Hsd11b1+/+ + arthritis, n=3 2.83 ± 0.13 p<0.01 B220-/Thy-1+ 
Hsd11b1-/- + arthritis, n=3 2.07 ± 0.15   
Hsd11b1+/+ + arthritis, n=3 8.24 ± 1.01 p>0.05 CD11b-/Gr-1+ 
Hsd11b1-/- + arthritis, n=3 5.87 ± 0.97   
Hsd11b1+/+ + arthritis, n=3 20.53 ± 1.58 CD11b+/Gr-1+ 
Hsd11b1-/- + arthritis, n=3 25.42 ± 6.27 
p>0.05 
Hsd11b1+/+ + arthritis, n=3 4.89 ± 0.42 CD11b+/Gr-1- 
Hsd11b1-/- + arthritis, n=3 7.69 ± 1.01 
p<0.05 
 210 
Appendix I, Table 3.  Flow cytometry comparison of BM cells, peritoneal 




BM Cells                 Group  Mean   T-test 
WT(KO) 14.1 ± 2.8 B220+/Thy-1- 
KO(WT) 11.0 ± 1.8 
p>0.05 
WT(KO) 3.9 ± 0.8 B220-/Thy-1+ 
KO(WT) 3.7 ± 0.9 
p>0.05 
WT(KO) 5.4 ± 1.6 p>0.05 CD11b-/Gr-1+ 
KO(WT) 5.7 ± 1.1   
WT(KO) 62.5 ± 2.6 CD11b+/Gr-1+ 
KO(WT) 65.4 ± 2.2 
p>0.05 
WT(KO) 3.3 ± 0.6 CD11b+/Gr-1- 





Peritoneal Cells      Group  Mean   T-test 
WT(KO) 27.5 ± 7.3 Lin+ 
KO(WT) 25.0 ± 2.2 
p>0.05 
WT(KO) 30.2 ± 4.1 CD45+ 
KO(WT) 36.5 ± 7.0 
p>0.05 
WT(KO) 17.2 ± 4.3 c-kit+  
KO(WT) 14.1 ± 3.3 
p>0.05 
WT(KO) 48.5 ± 7.5 B220+/Thy-1- 
KO(WT) 46.5 ± 6.0 
p>0.05 
WT(KO) 20.8 ± 7.2 B220-/Thy-1+ 
KO(WT) 21.0 ± 6.8 
p>0.05 
WT(KO) 2.0 ± 0.7 p>0.05 CD11b-/Gr-1+ 
KO(WT) 1.8 ± 0.4   
WT(KO) 66.4 ± 4.6 CD11b+/Gr-1+ 
KO(WT) 60.8 ± 7.0 
p>0.05 
WT(KO) 30.2 ± 4.1 CD11b+/Gr-1- 





Spleenocytes           Group  Mean   T-test 
WT(KO) 14.2 ± 2.6 Lin+ 
KO(WT) 15.5 ± 4.9 
p>0.05 
WT(KO) 65.2 ± 27.1 CD45+ 
KO(WT) 57.3 ± 18.7 
p>0.05 
WT(KO) 0.8 ± 0.1 c-kit+  
KO(WT) 0.8 ± 0.1 
p>0.05 
WT(KO) 63.1 ± 4.5 B220+/Thy-1- 
KO(WT) 56.0 ± 5.2 
p>0.05 
WT(KO) 21.7 ± 2.9 B220-/Thy-1+ 
KO(WT) 24.5 ± 5.2 
p>0.05 
WT(KO) 1.1 ± 0.3 CD11b-/Gr-1+ 
KO(WT) 0.9 ± 0.2 
p>0.05 
  
WT(KO) 2.3 ± 0.5 CD11b+/Gr-1+ 
KO(WT) 3.3 ± 0.7 
p>0.05 
WT(KO) 5.8 ± 1.5 CD11b+/Gr-1- 
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